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SUMMARY 
 
Neuroblastoma (NB), a childhood tumor arising from immature sympathetic nervous system cells, is 
a heterogeneous disease with prognosis ranging from excellent long-term survival to high-risk with 
fatal outcome. In order to determine the most appropriate treatment modality, patients are 
stratified into risk groups at the time of diagnosis, based on combinations of clinical and biological 
parameters, namely age of the patient, tumor stage, histology, grade of differentiation, MYCN 
oncogene amplification, chromosome 11q aberration and DNA ploidy. However, use of this risk 
classification system has shown that accurate assessment of NB prognosis remains difficult and that 
additional prognostic markers are warranted. Therefore, we aimed to identify prognostic tumor DNA 
methylation biomarkers for NB. 
 
To find new biomarkers, we profiled the primary tumor DNA methylome using methyl-CpG-binding 
domain (MBD) sequencing, i.e. massively parallel sequencing of methylation-enriched DNA fractions, 
captured using the high affinity of MBD to bind methylated cytosines. As proof of principle, we 
applied this technology to 8 NB cell lines, and in combination with mRNA expression studies, this led 
to a first selection of 43 candidate biomarkers. Next, methylation-specific PCR (MSP) assays were 
designed, to allow candidate-specific methylation analysis in a primary tumor cohort of 89 samples. 
As such, we identified new prognostic DNA methylation biomarkers, and delineated the technological 
aspects and data analysis pipeline to set up a more extended biomarker study. In this follow-up 
study, the DNA methylome of 102 primary tumors, selected for risk classification and survival, was 
characterized by MBD sequencing. Differential methylation analyses between the prognostic patient 
groups put forward 78 top-ranking biomarker candidates, which were subsequently tested on two 
independent cohorts of 132 and 177 samples, adopting the high-throughput MSP pipeline of our 
pilot study. Multiple individual MSP assays were prognostically validated and through the 
implementation of a newly developed statistical framework, a robust 58-marker methylation 
signature predicting overall and event-free survival was established. This study represents the largest 
DNA methylation (biomarker) study in NB so far. 
 
The MBD sequencing data were shared with the research community through the format of a data 
descriptor. As such, these data are fully available to others, ensuring its reusability for other research 
purposes. To illustrate how these data can be applied to gain new insights into the NB pathology, we 
characterized the DNA methylome of stage 4S NB, a special type of NB found in infants with 
widespread metastases at diagnosis that paradoxically is associated with an excellent outcome due 
to its remarkable capacity to undergo spontaneous regression. More specifically, we compared 
promoter methylation levels between stage 4S, stage 1/2 (localized disease with favorable prognosis) 
and stage 4 (metastatic disease with dismal prognosis) tumors, and showed that specific 
chromosomal locations are enriched in stage 4S differentially methylated promoters and that specific 
subtelomeric promoters are hypermethylated in stage 4S. Furthermore, genes involved in important 
oncogenic pathways, in neural crest development and differentiation, and in epigenetic processes 
are differentially methylated and expressed in stage 4S. 
 
In conclusion, by exploring the DNA methylome of NB, we have not only demonstrated that DNA 
methylation patterns are intimately related to NB biology, but also found additional clinically 
relevant prognostic biomarkers. 
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SAMENVATTING 
 
Neuroblastoom (NB) is een kindertumor die ontstaat uit immature sympathische zenuwcellen en 
wordt gekenmerkt door een grote klinische heterogeniteit met een prognose variërend van zeer 
gunstig tot fataal. Bij diagnose worden de patiënten ingedeeld in een specifieke risicogroep, een 
classificatie die gebaseerd is op combinaties van specifieke klinische en genetische karakteristieken 
(leeftijd van de patiënt, tumorstadium, histologie, differentiatiegraad, MYCN-oncogenamplificatie, 
chromosoom 11q-afwijkingen en DNA-ploïdie), om zo voor elke patiënt de meest geschikte therapie 
te bepalen. Follow-up studies hebben echter aangetoond dat exacte prognosebeoordeling voor NB 
moeilijk blijft en dat bijkomende prognostische merkers noodzakelijk zijn. Vandaar dat in dit 
onderzoek werd getracht prognostische tumor-DNA-methylatiebiomerkers te identificeren. 
 
Hiertoe werden de DNA-methylatiepatronen van primaire NB-tumoren op een genoomwijde manier 
in kaart gebracht met behulp van methyl-CpG-binding domain (MBD)-sequenering. Deze techniek is 
gebaseerd op de verrijking van gemethyleerd DNA, gebruikmakend van de hoge affiniteit van MBD 
om te binden met gemethyleerde cytosines, gevolgd door sequeneringsanalyse van deze verrijkte 
DNA-fractie. Ter optimalisatie van de analyseprocedure werd deze techniek initieel toegepast op 8 
NB-cellijnen, wat in combinatie met mRNA-expressiestudies leidde tot een eerste selectie van 43 
kandidaatbiomerkers. Vervolgens werd methylatie-specifieke PCR (MSP) geïmplementeerd om deze 
merkers verder te evalueren in 89 primaire NB-tumoren. Zo werden verscheidene nieuwe 
prognostische DNA-methylatiebiomerkers geïdentificeerd en werden de technologische aspecten en 
data-analysepijplijn voor een meer uitgebreide biomerkerstudie vastgelegd. In deze vervolgstudie 
werd het DNA-methyloom van 102 primaire NB-tumoren, die geselecteerd werden op basis van 
risicoclassificatie en overlevingsstatus, geprofileerd met MBD-sequenering. Differentiële 
methylatieanalyses tussen de prognostische patiëntengroepen lieten toe 78 kandidaatbiomerkers te 
prioriteren, die vervolgens op twee onafhankelijke cohortes van 132 en 177 stalen werden getest 
met behulp van de MSP-pijplijn uit de pilootstudie. De prognostische waarde van verscheidene 
individuele MSP assays werd gevalideerd en via de implementatie van een nieuw ontwikkeld 
statistisch kader werd een robuuste prognostische methylatiesignatuur bestaande uit 58 merkers 
ontwikkeld en gevalideerd. Dit is de grootste DNA-methylatie(biomerker)studie in NB dusver. 
 
De MBD-sequeneringsdata werd publiek beschikbaar gemaakt onder de vorm van een data 
descriptor. Hierdoor kan de data ook voor andere onderzoeksdoeleinden worden aangewend en 
kunnen zo nieuwe mechanismes in de NB-pathologie worden ontrafeld. Ter illustratie hiervan werd 
het DNA-methyloom van stadium 4S-NB gekarakteriseerd. Dit tumorstadium komt enkel voor bij 
jonge kinderen en wordt getypeerd door metastasen die doorgaans spontaan regresseren, met een 
gunstige prognose tot gevolg. Differentiële promotormethylatie-analyses tussen stadium 4S, stadium 
1/2 (gelokaliseerde ziekte met gunstige prognose) en stadium 4 (metastatische ziekte met 
ongunstige prognose) toonden aan dat specifieke chromosomale regio’s rijk zijn aan promotoren 
differentieel gemethyleerd in stadium 4S, en dat dit tumorstadium gekenmerkt wordt door 
hypermethylatie van specifieke promotoren in subtelomeren. Verder bleek dat genen die een 
belangrijke rol spelen in kanker, in neurale kamontwikkeling en -differentiatie, en in epigenetische 
processen differentieel gemethyleerd zijn in stadium 4S.  
 
Samengevat kon door exploratie van het NB-DNA-methyloom niet alleen worden aangetoond dat 
DNA-methylatieprofielen de NB-biologie bepalen, maar konden eveneens bijkomende klinisch 
relevante prognostische biomerkers worden gevonden. 
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1.1 DNA methylation: inherited information beyond the DNA sequence 
 
Deoxyribonucleic acid (DNA) occurs as a double helix of which each strand is made up of a sequence 
of nucleotides consisting of a phosphate and a sugar linked to one of the four following bases: 
cytosine (C), thymine (T), adenine (A) or guanine (G). Hydrogen bonds between the A-T and C-G base 
pairs (bp) hold the two strands together. The DNA is further intimately complexed with various 
specialized proteins, which together form chromatin. Nucleosomes form the fundamental repeating 
units of chromatin and consist of 147 bp of DNA wrapped around a histone octamer (Figure 1). 
Additional levels of higher-order chromatin organization lead to further packaging into chromatin 
fibers, larger looped chromatin domains and eventually to the formation of chromosomes. The 
human genome is organized into two sets of 23 chromosomes, of which one set is inherited from 
each parent.  
 
 
 
 
Figure 1. Various epigenetic mechanisms contribute to modulation of the chromatin structure. me: DNA 
methylation; mod: histone modification; ncRNA: non-coding RNA. Based on [1]. 
 
 
 
Chromatin is a dynamic molecule existing in many configurations, ranging from highly condensed 
chromatin (heterochromatin) to a less compacted type (euchromatin) where genes are typically 
expressed. These chromatin variations are established through various so-called epigenetic 
mechanisms (Figure 1), including the dynamic shuffling of histone variants in and out of 
nucleosomes, chromatin remodeling resulting in nucleosome repositioning, the addition of chemical 
flags to histone proteins, the targeting role of non-coding ribonucleic acids (ncRNAs) and DNA 
methylation. In concert with transcription factor regulation, these epigenetic mechanisms 
collectively effectuate different patterns of gene expression and silencing from the same genome, 
creating different cell types [1]. Importantly, this epigenetic machinery needs to be well orchestrated 
to avoid that cellular identity gets lost, leading to malignancies such as cancer. Epigenetics have 
therefore heralded a new era of cancer research, in which it has become clear that something 
beyond the DNA sequence can be inherited and disrupted. These epigenetic alterations can be 
identified and used both in a diagnostic and therapeutic setting. 
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 Principles and functions of DNA methylation 1.1.1
 
1.1.1.1 DNA methylation and demethylation 
 
DNA methylation is the addition of a methyl group (CH3) to the C5 position of cytosines in CpG 
dinucleotides (the ‘p’ refers to the phosphodiester bond between the cytosine and the guanine) and 
occurs in 60-80% of the 56 million CpG dinucleotides in the human genome, which corresponds to 4-
6% of all cytosines. CpG dinucleotides are underrepresented in relation to other dinucleotides, 
because of the hydrolytic deamination of 5-methylcytosine to thymine during molecular evolution, 
and are unequally distributed across the genome. Depletion of CpGs is observed in intergenic and 
intragenic regions, whereas repetitive DNA and CpG islands are CpG-rich [2]. CpG islands are defined 
as regions of at least 200 bp that have a GC content of 50% and an observed/expected CpG ratio of 
more than 0.6 [3]. For comparison, the observed/expected CpG ratio in the bulk of the genome is 
0.1-0.2. DNA methylation is achieved by DNA methyltransferases (DNMTs), that catalyse the transfer 
of the methyl group from S-adenosyl-l-methionine (SAM) to the cytosine C5 position. The initial DNA 
methylation pattern is set during embryonic development (Figure 2) by the de novo DNMT3A and 
DNMT3B DNA methyltransferases. After each round of DNA replication, hemimethylated DNA is 
obtained, in which only the parental strand carries methylation marks. The newly synthesized 
daughter strand, which is initially devoid of methylation, then gets methylated by the maintenance 
DNA methyltransferase DNMT1. The preference of DNMT1 for hemimethylated sites prevents 
methylation of previously unmethylated sites and thereby preserves the DNA methylation pattern 
through cell division [2].  
 
 
Figure 2. DNA methylation levels change dynamically during human development. Primordial germ cells 
(PGCs) emerge in embryos at embryonic day 7.25. Concomitant with their proliferation and migration towards 
the genital ridge, DNA methylation is globally erased. Following sex determination, new DNA methylation 
landscapes are established in the germ cell precursors of the male or female embryo. In males, this de novo 
DNA methylation is completed before birth. In females, de novo DNA methylation is established after birth, 
during the follicular/oocyte growth phase. Following fertilization, a new wave of DNA demethylation takes 
place that is distinct on the parental genomes. In the zygote, DNA methylation of the paternal genome is 
rapidly erased by an active mechanism. Demethylation of the maternal genome is slower and dependent on 
DNA replication (passive demethylation). During blastocyst implantation and cell lineage determination, new 
methylation landscapes are established, associated with cellular differentiation. Based on [4]. 
 
Although DNA methylation has been viewed as a stable epigenetic mark, recent studies have 
indicated that it is more dynamic than originally thought. DNA demethylation has been observed in 
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specific contexts, for example during specific developmental stages (Figure 2), and can occur through 
passive or active mechanisms. If DNMT1 is inhibited or absent when cells divide, the newly 
synthesized DNA strands will not be methylated and successive rounds of cell division will result in 
passive DNA demethylation. Additionally, several modes of active DNA demethylation have been 
described, which include enzymatic DNA demethylation, (deamination of 5-methylcytosine to 
thymine followed by) base excision repair, nucleotide excision repair and mechanisms influencing the 
availability or biochemical features of SAM [5]. Key players in the enzymatic DNA demethylation 
processes are the Ten-eleven translocation proteins TET1, TET2 and TET3. These enzymes generate 
5-hydroxymethylcytosine from existing 5-methylcytosine, which they can further process to 5-
formylcytosine and 5-carboxylcytosine (Figure 3) [6]. Subsequently, these oxidation products are 
recognized by thymine-DNA glycosylase and excised through base excision repair to install an 
unmodified cytosine [7, 8]. Alternatively, 5-hydroxymethylcytosine can also be converted to 5-
hydroxymethyluracil by the AID/APOBEC family of cytidine deaminases, and 5-hydroxymethyluracil is 
then excised through base excision repair (Figure 3) [9, 10]. Apart from their role as intermediates in 
this active DNA demethylation pathway, several studies have also indicated direct functions of 5-
hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine. As a consequence, these 
epigenetic marks are increasingly being studied, also in cancer [6, 9, 11–16].  
 
1.1.1.2 DNA methylation regulates gene expression  
 
Gene expression is regulated by a sophisticated interplay between transcription factors (reviewed 
elsewhere [17]) and numerous epigenetic actors, in which the precise role of DNA methylation has 
proved to be challenging to unravel, as its function seems to vary with genomic context [18]. Initial 
DNA methylation studies focused on CpG islands at promoters and postulated that active promoters, 
characterized by nucleosome-depleted regions (NDRs) upstream of their transcription start sites 
(TSSs), normally lack DNA methylation. These promoters are further marked by the presence of 
specific histone modifications, such as H3 trimethylation at lysine 4 (H3K4me3) and lysine 
acetylation, and histone variant H2A.Z. On the other hand, genes of which the promoter lacks H2A.Z 
and has nucleosomes positioned over the TSS harbouring repressive histone marks 
(H3K27me3/H3K9me2/H3K9me3), can be stably silenced by DNA methylation [19]. Nevertheless, 
most promoters remain unmethylated and the transcriptional level of these genes is regulated by 
transcription factors [17]. Importantly, about 40% of human genes does not show CpG islands at 
their promoters, and because of the long-standing focus on CpG islands, the role of promoter 
methylation in controlling transcription of these genes is not yet fully understood. Recent studies 
further indicate that methylation of CpG island shores and shelves, i.e. regions of relatively low CpG 
density that flank CpG islands, as well as methylation of gene bodies and regulatory sites, such as 
enhancers and insulators, also play a role in fine-tuning gene expression. Although the majority of 
the gene bodies is CpG-poor, they are extensively methylated and, in contrast to promoter 
methylation, this is generally positively correlated with gene expression. However, the detailed 
mechanism by which DNA methylation of these different genomic regions orchestrates transcription 
regulation remains to be elucidated [18]. Systematic investigation of DNA methylation patterns at 
genome-wide level has been hampered by the presence of a large number of epigenomes; each 
individual has essentially one genome, but each cell type in each individual is believed to have a 
distinct epigenome. Therefore, in analogy to the Human Genome Project, several large-scale 
epigenomics projects have been initiated (Box 1), to produce a public resource of epigenome data 
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that includes maps of DNA methylation, histone modifications, chromatin accessibility and RNA 
expression of cell types and tissues relevant to important biological processes and diseases. These 
genome-wide data will indisputably improve our understanding of gene expression regulation and 
the role of DNA methylation herein [20, 21]. 
 
 
Figure 3. Enzymatic DNA demethylation occurs via multiple intermediates. DNMT proteins are responsible for 
the methylation of cytosines. Two pathways of active demethylation have been described. Most evidence 
exists for a pathway in which TET proteins convert 5-methylcytosine into 5-hydroxymethylcytosine, 5-
formylcytosine and 5-carboxylcytosine through three consecutive oxidation reactions. Subsequently, 5-
formylcytosine and 5-carboxylcytosine are recognized by thymine-DNA glycosylases (TDGs) which activate the 
base excision repair pathway. In addition, evidence exists for a pathway in which AID/APOBEC proteins 
deaminate 5-hydroxymethylcytosine to 5-hydroxymethyluracil, followed by TDG-mediated base excision repair. 
Based on [9]. 
 
Box 1. Several large-scale epigenomics projects have been initiated [20, 21]. 
 
The International Human Epigenome Consortium (IHEC) was launched in 2010 to offer a forum for coordination 
of other initiatives, with the objective of avoiding redundant research efforts, implementing high data quality 
standards and thus maximizing efficiency among scientific research centers. Several projects have been 
initiated, each contributing to the IHEC’s major goal - mapping 1,000 epigenomes by 2020 (www.ihec-
epigenomes.org). The BLUEPRINT project is a European initiative focusing on distinct types of hematopoietic 
cells from healthy individuals and their malignant leukemic counterparts (www.blueprint-epigenome.eu). The 
German epigenome project DEEP analyzes cell types connected to complex diseases, such as metabolic diseases 
and inflammatory diseases of the joints and the intestine (www.deutsches-epigenom-programm.de). The 
following categories of human cell and tissue types are studied by the Canadian Epigenetics, Environment and 
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Health Research Consortium (CEEHRC): stem and differentiated cell types relevant to complex diseases 
(including cancer), placental tissue and tissues relevant to disorders of genomic imprinting, central nervous 
system tissues, tissues relevant to cancer heterogeneity, breast cancer, tissues relevant to cardiovascular 
diseases and tissues related to human immune function (www.cihr-irsc.gc.ca/e/43602.html). The Core Research 
for Evolutional Science and Technology (CREST)/IHEC, Team Japan aims to produce reference epigenomes of 
gastrointestinal epithelial cells, vascular endothelial cells and cells of reproductive organs (www.crest-
ihec.jp/english/index.html). The National Institutes of Health (NIH) Roadmap Epigenomics Program in the US, 
which was already launched in 2008, now also contributes to the IHEC (www.roadmapepigenomics.org), and 
also the Encyclopedia of DNA Elements (ENCODE) Consortium maps epigenomes (www.encodeproject.org). 
 
 DNA methylation in normal cellular processes   1.1.2
 
1.1.2.1 Subtelomeric and pericentromeric repeat silencing 
 
Telomeres are nucleoprotein structures at the ends of chromosomes and consist of TTAGGG tandem 
repeats bound by a multiprotein complex known as shelterin. Telomeres are essential for 
chromosome end protection and chromosomal stability. Subtelomeres, located proximal to 
telomeres, are also enriched in repetitive DNA and are further characterized by a low gene density 
and the presence of CpG dinucleotides, that are absent in telomeres. Pericentromeres flank 
chromosome centromeres and are involved in kinetochore function and sister chromatid cohesion 
during cell division. These three types of repeat-rich chromatin regions exhibit histone modifications 
commonly found in heterochromatin, such as H3K9me3 and H4K20me3, and are enriched in 
heterochromatin protein HP1. Additionally, subtelomeres and pericentromeres are also typified by 
DNA methylation. These heterochromatic marks have important functions in chromosome 
segregation, act as a negative regulator of homologous recombination in these regions, and suppress 
telomere elongation [22]. 
 
1.1.2.2 Transposon silencing 
 
The human genome is strewn with transposons, also called transposable elements, DNA sequences 
that can migrate (‘transpose’) within the genome. Depending on their mechanism of transposition, 
transposons are grouped into two categories: DNA transposons and retrotransposons. While DNA 
transposons move around by a cut-and-paste mechanism, retrotransposons are spread by a copy-
and-paste mechanism, which involves transcription into an RNA intermediate and integration of the 
reverse-transcribed cDNA copy at a new locus. Active transposons are highly mutagenic and can 
influence neighbouring genes by altering splicing and polyadenylation patterns, or by functioning as 
enhancers or promoters. To prevent transposon-induced damage to the genome, defense 
mechanisms have been developed, including suppression of transcriptional activity of transposons by 
DNA methylation and chromatin modifications, such as H3K9 methylation [23, 24].  
 
1.1.2.3 X chromosome inactivation 
 
Dosage compensation for X-linked gene products between the sexes is achieved by X-inactivation in 
females, which involves multiple levels of epigenetic modifications. X-inactivation is initiated at the X-
inactivation center (XIC) which contains the long non-coding RNA X-inactive-specific-transcript (XIST). 
During early differentiation, XIST is monoallelicly expressed and binds to high affinity sites on the 
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chromosome from which it is transcribed, resulting in XIST RNA coating of the future inactive X 
chromosome. Although the precise mechanisms underlying the repressive effect of XIST RNA are 
unknown, XIST RNA coating is followed by loss of euchromatic histone marks (H3K4me2/3, H3K9Ac 
and H4Ac). During this time window, X-linked gene silencing initiates by accumulation of the PRC2 
and PRC1 complex proteins, causing enrichment of repressive histone modifications (H3K27me3, 
H3K9me2, H2Aub1 and H4K20me1). At the final differentiation stage, in the maintenance phase, the 
PRC2 and PRC1 complexes no longer appear to be present and macroH2A becomes associated with 
the imprinted X chromosome. Finally, DNA methylation marks the promoters of X-linked genes [25]. 
 
1.1.2.4 Genomic imprinting 
 
Genomic imprinting is an epigenetic phenomenon that results in monoallelic gene expression 
according to parental origin. Most of the approximately 80 known imprinted genes (e.g. DLK1, GNAS, 
GRB10, IGF2 and SNURF) occur in clusters that contain 2 to 15 genes and that vary in size from less 
than 100 kilobase to several megabases [26]. The parent-specific expression of these gene clusters is 
under the overall control of a cis-acting imprinting control region (ICR), which shows parental allele-
specific DNA methylation and chromatin modifications. DNA methylation of the ICR is acquired in 
either maternal or paternal germ cells and is resistant to the extensive reprogramming of the 
genome that occurs in the embryo after fertilization (Figure 2). Imprinted genes have major effects 
on prenatal and postnatal development, survival and growth, as well as on metabolism, and neural 
and behavioural processes. Alterations of DNA methylation in imprinted regions may lead to disease. 
For example, lack of maternal GNAS methylation imprinting results in pseudohypoparathyroidism 
type 1b [26]. 
 
 Cancer: when DNA methylation goes awry  1.1.3
 
It is now generally accepted that epigenetic aberrations, next to genetic lesions, contribute to cancer 
initiation and progression. Cancer cells present a profoundly distorted epigenetic landscape in which 
multiple epigenetic players can be affected, including DNA methylation [27]. Since DNA methylation 
alterations are commonly observed in benign neoplasms and early-stage tumors, epigenetic 
deregulation has been considered an early event in tumorigenesis which may precede the classical 
genetic changes [28]. Of note, DNA methylation patterns are directly affected by a person’s diet and 
exogenous stimuli such as viruses and bacteria, which may initiate cancer formation [29]. However, 
recent evidence indicates that deregulation of epigenetic and genetic mechanisms are not separate 
events in cancer, but that they intertwine and take advantage of each other; genetic alterations of 
the epigenome may contribute to tumorigenesis and epigenetic processes may cause point 
mutations and disable DNA repair functions [30].  
 
1.1.3.1 Hypomethylation 
 
One of the first epigenetic alterations found in human cancer is the presence of massive global loss 
of DNA methylation. This global DNA hypomethylation contributes in several ways to the 
development of cancer (Figure 4). It mainly occurs at repetitive sequences of subtelomeric and 
pericentromeric regions, promoting chromosomal instability and rearrangements, mitotic 
recombination and aneuploidy. Additionally, DNA hypomethylation can lead to reactivation of 
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transposons. An example hereof is the LINE-1 retrotransposon, which is silenced in normal cells, but 
becomes hypomethylated and transcriptionally reactivated in breast, lung, bladder and liver tumors. 
Also, loss of imprinting due to DNA hypomethylation increases the risk of cancer. Loss of imprinting 
of IGF2, for example, is accompanied by an increased risk for colorectal cancer and contributes to the 
development of Wilm’s tumor. Finally, DNA hypomethylation can activate aberrant expression of 
alternative transcripts from a gene, due to loss of DNA methylation in coding regions and introns, 
and can induce the expression of oncogenes [27, 29, 31].  
 
 
Figure 4. DNA methylation alterations contribute to carcinogenesis via several mechanisms. A. Lollipop 
diagram of a normal and tumor cell. DNA methylation states are indicated as white (unmethylated) or black 
(methylated) lollipops (CpG dinucleotides). B. These alterations can lead to deregulated expression (of onco- 
and tumor suppressor genes), transposon reactivation, chromosomal instability and telomeric deregulation. 
TSS: transcription start site. Based on [32]. 
 
1.1.3.2 Hypermethylation 
 
Another common epigenetic feature of human cancers is hypermethylation at CpG islands of 
promoters (Figure 4). Remarkably, only specific promoters become hypermethylated, while others 
remain unmethylated, and this hypermethylation pattern is tumor-specific. Transcriptional 
inactivation caused by promoter hypermethylation frequently affects tumor suppressor genes and 
genes involved in the main cellular pathways: DNA repair (MLH1, MGMT, WRN, BRCA1), vitamin 
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response (RARB, CRBP1), RAS signaling (RASSF1, RASSF5), cell cycle control (CDKN2A, CDKN2B, RB1), 
TP53 network (TP73, HIC1) and apoptosis (PYCARD, DAPK1, WIF1, SFRP1). Recent findings further 
indicate that aberrant DNA methylation of CpG island shores (e.g. at HOXA2 and GATA2) also 
frequently occurs in cancer [27]. Importantly, monoallelic DNA methylation silencing may act as one 
of the two hits in addition to a genetic lesion to fulfill Kundson’s two-hit hypothesis, which states that 
disruption of gene function requires loss of both copies of the involved gene. An example of this 
close epigenetic-genetic cooperation is observed in the colon cancer cell line HCT116, in which one 
allele of MLH1 and CDKN2A is genetically mutated, whereas the other is silenced by DNA 
methylation. Finally, DNA methylation can induce the generation of disease-causing mutations, due 
to the spontaneous hydrolytic deamination of 5-methylcytosine to thymine [30].  
 
1.1.3.3 Genetic lesions of the DNA methylation machinery 
 
Next to mutations in histone-modifying enzymes, also enzymes involved in the DNA methylation 
machinery can be genetically perturbed in cancer. DNMT3A mutations have been reported in acute 
myeloid leukemia and are associated with poor prognosis, and DNMT1 mutations are detected in 
colorectal cancer [30].  
 
 A plethora of technologies to illuminate DNA methylomes 1.1.4
 
As 5-methylcytosine and cytosine roughly have the same base pairing characteristics, standard 
sequence detection technologies cannot discriminate between them. To overcome this, several DNA 
modification and preparation steps have been introduced to enable DNA methylation analysis. The 
most frequently applied methodologies are based on the use of (methylation state) restriction 
enzymes, precipitation of methylated DNA fragments and/or DNA bisulfite treatment (Table 1). 
 
Restriction enzyme-based DNA methylation analyses make use of methylation-sensitive restriction 
enzymes, of which the endonuclease activity is influenced (in most cases inhibited) by methylation of 
the CpG(s) in the recognition site of the enzyme. Subsequent analysis of the restriction pattern then 
reveals DNA methylation information. The most widely used methylation-sensitive restriction 
enzymes are HpaII (recognition sequence C˅CGG) and SmaI (recognition sequence CCC˅GGG), 
because they each have an isoschizomer (MspI for HpaII) or neoschizomer (XmaI for SmaI) that is not 
inhibited by CpG methylation. The very first analysis methods used gel electrophoresis or Southern 
blots, but later on, more advanced technologies, such as (quantitative) polymerase chain reaction 
((q)PCR), arrays and sequencing, were combined with methylation-sensitive restriction enzymes 
(Table 1) [33]. It should be noted that some methylation-sensitive restriction enzymes are also 
sensitive to hydroxymethylation (§1.1.1.1), possibly confounding DNA methylation analyses [34]. 
 
Bisulfite conversion-based methods rely on the detection of chemically induced methylation-specific 
nucleotide changes in the DNA sequence, making use of a difference in reaction kinetics between 
cytosine and 5-methylcytosine with bisulfite. Deamination by bisulfite proceeds by three steps 
(Figure 5). The process begins with the nucleophilic addition of HSO3
- to the C6 of the pyrimidine ring 
(sulfonation step), which can only occur at (5-methyl)cytosines not involved in base-pairing, as in 
double-stranded DNA the bases are locked in the anti-conformation in which C6 is sterically 
impeded. The amino group at position 4 is destabilized by this sulfonation, so that hydrolytic 
  
 
 
Table 1. Multiple DNA methylation detection methodologies, making use of restriction enzymes, affinity enrichment and/or bisulfite conversion, have been developed. 
method ref. 
year of 
publication 
Google Scholar 
citations 
(d.d. 01/07/2016) 
analysis strategy detection technology 
restriction 
enzyme 
bisulfite 
conversion 
affinity 
enrichment 
PCR and/or 
gel/ 
electrophoresis 
array sequencing 
RLGS [35] 1991 388       
MS-AP-PCR [36] 1997 229       
MSRF [37] 1997 149       
MCA-RDA [38] 1999 513       
AIMS [39] 2002 121       
MS-MLPA [40] 2005 314       
DMH [41] 1999 470       
McrBC/array [42] 2004 67       
MethylScope [43] 2005 119       
MMASS [44] 2006 43       
MSNP [45] 2006 60       
MCAM [46] 2007 128       
CHARM [47] 2008 337       
HELP assay [48] 2006 348       
high-resolution 
HELP assay  
[49] 2009 113       
MSDK [50] 2006 29       
Methyl seq [51] 2009 211       
MSCC [52] 2009 617       
Methyl-MAPS [53] 2010 102       
MRE seq [54] 2010 809       
(continues) 
Note. This overview is limited to methods making use of restriction enzymes, bisulfite conversion and/or affinity enrichment, in combination with PCR and/or 
gel/electrophoresis, array and/or sequencing. Technologies indicated with * are discussed in more detail in §1.1.4.1, §1.1.4.2, §1.1.4.3 and §1.1.4.4. AIMS: amplification of 
intermethylated sites; CHARM: comprehensive high-throughput arrays for relative methylation; DMH: differential methylation hybridization; HELP: HpaII tiny fragment 
enrichment by ligation-mediated PCR; MCAM: methylated CpG island amplification microarray; MCA-RDA: methylated CpG island amplification with representational 
difference analysis; Methyl-MAPS: methylation mapping analysis by paired-end sequencing; MMASS: microarray-based methylation assessment of single samples; MRE seq: 
methylation-sensitive restriction enzyme sequencing; MS-AP-PCR: methylation-sensitive arbitrarily primed PCR; MSCC: methyl-sensitive cut counting; MSDK: methylation-
specific digital karyotyping; MS-MLPA: methylation-specific multiplex ligation-dependent probe amplification; MSNP: methylation-sensitive single nucleotide polymorphism 
chip analysis; MSRF: methylation-sensitive restriction fingerprinting; PCR: polymerase chain reaction; RLGS: restriction landmark genomic scanning.  
  
 
 
Table 1. Multiple DNA methylation detection methodologies, making use of restriction enzymes, affinity enrichment and/or bisulfite conversion, have been developed. 
(continued) 
method ref. 
year of 
publication 
Google Scholar 
citations 
(d.d. 01/07/2016) 
analysis strategy detection technology 
restriction 
enzyme 
bisulfite 
conversion 
affinity 
enrichment 
PCR and/or 
gel/ 
electrophoresis 
array sequencing 
COBRA [55] 1997 1139       
RRBS* [56] 2005 436       
scRRBS* [57] 2013 79       
RRMAB seq [58] 2016 0       
MB-PCR [59] 2006 57       
MSP* [60] 1996 6032       
MS-DGGE [61] 1999 131       
MethyLight* [62] 2000 1151       
MS-MCA [63] 2001 168       
Ms-SNuPE [64] 2002 65       
MS-SSCA [65] 2002 18       
HeavyMethyl* [66] 2004 131       
MS-HRM [67] 2007 316       
MethyLight ddPCR [68] 2015 4       
HT-TREBS [69] 2014 6       
BisPCR
2 
[70] 2015 2       
MSO [71] 2002 334       
GoldenGate assay* [72] 2006 510       
Illumina 27 K 
array* 
[73] 2009 338       
(continues) 
Note. This overview is limited to methods making use of restriction enzymes, bisulfite conversion and/or affinity enrichment, in combination with PCR and/or 
gel/electrophoresis, array and/or sequencing. Technologies indicated with * are discussed in more detail in §1.1.4.1, §1.1.4.2, §1.1.4.3 and §1.1.4.4. COBRA: combined 
bisulfite restriction analysis; ddPCR: digital droplet PCR; HT-TREBS: high-throughput targeted repeat element bisulfite sequencing; MAB seq: methylation-assisted bisulfite 
sequencing; MB-PCR: methyl-binding PCR; MS-DGGE: methylation-specific denaturing gradient gel electrophoresis; MS-HRM: methylation-sensitive high-resolution melting; 
MS-MCA: methylation-specific melting curve analysis; MSO: methylation-specific oligonucleotide; MSP: methylation-specific PCR; Ms-SNuPE: methylation-sensitive single 
nucleotide primer extension; MS-SSCA: methylation-sensitive single strand conformation analysis; PCR: polymerase chain reaction; RRBS: reduced representation bisulfite 
sequencing; RRMAB seq: reduced-representation MAB seq; scRRBS: single cell RRBS. 
  
  
 
 
Table 1. Multiple DNA methylation detection methodologies, making use of restriction enzymes, affinity enrichment and/or bisulfite conversion, have been developed. 
(continued) 
method ref. 
year of 
publication 
Google Scholar 
citations 
(d.d. 01/07/2016) 
analysis strategy detection technology 
restriction 
enzyme 
bisulfite 
conversion 
affinity 
enrichment 
PCR and/or 
gel/ 
electrophoresis 
array sequencing 
Illumina 450 K 
array* 
[74] 2011 533       
TAB-array [75] 2014 8       
MSBE [76] 2005 8       
BS seq [77] 2008 1211       
scBS seq* [78] 2014 112       
scWGBS* [79] 2015 35       
µWGBS* [79] 2015 35       
MethylC seq* [80] 2008 1430       
BSPP [81] 2009 396       
LHC-BS [82] 2011 15       
LD-BSP [83] 2015 1       
MAB seq [58] 2016 0       
MeDIP chip [84] 2005 1335       
MeCP2 chip* [85] 2006 1129       
MBD2 chip* [86] 2006 166       
MIRA [87] 2010 40       
MeDIP seq [88] 2008 474       
MethylCap seq* [89] 2010 134       
MiGS* [90] 2010 239       
Note. This overview is limited to methods making use of restriction enzymes, bisulfite conversion and/or affinity enrichment, in combination with PCR and/or 
gel/electrophoresis, array and/or sequencing. Technologies indicated with * are discussed in more detail in §1.1.4.1, §1.1.4.2, §1.1.4.3 and §1.1.4.4. BSPP: bisulfite 
sequencing padlock probes; BS seq: bisulfite sequencing; LD-BSP: limiting dilution bisulfite pyrosequencing; LHC-BS: liquid hybridization capture-based bisulfite sequencing; 
MAB seq: methylation-assisted bisulfite sequencing; MBD2: methyl-CpG-binding domain protein 2; MeCP2: methyl-CpG-binding protein 2; MeDIP: methylated DNA 
immunoprecipitation; MethylC seq: cytosine methylome sequencing; MiGS: MBD-isolated genome sequencing; MIRA: methylated CpG island recovery assay; MSBE: 
methylation-specific single base extension; scBS seq: single cell BS seq; scWGBS: single cell WGBS; TAB-array: TET-assisted bisulfite conversion with array analysis; WGBS: 
whole-genome bisulfite sequencing; µWGBS: WGBS in very small cell populations. 
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liberation of NH3 takes place, the rate-limiting key deamination step. On treatment with alkali, HSO3
-
is then again released to regenerate the 5,6-double bond (desulfonation step). In this way, both 
cytosine and 5-methylcytosine can be converted to either uracil or thymine, respectively, but the fact 
that the deamination reactions of sulfonated cytosine and 5-methylcytosine proceed at very 
different reaction rates, such that the deamination of cytosine will be complete before substantial 5-
methylcytosine deamination has occurred, allows distinguishing these two bases in DNA. Namely, 
under specific reaction conditions, bisulfite treatment only converts cytosines to uracils, while 
methylated cytosines remain unchanged. These methylation-specific induced single nucleotide 
changes can subsequently be analyzed using various molecular techniques (Table 1) [91, 92]. 
Importantly, bisulfite-based methods cannot distinguish between 5-methylcytosine and 5-
hydroxymethylcytosine, as 5-hydroxymethylcytosine is also resistant to bisulfite conversion [34, 93]. 
 
 
Figure 5. Bisulfite converts cytosine to uracil. The conversion process proceeds in three steps: sulfonation, 
deamination and desulfonation.    
 
Methodologies making use of affinity enrichment are based on enrichment of methylated DNA using 
antibodies specific for 5-methylcytosine or using methyl-binding proteins with affinity for methylated 
genomic DNA. The most frequently used proteins to precipitate methylated DNA are methyl-CpG-
binding domain protein 2 (MBD2) and methyl-CpG-binding protein 2 (MeCP2). After enrichment, the 
DNA fraction is analyzed using array or sequencing technology (Table 1).  
 
1.1.4.1 Methylation-specific PCR  
 
Historically seen, methylation-specific PCR (MSP) was developed to encounter disadvantages of 
earlier established DNA methylation detection methodologies, such as Southern blotting and PCR-
based approaches after digestion of the DNA with methylation-sensitive restriction enzymes. 
Namely, these methods could only shed light on CpG methylation in the restriction sites of the used 
enzymes and only assess the overall methylation status of CpG islands. In 1996, Herman et al. 
introduced the first MSP method, applicable to any block of CpG sites in the genome, allowing site-
specific methylation analysis. Principally, their method relies on the bisulfite-mediated conversion of 
cytosines to uracils, followed by PCR with specific primer pairs designed on the resultant modified 
DNA, and polyacrylamide gel electrophoresis [60]. In order to render a more quantitative format 
suitable for clinical settings where high-throughput is required, many other researchers soon started 
to adapt this MSP methodology. The most important adjustments made are the use of fluorescence-
based real-time PCR technology (MethyLight) [62], and methylation-specific oligonucleotide blockers 
and probes for the analysis of very low concentrations of methylated DNA (HeavyMethyl) [66] (Figure 
6). Although careful attention should be paid to MSP primer design, the method is relatively easy to 
perform.  
NH
2
 
N 
N O 
NH
2
 
N 
N O SO
3
- 
O 
HN 
N O SO
3
- 
O 
HN 
N O 
HSO
3
- 
HSO
3
- 
NH
3
 
sulfonation deamination desulfonation 
1 2 
3 
4 
5 
6 
H H H H 
 introduction 
- 19 - 
 
 
                   
Figure 6. Methylation-specific PCR (MSP) allows site-specific DNA methylation analysis. First, the DNA is 
treated with bisulfite, converting unmethylated cytosines (white) to uracil. Methylated cytosines (dark) remain 
as cytosines. MSP primer pairs are designed to only amplify the bisulfite-converted target region and do not 
anneal to genomic DNA. For simplicity, only one primer and its template are depicted. As each primer contains 
at least two CpG sites, this means that only if the template is methylated, a PCR product will be generated. 
qPCR: quantitative polymerase chain reaction. 
 
1.1.4.2 Methylation microarrays 
 
Over the past decade Illumina has developed several DNA methylation analysis technologies that are 
based on genotyping bisulfite-converted DNA using arrays. First, the GoldenGate Assay for 
Methylation, implemented on a BeadArray platform, was introduced to investigate the methylation 
status of 1,536 specific CpG sites in 96 samples simultaneously [72]. Later on, this technology was 
replaced by the Infinium HumanMethylation27 BeadChip Kit (Illumina 27 K array [73]), that allows a 
more genome-wide screening of DNA methylation patterns by interrogating approximately 27,000 
CpG sites. This kit makes use of a pair of bead-bound probes (Infinium I Assay) per CpG locus to 
detect the presence of an ‘unmethylated’ T or ‘methylated’ C by hybridization, followed by single-
base extension with a labelled nucleotide. Then, the array is fluorescently stained, scanned and the 
intensities of the methylated and unmethylated bead types measured. Afterwards, the methylation 
status of each CpG site is quantified in a β-value, which represents the ratio of the intensity of the 
methylated bead type to the combined locus intensity (0 is completely unmethylated; 1 is completely 
methylated) [74]. Subsequently, the Infinium HumanMethylation450 BeadChip (Illumina 450 K array 
[74]) and Infinium MethylationEPIC BeadChip Kit were developed, expanding the number of 
interrogated CpG sites to approximately 480,000 and 850,000, respectively, by making use of an 
additional assay type (Infinium II Assay). This assay type uses only one bead-bound probe per CpG 
methylated DNA unmethylated DNA 
bisulfite treatment 
MSP primer design 
- 
qPCR and amplicon sizing 
PCR product PCR product 
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locus, of which the 3’ terminus complements the base directly upstream of the queried CpG site, 
allowing hybridization to both ‘methylated’ and ‘unmethylated’ alleles. Here, the single-base 
extension depends on the methylation status of the hybridized allele and results in the addition of a 
labeled G or A, complementary to either the ‘methylated’ C or ‘unmethylated’ T, respectively. As the 
G and A are differently labeled, β-values can then be calculated by using a dual-color readout for 
intensity measurement [74, 94].    
 
1.1.4.3 Methyl-CpG-binding domain precipitation 
 
Affinity enrichment-based strategies making use of methyl-CpG-binding domain precipitation rely on 
the natural ability of methyl-binding proteins, such as MBD2 and MeCP2, to bind methylated CpGs. 
Methodologically, fragments of sonicated double-stranded DNA are exposed to MBD capture. 
Methylated fragments are bound, precipitated and subsequently analyzed using array (MeCP2 chip 
[85], MBD2 chip [86]) or sequencing technology (MethylCap seq [89], MiGS [90]; Figure 7). Since 
regions with a high density of methylated CpGs are preferentially or more effectively captured, these 
DNA methylation profiling approaches are biased towards CpG-dense regions, such as CpG islands 
[89, 90]. As such, when comparing DNA methylation levels of different genomic regions, MBD 
sequencing is less accurate for methylation quantification, as it measures the relative enrichment of 
methylated DNA rather than absolute DNA methylation levels. Another disadvantage is that it does 
not provide single-nucleotide resolution. Nevertheless, MBD sequencing has a higher genomic 
coverage (approximately 18%) than the Illumina 27 K and 450 K arrays (less than 4%) and can be used 
to identify differentially methylated regions (DMRs) between different samples (Box 2) [95, 96].  
 
1.1.4.4 Reduced representation and whole-genome bisulfite sequencing 
 
For reduced representation bisulfite sequencing (RRBS), the genomic DNA is first digested using a 
methylation-insensitive restriction enzyme, usually MspI which recognizes the sequence C˅CGG, 
followed by size selection using gel electrophoresis and band excision to select genomic regions with 
moderate to high CpG density [97, 98]. This reduced representation (or library) of the genome is then 
profiled using bisulfite sequencing. RRBS allows single-base resolution, but covers less than 4% of all 
CpG dinucleotides [96, 99]. In contrast, whole-genome bisulfite sequencing (WGBS) provides single-
base resolution and whole-genome coverage. The first human methylomes, originating from 
embryonic stem cells and fetal lung fibroblasts [100], were reported in 2009 (MethylC seq) and later 
on also cancer methylomes were determined [101, 102]. Yet, the number of studies using WGBS is 
still relatively limited, likely due to the high sequencing cost, as sufficient sequencing depth across 
the full genome is needed to accurately quantitate methylation of individual CpG sites, as well as due 
to the technical expertise and downstream computation requirements [96]. For example, accurate 
mapping of bisulfite sequencing reads is challenging, due to the lower sequence complexity and 
reduced GC content of bisulfite-converted DNA, and requires specific alignment tools [103]. Very 
recently, RRBS and WGBS that enables DNA methylation mapping in very small cell populations 
(µWGBS) and single cells (scBS seq, scWGBS, scRRBS) has been developed [57, 78, 79].  
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Figure 7. Methyl-CpG-binding domain (MBD) sequencing allows genome-wide DNA methylation analysis. 
Prior to MBD-based capture, the DNA is sheared or sonicated to create (methylated and unmethylated) DNA 
fragments. These DNA fragments are subsequently exposed to MBD proteins, which bind methylated DNA. 
Upon capture with magnetic beads, wash steps are performed to remove unbound (unmethylated) DNA 
fragments. Finally, the captured DNA fragments are eluted from the beads and can be sequenced. Based on the 
MethylCap Kit of Diagenode. 
 
Box 2. Differential methylation analyses based on MBD sequencing data make use of several bioinformatics 
tools.  
 
Differential methylation analyses based on MBD sequencing data make use of a bioinformatics pipeline, 
consisting of multiple consecutive steps: (1) quality control on the raw sequencing data, (2) read mapping, (3) 
peak calling, (4) data visualization, and (5) differential methylation analysis. For each of these steps, different 
bioinformatics tools can be used [104, 105].  
 
First, some quality control checks on the raw sequencing data are performed, for example by using FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), in order to detect potential sequencing errors. 
For example, the per base sequence quality scores and per sequence GC content can be evaluated. The per 
base sequence quality score reflects the probability that the corresponding base has been called incorrectly, 
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and can thus be used to check if the base calls are of good quality [106]. For MBD sequencing, evaluation of the 
per sequence GC content enables a first check of the presence of enrichment towards CpG-dense sequences. 
 
The following step is alignment of the sequences (reads) to the reference genome of the organism of interest, 
called read mapping. A wide variety of mapping tools exists, each with its own specific features. An extensive 
overview of the most commonly used alignment algorithms and software tools is given by Li et al. [104] and Su 
et al. [107]. Important aspects to take into account when selecting a mapping tool for MBD sequencing are the 
performance (speed/accuracy balance), the use of the quality information of the reads and the ability to map 
short paired-end sequencing reads. An example of a frequently used mapping tool suited for MBD sequencing 
analysis is Bowtie2 [108].  
 
Once the sequencing reads are mapped to the reference genome, genomic regions significantly enriched upon 
MBD capture need to be identified. The process of converting mapped sequencing reads to coverage vectors 
and the detection of enriched regions (peaks) is referred to as peak calling. Wilbanks et al. [105] have 
compared the performance of the most frequently used peak calling programs, including MACS [109], and 
measured their sensitivity, accuracy and usability. In addition to the location of the identified peaks and their 
significance scores, MACS also outputs files for data visualization, as exemplified in Decock et al. [110]. 
 
Differential methylation analyses between sample groups can be performed by using for example the R 
package DESeq [111], which uses raw counts of sequencing reads as input. For each region of interest included 
in the analysis, DESeq then yields the mean normalized counts per sample group, as well as the fold change 
between the sample groups, describing how much the methylation level differs between the two groups, and a 
p-value for the statistical significance of this difference. Also p-values adjusted for multiple testing with the 
Benjamini-Hochberg procedure, which controls false discovery rate (FDR), are reported [112].  
 
 DNA methylation as clinically useful biomarker 1.1.5
 
Biomarkers are molecular targets of which quantitative or qualitative analysis enables personalized 
tailoring of patient management. To be clinically applicable, biomarkers must be specific, sensitive 
(Box 3 and Table 2) and preferably detectable in specimens obtained through minimally invasive 
procedures. Several studies have shown that tumor-specific DNA methylation aberrations can be 
detected in blood or in body fluids that have been in physical contact with the site of the tumor, such 
as in urine for bladder cancer and in sputum for lung cancer. Additionally, several DNA methylation 
detection methodologies are applicable to formalin-fixed paraffin-embedded tumor samples. As 
such, DNA methylation might become the biomarker of choice for the clinical management of cancer 
patients. Until a few years ago, the search for DNA methylation biomarkers has mainly been focused 
on promoter-associated CpG islands, where methylation is in most cases inversely correlated to the 
transcriptional activity of the corresponding gene. However, also methylation of CpGs outside 
promoter regions should be investigated as potential biomarkers, given the increasing evidence on 
their involvement in cancer (§1.1.3) [113].  
 
DNA methylation biomarkers can be used in various clinical applications. For example, as changes in 
the DNA methylation pattern frequently occur early in tumorigenesis (§1.1.3), DNA methylation 
biomarkers can contribute to the detection of early-stage neoplasia [113]. A study by Palmisano et al. 
has demonstrated that aberrant DNA methylation of CDKN2A in smokers is detectable up to three 
years before the individuals are diagnosed with squamous cell lung carcinoma, and Scesnaite et al. 
showed that also never-smokers exposed to second-hand tobacco have a tendency of CDKN2A 
hypermethylation [113–115]. Besides early detection, DNA methylation biomarkers can also be used 
to characterize and classify cancers, as well as for prognosis prediction. One of the most 
quintessential examples hereof is the CpG island methylator phenotype (CIMP), described as the
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Box 3. Several statistical metrics can be used to evaluate biomarker performance [113, 116]. 
 
The performance of a biomarker can be evaluated by analyzing the test outcome in a population containing 
both individuals with and without the tested condition (e.g. the presence of cancer). As such, four groups of 
patients can be distinguished: cancer patients with a positive test (true positives; TP), cancer patients with a 
negative test (false negatives; FN), cancer-free patients with a positive test (false positives; FP) and cancer-free 
patients with a negative test (true negatives; TN). Using these four population parameters, following statistical 
metrics can be calculated (for calculations see Table 2):  
 
* The specificity or true negative rate is the percentage of cancer-free patients with a negative test. 
 
* The sensitivity or true positive rate or recall is the percentage of cancer patients with a  positive test.  
 
* The negative predictive value is the percentage of patients with a negative test result that is truly cancer-
free.  
 
* The positive predictive value or precision is the percentage of patients with a positive test result that truly 
has cancer. 
 
Other commonly used statistical tools are the accuracy or balanced accuracy (BAC; for imbalanced population 
cohorts) and the area under the Receiver Operating Characteristic (ROC) curve. This curve can be plotted as the 
sensitivity against 1-specificity, in which each point in the curve represents the fraction of cancer patients with 
a biomarker measurement above a specific threshold versus the corresponding fraction of cancer-free patients 
above the same threshold. The area under the ROC curve then represents the probability that a randomly 
chosen cancer patient is ranked as more likely to have cancer than a randomly chosen cancer-free patient. This 
value is a useful way to describe the performance of a biomarker with a continuous output variable, regardless 
of the threshold level. 
 
Table 2. Biomarkers can be evaluated by calculating several statistical metrics.  
 
condition 
 
 positive negative statistical metrics 
test 
outcome 
positive 
true positive false positive 
positive predictive value 
PPV 
TP FP = TP/(TP+FP) 
negative 
false negative true negative 
negative predictive value 
NPV 
FN TN = TN/(TN+FN) 
 
statistical 
metrics 
true positive rate 
TPR 
true negative rate               
TNR 
accuracy                              
ACC 
= TP/(TP+FN) = TN/(FP+TN) = (TP+TN)/(TP+FP+FN+TN) 
false negative rate 
FNR 
false positive rate                
FPR 
 
= FN/(TP+FN) = FP/(FP+TN) 
Note. Specificity is TNR; sensitivity or recall is TPR; precision is PPV. Balanced accuracy (BAC) is the arithmetic 
mean of sensitivity and specificity. 
 
aberrant and concordant hypermethylation of multiple promoter CpG islands, which can distinguish 
subgroups of colorectal cancer with different clinical, pathological and biological characteristics [113, 
117]. DNA methylation biomarkers can also help in predicting and monitoring a patient’s response to 
treatment, as illustrated by the DNA methylation markers ESR1 and ARH1 which are predictive 
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markers of response to tamoxifen treatment in breast cancer patients [113, 118]. Most of the studies 
so far mainly focused on promoter-associated CpG islands of single genes. However, it should be 
noted that apart from CIMP, also other panels of DNA methylation biomarkers have been described. 
In esophageal adenocarcinoma, methylation of four or more genes among APC, DAPK, CDH1, ESR1, 
MGMT, CDKN2A and TIMP3 was associated with higher risk for early tumor recurrence and poor 
survival when taken together as a panel, while none of the single genes was prognostic when used as 
a single marker [113, 119]. Additional examples of clinically implemented DNA methylation 
biomarkers are given in Figure 8.  
 
 
                                
Figure 8. DNA methylation biomarkers are used in many clinical applications. For the depicted markers, 
commercially available test have been developed and clinically implemented. Based on [120]. 
 
 DNA methylation as therapeutic target 1.1.6
 
Considering the crucial role of epigenetic alterations in cancer pathogenesis, there has been a 
growing interest in the utility of these changes in the development of strategies for cancer 
treatment. A plethora of epigenetic modulators of both DNA methylation and histone marks has 
been investigated and clinically implemented. The most important DNA methylation modulators are 
described in detail in the following sections. An overview of histone modulators is given in Box 4.  
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Box 4. Several classes of histone modulators have been developed and clinically implemented [121, 122]. 
 
An overview of the most important classes, subclassses and examples of histone modulators is given below. For 
detailed descriptions of their mechanisms of action and clinical trials using these drugs, the reader is referred 
to Nebbioso et al. and Juo et al. [121, 122].  
 
* histone deacetylase (HDAC) inhibitors 
  ° short-chain and aromatic fatty acids  
    valproic acid, phenylbutyrate, pivaloyloxymethyl butyrate 
  °  hydroxamic acids and derivatives  
  trichostatin A, pyroxamide, vorinostat, panobinostat, CHR-3996, tefinostat, pracinostat, 
 givinostat, belinostat, JHJ-26481585, dacinostat 
° benzamides   
  entinostat, mocetinostat, chidamide 
° cyclic peptides  
  trapoxin A and B, romidepsin, apicidin 
° sirtuin inhibitors 
    splitomicin, tenovins, AGK2, sirtinol, suramin, EX-257, salermide, UVI5008 
* HDAC activators 
° sirtuin activators 
    resveratrol 
* histone acetyl transferase (HAT) inhibitors 
° p300/CBP inhibitors 
    anacardic acid, garcinol, curcumin 
* HAT activators 
° p300 activators  
    N-(4- chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide 
* histone methyltransferase (HMT) inhibitors 
° lysine methyltransferase (KMT) G9a inhibitors  
    chaetocin, BIX-01294, UNC0224 
° EZH2 inhibitors  
    3-deazaneplanocin A 
° protein arginine methyltransferase (PRMT) inhibitors 
    AMI-1 
* histone demethylase (HDM) inhibitors 
  ° LSD1 inhibitors 
    tranylcypromine 
 
1.1.6.1 Nucleoside analogues  
 
The most archetypal examples of epigenetic cancer drugs are azacitidine (Vidaza) and decitabine 
(Dacogen). After their cellular uptake, these drugs are metabolized to 5-aza-2’-deoxycytidine-
triphosphate (azacytosine), which is then incorporated into replicating DNA, where it substitutes for 
the naturally occurring cytosine. Azacytosine-guanine dinucleotides are recognized by the DNMTs as 
natural substrate and the enzymes will initiate the methylation reaction by a nucleophilic attack. This 
results in the establishment of a covalent bond between the C6 of the cytosine pyrimidine ring and 
the enzyme. Normally, this bond is then resolved by β-elimination through the C5 atom of cytosine 
(§1.1.4), but with azacytosine, where the C5 is substituted by N, this reaction is blocked and the 
DNMT is trapped. As a consequence, active DNMTs are depleted after several cell cycles, leading to 
loss of DNA methylation [123]. As azacitidine also gets incorporated into RNA, it also causes 
ribosomal disassembly, defective tRNA function and inhibited protein synthesis. Azacitidine exhibits 
greater cytotoxicity during S-phase, supporting the greater importance of its DNA effects [121]. The 
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Food and Drug Administration (FDA) approved azacitidine and decitabine for the treatment of the 
leukemia predisposition disorder myelodysplastic syndrome [123]. Importantly, these drugs need to 
be administered at nanomolar concentrations, as they become cytotoxic at higher doses. More 
recently, low doses of azacitidine/decitabine have also been tested in the management of solid 
tumors, both as a single drug treatment and in combination therapy, especially with HDAC inhibitors. 
In adults with metastatic non-small cell lung cancer, tumor responses improved gradually and 
progressively over several months of treatment with low doses of azacitidine in combination with the 
HDAC inhibitor entinostat, and this effect was sustained even after cessation of epigenetic therapy 
[124]. Azacitidine is also used to prime solid tumors for response to subsequent cytotoxic therapy 
[124, 125]. For example, it was shown that azacitidine partially reverses platinum resistance in 
patients with ovarian cancer [125].  
 
Another nucleoside analogue is zebularine, which also inhibits cytidine deaminase, the enzyme 
responsible for inactivation of azacitidine and decitabine. Zebularine is more stable and less toxic 
compared to azacitidine and decitabine. This allows oral administration of the drug and simplifies 
continuous low-dose therapy. Importantly, this drug also shows a higher selectivity for tumor cells 
than azacitidine and decitabine [126]. Also of note is SGI-110, a derivative of decitabine with 
improved pharmacokinetics and metabolic stability, which results from a decreased degradation by 
cytidine deaminase [122]. 
 
1.1.6.2 Small molecule inhibitors 
 
In efforts to circumvent the toxicity and instability of nucleoside DNMT inhibitors, non-nucleoside 
small molecule inhibitors of DNMTs have been developed, such as hydralazine, procainamide, 
RG108, SGI-1027 and MG98.  
 
Hydralazine and procainamide are FDA approved drugs for the treatment of hypertension and 
cardiac arrhythmia, respectively. Procainamide specifically inhibits the maintenance 
methyltransferase activity of DNMT1, mainly by reducing the affinity of the enzyme for both DNA 
and SAM [127]. The demethylating action of hydralazine is still under investigation, but some 
evidence indicates that it binds to CpG-rich sequences and interferes with translocation of DNMTs 
along the DNA strand [121]. Although both compounds are considered weak DNA methylation 
inhibitors, a clinical trial on patients carrying solid tumors refractory to conventional therapy has 
demonstrated that hydralazine in combination with the HDAC inhibitor valproate causes DNA 
demethylation and overcomes chemotherapy resistance [127, 128]. Further pharmacological 
exploitation of these drugs might lead to the development of more potent DNA methylation 
inhibitors, as currently high levels of these drugs are needed to induce DNA demethylation [129].   
 
Small molecule DNMT inhibitors that block the active site of DNMTs also have been identified. Based 
on a three-dimensional model of the human DNMT1 catalytic domain, a small-molecule database 
was screened in silico in order to find candidate DNMT inhibitors. This led to the identification of 2-
(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid, later on renamed to RG108, 
which was predicted to strongly interact with the DNMT1 active site. In vitro work on HCT116 colon 
cancer cells further demonstrated that this compound efficiently blocked DNA methylation without 
the need to be incorporated into DNA and that the central carboxyl group of RG108 is responsible for 
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the specificity in the interaction between the inhibitor and the DNMT1 active site. These features 
make RG108 a promising DNMT inhibitor [130]. Another promising class of demethylating agents 
that inhibit DNMT activity represents synthetic small molecule inhibitors based on quinoline, a 
heterocyclic aromatic compound. Datta et al. have shown that one of these compounds, designated 
SGI-1027, effectively reactivates silenced tumor suppressor genes in colon cancer cells by 
demethylation of their respective CpG islands. SGI-1027 treatment also resulted in selective 
degradation of DNMT1 and exhibited minimal or no cytotoxic effect in rat hepatoma cells [131].  
 
Also antisense oligonucleotides (ASOs), synthetic nucleic acids that inhibit translation of specific 
messenger RNAs (mRNAs), or degrade them, by binding to a target region within the mRNA, are used 
to inhibit DNA methylation. The ASO MG98 specifically inhibits human DNMT1 mRNA, resulting in 
reduced DNMT1 protein levels and re-expression of silenced tumor suppressor genes. Clinical trials 
on patients with advanced solid tumors have demonstrated that MG98 treatment has antitumor 
activity and is generally well tolerated [132, 133].   
 
1.1.6.3 Natural compounds 
 
The DNMT inhibitory potency of naturally occurring molecules, such as psammaplin A and (–)-
Epigallocatechin-3-gallate (EGCG), have also been topic of investigation.  
 
Literature on the DNMT inhibitory effect of psammaplin A is controversial. Early studies indicated 
that this natural product isolated from marine sponges was an extremely potent inhibitor of both 
HDAC and DNMT, and showed cytotoxicity against human lung, ovarian, skin and colon cancer cell 
lines. Although more recent studies confirmed the antitumor activity of this compound, evidence of 
DNMT activity inhibition could not be demonstrated in these studies [134]. 
 
EGCG is a green tea polyphenol that has been shown to have antitumorigenic properties. 
Nandakumar et al. demonstrated that treatment of skin cancer cells with EGCG reduced the levels of 
DNA methylation and DNMT activity, resulting in re-expression of tumor suppressor genes. It also 
inhibited HDAC activity and increased levels of acetylated histones [135]. Additionally, also EGCG 
analogues have been developed. These molecules are currently being tested for different 
applications in cancer management [136]. 
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1.2 The quest for prognostic neuroblastoma markers 
 
In 1864, in a study on hyperplasia of the pineal and adrenal glands, Virchow described for the first 
time a child with an abdominal tumor which he denominated as glioma. Further examination of 
Marchand in 1891 showed histological similarities between tumors of the adrenal gland and the 
sympathetic nervous system [137]. Later on, in 1901, Pepper described a group of enigmatic adrenal 
sarcomas in infants associated with massive liver dissemination, of which the clinical and pathologic 
features closely resembled one another and a few years later, in 1907, Hutchison similarly reported 
on a separate group of adrenal sarcomas in older children with orbital and skeletal metastases [138, 
139]. In 1910, Wright pointed out that the adrenal tumors described by Pepper and Hutchison were 
mainly composed of an identical cell type, regardless their distinct patterns of spread. These cells had 
the same morphology as the cells from which the sympathetic nervous system and the medulla of 
the adrenal developed, and were regarded by embryologists as arising from migrated primitive nerve 
cells. Owing to their characteristic primitive neural cell origin, Wright collectively named these types 
of tumors ‘neuroblastoma’ [140, 141]. 
 
Today, neuroblastoma (NB) is appointed as a disease of the sympaticoadrenal lineage of the neural 
crest, a transient population of cells during embryonal development that arises at the border 
between the neural plate and the non-neural ectoderm (Figure 9 and Table 3). Precursors with the 
potential to form neural crest cells initially are contained within the dorsal portion of the neural tube. 
Subsequently, these premigratory neural crest cells emerge from the neural tube and start migrating 
along characteristic pathways to give rise to diverse and numerous derivatives. These migratory 
pathways are regionalized according to the original position of the neural crest cells along the neural 
axis, such that cells from a given axial level give rise to a characteristic array of progeny and follow 
distinct pathways from those arising at other axial levels (Table 3). For example, ventrally migrating 
trunk neural crest cells give rise to the peripheral nervous system (PNS) of the trunk, including the 
chain of the sympathetic ganglia and dorsal root ganglia, as well as chromaffin cells of the adrenal 
medulla. In addition to these neurons, these neural crest cells also generate glia of the peripheral 
ganglia, non-neural cells supporting and protecting neurons, including Schwann cells that ensheate 
and myelinate peripheral axons. Cessation of neural crest cell migration and subsequent 
neurogenesis in the developing peripheral nervous system (PNS) is not yet completely understood, 
but local environmental signals seem to critically control neural and glial cell fate. For example, bone 
morphogenetic proteins (BMPs) are essential for the development of the sympathetic nervous 
system. An interesting feature of the developing PNS is that migrating neural crest cells proliferate 
rapidly as they move. Even after exhibiting defined neural characteristics, some neural crest 
derivatives continue to divide. For example, in the developing sympathetic ganglia, neural-crest 
derived cells express neurotransmitters and other proteins characteristic of sympathetic neurons, 
but remain actively mitotic [142]. 
 
Clearly, the processes involved in the development of the sympathetic nervous system are very 
complex and alterations herein can initiate disease pathogenesis. Although the molecular aberrations 
that cause NB are not yet fully unraveled, it has been shown that these tumors develop from 
immature sympathetic nervous system cells, called neuroblasts. As such, NB can develop anywhere 
in this system, which contributes to the most important hallmark of this type of tumor: 
heterogeneity. The early reports of NB by Pepper and Hutchison, which today would have been 
 introduction 
- 29 - 
 
staged as MS and M respectively, perfectly illustrate this clinical heterogeneity. Stage MS and M 
tumors both represent metastatic disease, but where patients with stage M often show relentless 
progression, stage MS tumors usually regress spontaneously [143]. These extreme differences in 
disease course have triggered a quest for markers that allow prognosis prediction at the time of 
diagnosis, a still persisting effort with the ultimate goal to fine-tune the treatment protocol for each 
patient. 
 
 
 
Figure 9. The neural crest is a transient population of cells during embryonal development. At embryonic day 
17, the developing embryo consists of three primary germ layers (ectoderm, mesoderm and endoderm; top 
left). The notochord defines the body axis, i.e. the midline that divides the left and right side of the body, and is 
the site of the future vertebral column. The amniotic sac is filled with fluid and buffers the developing embryo 
from physical shock until the time of birth. The yolk sac will form part of the future digestive system. As the 
notochord develops, it signals the overlying ectoderm to start forming the spinal cord and brain, an event 
called neurulation (close-up views of the ectoderm at the right of the figure). Specifically, the ectoderm in the 
dorsal midline thickens into a neural plate, and then starts to fold inwards as a neural groove. This groove 
deepens until a hollow neural tube is pinched off into the body (at embryonic day 22). Complete closure of the 
neural tube occurs by the end of week 4. Neural crest cells originate from ectodermal cells on the lateral ridges 
of the neural plate, and are pulled into the body along with the invaginating neural tube. According to the 
original position of the neural crest cells along the neural axis, they will give rise to specific body structures 
(Table 3). Based on [144]. 
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Table 3. Different populations of neural crest cells arising along the neural axis give rise to distinct cell types. 
neural crest cell population derivatives 
cranial 
cranial sensory ganglia 
parasympathetic ciliary ganglia 
cartilaginous elements of the facial skeleton 
vagal enteric nervous system 
trunk 
melanocytes 
sympathetic ganglia 
dorsal root ganglia 
chromaffin cells of the adrenal medulla 
glia 
Schwann cells 
lumbosacral enteric nervous system 
Note. Neuroblastoma is appointed as a disease of the sympaticoadrenal lineage of the neural crest, a specific 
subset of trunk neural crest cells. Based on [142]. 
 
The prognostic value of a great diversity of parameters has already been investigated, including the 
primary tumor site and volume [145, 146], the metastatic site [147], the ratio of the amount of the 
catecholamine metabolite markers vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine 
[148, 149], the serum neuron-specific enolase (NSE) [150], ferritin [149, 151], lactate dehydrogenase 
(LDH) [149, 151], chromogranin A [152] and neuropeptide Y level [153], and many others. However, 
the best studied and widely used prognostic factors are the age of the patient at diagnosis, tumor 
histology and stage, MYCN oncogene amplification, DNA index and specific chromosome gains and 
losses. Additionally, during the last decades, the development of high-resolution and high-
throughput (epi)genome and transcriptome profiling methods has provoked the advent of new 
molecular prognostic markers, such as mRNA and microRNA (miRNA) signatures, as well as DNA 
methylation biomarkers. Widely used prognostic parameters have been combined into a 
pretreatment risk classification system [154].  
 
 Widely used prognostic markers  1.2.1
 
1.2.1.1 Age of the patient at diagnosis 
 
One of the most remarkable characteristics of NB is its age-specific incidence. According to the 
Surveillance, Epidemiology, and End Results (SEER) Program 1975-2012 of the National Cancer 
Institute, the incidence rate of NB is 10.1 per million children under 15 years of age, but this rate 
increases to 20.5 per million in the 1-4 years of age group and even to 49.2 per million during infancy 
(grouped category data of NB and ganglioneuroblastoma (GNB), a more differentiated variant of NB 
(§1.2.1.2)) [155]. Although NB is one of the most common cancers of infancy, it is also diagnosed in 
adolescents and adults. However, these cover less than 10% of all cases, as 90% is diagnosed by the 
age of 6 years (median age of diagnosis is approximately 20 months) [156]. 
 
It has long been observed that NB prognosis varies markedly with the age of the patient at diagnosis. 
More than 40 years ago, Breslow and McCann [157] found that survival probabilities (Box 5) 
decreased with increasing age of the patient during the first two years and that the age effect 
tapered off thereafter. These results suggest that days of age should be used for risk stratification as 
a continuous variable, but as this is not clinically practical to tailor therapy, a convenient age cutoff of 
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12 months was applied. Hereby, patients older than 12 months receive more therapy than younger 
patients [158]. In 2003, Schmidt et al. [159] showed that the survival rates of some patients slightly 
older than 12 months (between 12 and 18 months) were significantly better than those of older 
patients, although they received the same therapy. Two years later, in order to maximally lower the 
burden of therapy (and accompanying late-term side effects) for these patients, London et al. 
retrospectively analyzed the influence of age on outcome in 3,666 patients to identify a better, 
statistically optimal age cutoff. Their findings indicate that the optimal age cutoff was between 15 
and 19 months [158]. 
 
Box 5. Survival probabilities can be estimated using the Kaplan-Meier method [160].  
 
Kaplan-Meier curves and estimates of survival data are frequently used to analyze survival, as this method can 
be performed on patient data with differing survival times, i.e. times-to-event, as well as censored data. The 
time-to-event variable can be described as the clinical-course duration or follow-up time of a patient and the 
event may be any event of interest, for example death (when studying overall survival (OS)) or 
progression/relapse (when studying event-free survival (EFS)) of a specific disease. Survival studies are often 
performed to determine whether different patient groups, stratified according to a nominal variable of interest 
(for example age group of the patient), show statistically different survival rates. In such studies, each patient is 
characterized by three parameters: its clinical-course duration (time-to-event), its event status at the end of its 
clinical-course duration (i.e. event occurred or patient is censored), and its study group. Using these 
parameters, Kaplan-Meier curves can be constructed, as exemplified in Figure 10. Kaplan-Meier curves exist of 
horizontal lines, representing clinical-course duration intervals, and vertical lines, showing changes in the 
cumulative survival probability as the curve advances. Each event in the data set ends an interval and begins 
another interval. Censored patients do not demarcate intervals and their times-to-event are indicated with 
ticks. Importantly, these patients strongly effect survival rates and for this reason, it is recommended to 
indicate patient numbers at risk below the curves. The cumulative survival probability for an interval defines 
the probability of survival at the beginning and throughout the interval, and is calculated by multiplying the 
interval survival rates up to that interval. Kaplan-Meier curves of multiple study groups can be statistically 
compared by the log-rank test or by calculating Cox proportional hazards. The log-rank test calculates the chi-
square for each event time for each group and sums the results. The summed results for each group are added 
to derive the ultimate chi-square to compare the full curves of each group. Cox proportional hazards show the 
increased rate of having an event in one curve versus the other [160]. 
 
 
Figure 10. Kaplan-Meier curves are used to analyze survival data. Horizontal lines represent clinical-course 
duration intervals. Vertical lines represent changes in the cumulative survival probability. Censored patients are 
indicated with ticks and patient numbers at risk are shown below the Kaplan-Meier curves. Based on [160]. 
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1.2.1.2 Tumor histology and differentiation grade 
 
Tumors that belong to the heterogeneous group of neuroblastic tumors, such as NB, are typified by 
different morphologic characteristics. During the past, these differences in histological appearance 
have led to the development of several histopathologic grading systems that showed to be of 
prognostic importance [161]. The initial grading systems, proposed by Beckwith and Martin [162], 
Mäkinen [163], and Hughes [164], were based on the degree of differentiation of the neuroblasts 
into ganglion cells and Schwann cells (§1.2) by evaluating histologic signs of maturation. It was 
generally acknowledged that differentiated tumors had a more favorable prognosis than 
undifferentiated tumors. Shimada et al. took a new approach with their age-linked classification and 
divided neuroblastic tumors into Schwannian stroma-rich and -poor tumors. Further subdivisions 
depended on the grade of differentiation and nuclear morphology of the neuroblasts. The latter was 
quantified in the mitosis-karyorrhexis index (MKI), which reflected the percentage of neuroblasts in 
mitosis (demonstrating cell proliferation) and in the process of karyorrhexis (i.e. nuclear 
fragmentation, demonstrating cell death) [161, 165, 166]. Also Joshi et al. proposed an age-linked 
grading system based on tumor calcification and the mitotic rate, later on replaced by the MKI [167, 
168]. In 1994, the International Neuroblastoma Pathology Committee (INPC) was formed, which 
aimed at testing the prognostic significance of the different morphologic features and their 
combination. Based on detailed definitions of these features and statistical analyses of pathology 
review data, the International Neuroblastoma Pathology Classification was proposed, which largely 
adopted the Shimada classification (Table 4). In this classification, NB tumors are defined as 
neuroblastic Schwannian stroma-poor tumors (i.e. the proportion of tumor tissue with stroma-rich 
histology does not exceed 50%) and are further categorized in undifferentiated, poorly differentiated 
and differentiating subtypes. In the undifferentiated subtype (Figure 11A), the tumor tissue is 
composed of undifferentiated neuroblasts without identifiable neuropil or Homer Wright rosettes 
(Box 6). In order to establish the diagnosis, supplementary tests such as immunohistochemistry, 
electron microscopy, and/or molecular/cytogenetic analyses are usually required. Diagnosis of the 
poorly differentiated subtype (Figure 11B) is relatively easy, because of the presence of varying 
amount of neuropil and/or rosettes. Most of the tumor cells in this subtype are undifferentiated: less 
than 5% of the population has morphological evidence of differentiation. Tumors of the 
differentiating subtype (Figure 11C) usually have abundant neuropil. At least 5% of the tumor cells 
are differentiating neuroblasts, which are characterized by synchronous differentiation of the 
nucleus (enlarged, eccentrically located with vesicular chromatin pattern, and a single prominent 
nucleolus) and of the cytoplasm (eosinophilic/amphophilic (having affinity for both acid and basic 
dyes) with a diameter two or more times larger than the nucleus) [169]. 
 
1.2.1.3 Tumor stage 
 
The practice of dividing NB tumors into stages arose from the fact that patient survival rates differed 
between patients with localized disease and patients in which the disease had extended beyond the 
site of origin. As a result, multiple NB tumor staging systems have been proposed in the past to aid in 
estimating prognosis [170, 171]. These include that of James [172], Pinkel [173, 174], Cohen [175], 
and Thurman and Donaldson [176], which are based on the extent of the disease, the surgical 
resectability, the pattern of metastatic spread and, in some cases, the degree of histologic 
differentiation. The first internationally accepted staging schema though, was that of Evans (and the
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Table 4. The International Neuroblastoma Pathology Classification (Shimada System) stratifies 
neuroblastomas into favorable and unfavorable tumors, using the age of the patient and tumor 
differentiation grade.   
International Neuroblastoma Pathology Classification 
Shimada 
Classification 
NB  
(Schwannian 
stroma-poor)
 
favorable 
< 1.5 years 
poorly differentiated or 
differentiating and low or 
intermediate MKI tumor 
stroma-poor 
(favorable) 
1.5-5 years differentiating and low MKI tumor 
unfavorable 
< 1.5 years 
undifferentiated tumor
 
high MKI tumor 
stroma-poor 
(unfavorable) 1.5-5 years 
un- or poorly differentiated tumor 
intermediate or high MKI tumor 
≥ 5 years all tumors 
GNB, intermixed 
(Schwannian stroma-rich) 
stroma-rich, 
intermixed 
(favorable) 
GN  
(Schwannian stroma-dominant) 
maturing 
well differentiated 
(favorable) 
mature 
GN  
(favorable) 
GNB, nodular  
(composite Schwannian stroma-rich/stroma-dominant and stroma-poor) 
stroma-rich, nodular 
(unfavorable) 
Note. GN: ganglioneuroma; GNB: ganglioneuroblastoma; MKI: mitosis-karyorrhexis index; NB: neuroblastoma 
[161]. 
 
Box 6. The presence or absence of Homer Wright rosettes is used to determine the neuroblastoma 
differentiation grade. 
 
Rosettes consist of a halo or spoke-wheel arrangement of cells surrounding a central lumen or hub (Figure 
11B). Several types of rosettes are described in pathology literature. Typically, in NB the halo is formed by 
neuroblasts which enclose a central lumen or hub with a fibrillary collection of primitive neurites (neuropil). 
Although this type of rosettes was first described by Wright in NB, it also emerges in medulloblastoma, 
primitive neuroectodermal tumor (PNET) and pineoblastoma. The mechanism for the formation of the 
characteristic rosette pattern is not completely understood. The cell populations exhibiting neural 
differentiation are believed to secrete glycoproteins and glycolipids, which mediate cell-to-cell recognition and 
adhesion. One hypothesis is that these sticky cell surface markers cause the developing cell bodies to cluster or 
aggregate and their primitive neurites to tangle. As the cells grow, the neurite tangle remains centrally located 
and the cell bodies are squeezed to the periphery, explaining the rosette pattern [177].  
 
Children’s Cancer Study Group (CCSG)) [178, 179]. This staging system was based on lymph node 
involvement and used the anatomic midline of the body as a reference to describe the extent of the 
disease. Evans et al. also devised a special stage IV (IV-S) category, as it was recognized that a certain 
constellation of ominous findings did not have the grave prognosis usually predicted for other 
cancers under such circumstances (stage IV). More precisely, it was restricted to patients who would 
otherwise have been stage I or II (with localized primary tumors), but who had remote disease 
confined to liver, skin or bone marrow, and any combination of these, without involvement of the 
skeleton. Over the following years, two other major staging systems evolved in the management of 
NB: the tumor-node-metastases (TNM) system from the International Union against Cancer (UICC) 
and the American Joint Committee on Cancer (AJCC) [180, 181], and the system used by the St Jude 
Children’s Research Hospital (SJCRH) and the Pediatric Oncology Group (POG) [182, 183]. 
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Additionally, modifications of these systems have been proposed by the Italian Cooperative Working 
Group [184] and the Malignant Tumor Committee of the Japanese Society of Pediatric Surgeons [171, 
185]. 
 
 
Figure 11. Neuroblastoma tumors are categorized into undifferentiated, poorly differentiated and 
differentiating subtypes. A. Undifferentiated subtype. B. Poorly differentiated subtype. C. Differentiating 
subtype. Adapted from [169].  
 
Although each of these staging systems has its strengths, the plethora of diversiform systems made it 
difficult to compare the results of clinical trials and biological studies from different groups and 
countries. To aid in the development of a consensus system, a meeting was held in 1986 to address 
the problem of standardizing definitions for staging in NB. The resulting International Neuroblastoma 
Staging System (INSS) was published in 1988 [185] and revised (Table 5) in 1993 [186]. However, a 
major drawback of this system is that staging is based on the degree of surgical resection of the 
tumor and lymph node involvement, criteria that highly depend on the thoroughness and expertise 
of the physician. In 2009, the International Neuroblastoma Risk Group (INRG) Task Force [154] 
therefore proposed a new system, the INRG Staging System (INRGSS; Table 6), based on radiological 
risk factors for surgery, i.e. imaging characteristics (determined via computed tomography (CT), 
magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (123I-mIBG) scintigraphy 
and/or technetium-99m-methylene diphosphonate (99mTc-MDP) bone scintigraphy (Box 9)) which are 
associated with an increased risk of surgical complications. Staging based on these so-called image-
defined risk factors (IDRFs) is not only more robust and reproducible than one based on surgical 
findings, but also allows pretreatment risk stratification [143]. 
A. B. 
C. 
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Table 5. The International Neuroblastoma Staging System (INSS) stratifies neuroblastoma tumors into 
several tumor stages, based on the degree of surgical tumor resection and lymph node involvement. 
stage description 
1  
localized tumor with complete gross excision, with or without microscopic residual disease; 
representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to 
and removed with the primary tumor may be positive) 
2A 
localized tumor with incomplete gross excision; representative ipsilateral non-adherent lymph 
nodes negative for tumor microscopically 
2B 
localized tumor with or without complete gross excision, with ipsilateral non-adherent lymph 
nodes positive for tumor; enlarged contralateral lymph nodes must be negative microscopically 
3 
unresectable unilateral tumor infiltrating across the midline*, with or without regional lymph 
node involvement; or localized unilateral tumor with contralateral regional lymph node 
involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph 
node involvement 
4 
any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin 
and/or other organs (except as defined for stage 4S) 
4S 
localized primary tumor (as defined for stage 1, 2A or 2B), with dissemination limited to skin, 
liver, and/or bone marrow** (limited to infants < 12 months of age) 
Note. Multifocal primary tumors (for example bilateral adrenal primary tumors) should be staged according to 
the greatest extent of disease, as defined above, followed by subscript letter M. *The midline is defined as the 
vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the 
opposite side of the vertebral column. **Marrow involvement in stage 4S should be minimal, that is, < 10% of 
total nucleated cells identified as malignant on bone marrow biopsy or on marrow aspirate. More extensive 
marrow involvement would be considered to be stage 4. The MIBG scan (if performed) should be negative in 
the marrow [186]. 
 
Table 6. The International Neuroblastoma Risk Group Staging System (INRGSS) stratifies neuroblastoma 
tumors into several tumor stages, based on image-defined risk factors. 
stage description 
L1  
localized tumor not involving vital structures as defined by the list of IDRFs and confined to one 
body compartment 
L2 locoregional tumor with presence of one or more IDRFs 
M distant metastatic disease (except stage MS) 
MS 
metastatic disease in children < 18 months of age, with metastases confined to skin, liver, 
and/or bone marrow 
Note. Detailed criteria and list of IDRFs in Box 7 and Box 8, respectively. Patients with multifocal primary 
tumors should be staged according to the greatest extent of disease as defined in the table. IDRFs: image-
defined risk factors [143]. 
 
Box 7. The International Neuroblastoma Risk Group Staging System (INRGSS) stratifies neuroblastoma 
tumors into several tumor stages, based on image-defined risk factors [143]. 
 
Stage L1 tumors are localized tumors that do not involve vital structures as defined by the list of IDRFs. The 
tumor must be confined within one body compartment, neck, chest, abdomen, or pelvis. The isolated finding of 
intraspinal tumor extension that does not fulfill the criteria for an IDRF is consistent with stage L1. 
 
Stage L2 tumors are locoregional tumors with one or more IDRFs. The tumor may be ipsilaterally continuous 
within body compartments (i.e., a left-sided abdominal tumor with left-sided chest involvement should be 
considered stage L2). However, a clearly left-sided abdominal tumor with right-sided chest (or vice versa) 
involvement is defined as metastatic disease. 
 
Stage M is defined as distant metastatic disease (i.e., not contiguous with the primary tumor) except as defined 
for MS. Non-regional (distant) lymph node involvement is metastatic disease. However, an upper abdominal 
tumor with enlarged lower mediastinal nodes or a pelvic tumor with inguinal lymph node involvement is 
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considered locoregional disease. Ascites and a pleural effusion, even with malignant cells, do not constitute 
metastatic disease unless they are remote from the body compartment of the primary tumor.  
 
Stage MS is metastatic disease in patient younger than 18 months (547 days) with metastases confined to skin, 
liver, and/or bone marrow. Bone marrow involvement should be limited to less than 10% of total nucleated 
cells on smears or biopsy. MIBG scintigraphy must be negative in bone and bone marrow. Provided there is 
MIBG uptake in the primary tumor, bone scans are not required. The primary tumor can be L1 or L2 and there 
is no restriction regarding crossing or infiltration of the midline. 
 
 
Box 8. The International Neuroblastoma Risk Group Staging System (INRGSS) makes use of a list of image-
defined risk factors (IDRFs) to determine the neuroblastoma tumor stage [143]. 
 
ipsilateral tumor extension within two body compartments    
 neck-chest, chest-abdomen, abdomen-pelvis 
 
neck  
 tumor encasing carotid and/or vertebral artery and/or internal jugular vein 
 tumor extending to base of skull 
 tumor compressing the trachea 
 
cervico-thoracic junction 
 tumor encasing brachial plexus roots 
 tumor encasing subclavian vessels and/or vertebral and/or carotid artery 
 tumor compressing the trachea 
 
thorax  
 tumor encasing the aorta and/or major branches 
 tumor compressing the trachea and/or principal bronchi 
 lower mediastinal tumor, infiltrating the costo-vertebral junction between T9 and T12 
 
thoraco-abdominal  
 tumor encasing the aorta and/or vena cava 
 
abdomen/pelvis  
 tumor infiltrating the porta hepatis and/or the hepatoduodenal ligament 
 tumor encasing braches of the superior mesenteric artery at the mesenteric root 
 tumor encasing the origin of the coeliac axis, and/or of the superior mesenteric artery 
 tumor invading one or both renal pedicles 
 tumor encasing the aorta and/or vena cava 
 tumor encasing the iliac vessels 
 pelvic tumor crossing the sciatic notch 
 
intraspinal tumor extension  
 whatever the location provided that more than one third of the spinal canal in the axial plane is invaded 
 and/or the perimedullary leptomeningeal spaces are not visible and/or the spinal cord signal is abnormal 
 
infiltration of adjacent organs/structures  
 pericardium, diaphragm, kidney, liver, duodeno-pancreatic block, and mesentery 
 
conditions to be recorded, but not considered IDRFs 
 multifocal primary tumors 
 pleural effusion, with or without malignant cells 
 ascites, with or without malignant cells 
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Box 9. Radiological imaging is used to evaluate the presence or absence of image-defined risk factors. 
 
Computed tomography (CT) and/or magnetic resonance imaging (MRI) with three-dimensional measurements 
and of sufficient quality to address image-defined risk factors (IDRFs) is mandatory for imaging the primary 
tumor. The presence or absence of each individual IDRF should be evaluated and recorded (Box 8). When 
possible, metastatic sites should also be measured by CT and/or MRI, as this information may be needed to 
evaluate treatment response [143]. 
 
The iodine-123 meta-iodobenzylguanidine (
123
I-mIBG) scintigraphy imaging procedure is essential for the 
detection of metastases and is based on the intravenous administration of the radiopharmaceutical 
123
I-mIBG, 
followed by recording the distribution of the radioactivity using a camera, here a device used to image gamma 
radiation emitting radioisotopes. Being an analogue of noradrenalin, 
123
I-mIBG enters cells expressing the 
noradrenalin transporter and is stored in neurosecretory granules, which results in a concentration of 
radioactivity in these cells. Therefore, 
123
I-mIBG scintigraphy is useful to image tumors of neuro-endocrine 
origin, particularly those of the neuro-ectodermal (sympatho-adrenal) system, such as NB [187]. Occasionally, 
false-positive readings may occur because of uptake in mature ganglioneuroma or other neuro-endocrine 
tumors, or because of physiological uptake that may be mistaken for tumor in the adrenal gland, salivary gland, 
nasopharynx, brown fat or excretion through renal pelvis and bladder. False-negative scans may be observed in 
approximately 10% of NB tumors that do not concentrate 
123
I-mIBG, owing to low expression of the 
noradrenalin transporter or owing to blood-brain barrier or large areas of scar or necrosis. In addition, very 
small amounts of bone marrow tumor will often not be detected, and therefore 
123
I-mIBG scintigraphy must be 
supplemented with bilateral bone marrow biopsy [188]. 
 
Technetium-99m-methylene diphosphonate (
99m
Tc-MDP) bone scintigraphy is used to trace metastatic NB in the 
skeleton. The radiopharmaceutical 
99m
Tc-MDP is a marker of bone perfusion and turnover, as it is adsorbed to 
the crystalline structure of hydroxyapatite, the mineral component of bone built of crystals containing mainly 
calcium and phosphate. Therefore, visualization of tumor lesions in the bone using 
99m
Tc-MDP and gamma 
radiation imaging is possible, as the presence of the tumor in the bone causes changes in the bone remodelling 
activity [189]. 
99m
Tc-MDP bone scintigraphy is only required when 
123
I-mIBG positivity of the primary tumor 
cannot be confirmed [143]. 
 
1.2.1.4 MYCN amplification 
 
Double minutes (DMs) and homogeneously staining regions (HSRs) are karyotypic abnormalities 
frequently seen in tumor cells and point towards amplification of cellular genes (Box 10). In this way, 
an increase in gene dosage is caused and amplification of proto-oncogenes leads to activation of 
their oncogenic potential [190]. In 1983, upon the discovery of amplification of MYC (the human V-
Myc Avian Myelocytomatosis Viral Oncogene Homolog) in colon carcinoma, Schwab et al. 
demonstrated that NB tumors showed cytogenetic evidence for amplification of a DNA domain that 
exhibited homology to MYC [191]. One year later, the locus of this gene, designated as the V-Myc 
Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN), was mapped to 
the short arm of chromosome 2 (2p24). MYCN amplification in NB occurs in approximately 20-30% 
and copy numbers range from 10 to more than 500, but 50 to 100 copies are generally observed. 
Lower numbers are indicated as MYCN copy gain [190]. Normally, MYCN is only expressed during 
embryogenesis in pre-B cells, kidney, forebrain, hindbrain and intestine, with the highest expression 
in the developing brain. After embryonic development, the transcription factor is downregulated and 
in adult tissues it is no longer significantly expressed. The essential developmental role of MYCN is 
underscored by embryonic lethality of MYCN-null mice [192]. Additionally, it has been shown that 
enhanced expression of MYCN is a factor in tumorigenic cell conversion and that MYCN has multiple 
direct and indirect targets, including other important players in the NB pathogenesis such as ALK 
[193–195]. More recent mice experiments signify MYCN as an oncogenic driver gene in NB [196].  
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Box 10. Several technologies can be used to assess DNA gains and losses.   
 
Frequently applied technologies in NB molecular diagnostics are interphase fluorescence in situ hybridization (I-
FISH), PCR, array comparative genomic hybridization (aCGH) and multiplex ligation-dependent probe 
amplification (MLPA) [197].  
 
The MYCN amplification status is frequently determined via I-FISH, using a fluorophore-labeled probe in 2p24, 
and presents as extrachromosomal double minutes (DMs) or intrachromosomal homogeneously staining 
regions (HSRs; Figure 12) [198]. Usually, two color I-FISH is used, so that the MYCN signal can be compared with 
that of a reference probe located on chromosome 2q [197]. Other detection technologies are qPCR [199], and 
comparative genomic hybridization (CGH). For CGH, test DNA and normal reference DNA are hybridized 
simultaneously to normal chromosome spreads. As the hybridization is detected with two different 
fluorochromes, regions of gain or loss of DNA sequences are seen as changes in the ratio of the intensities of 
the two fluorophores along the target chromosomes [200]. Later on, these chromosome spreads were replaced 
by arrayed oligonucleotides, allowing fast and high-resolution measurements of DNA copy number changes. 
Furthermore, a NB-specific PCR-based MLPA kit was developed to analyze the prognostic impact of certain 
genomic changes in NB [201, 202].  
 
 
 
Figure 12. Fluorescence in situ hybridization of neuroblastoma cells depicts MYCN amplification as double 
minutes or intrachromosomal homogeneously staining regions. DMs: double minutes; HSRs: homogeneously 
staining regions. Adapted from [198]. 
 
Soon after its discovery, it was shown that MYCN amplification correlates with advanced disease 
stage and is associated with rapid progression and worse prognosis [203, 204]. Given its pronounced 
effect on survival rates, MYCN amplification became a key determinant in risk estimation and 
therapy stratification [154]. Also the mRNA and protein levels were tested on their prognostic 
significance, as it was noticed that tumors without MYCN amplification can still be characterized by 
high MYCN expression. Though, in literature controversy exists whether these factors have 
prognostic value or not [205–207]. Of note, in the absence of MYCN amplification, high-stage NB 
tumors frequently show high expression of MYC, and activated MYC signaling is associated with poor 
outcome [208, 209].  
 
1.2.1.5 Chromosome aberrations 
 
1.2.1.5.1 DNA hyperdiploidy 
 
Next to amplification of MYCN (§1.2.1.4), NB tumors often show a hyperdiploid chromosomal 
constitution. This means that the tumor cells gained extra chromosomal copies resulting in a higher 
DNA content (triploid, tetraploid,…) compared to normal cells (diploid). The ploidy status is clearly 
associated with the age of the patient at diagnosis and MYCN copy number. By flow cytometric 
determination of the DNA index, George et al. showed that the frequency of hyperdiploid tumors 
was the highest in infants and that a diploid DNA content was associated with MYCN amplification in 
children younger than 24 months [210]. It has been shown that a diploid DNA index and MYCN 
DMs HSRs 
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amplification confer a very high risk of treatment failure in infants with disseminated NB, while 
hyperdiploidy with non-amplified MYCN is associated with a very favorable outcome in infants 
younger than 18 months, even if the disease is widely disseminated at diagnosis. In older children, 
DNA ploidy measurements have no prognostic value [210]. 
 
1.2.1.5.2 Numerical and segmental chromosome aberrations 
 
Thoroughly screening the entire genome for DNA copy number gains and losses only became 
possible with the advent of comparative genomic hybridization (CGH; Box 10). NB tumors are 
typically characterized by gains and losses of various chromosomes and chromosome parts, coined 
numerical (NCAs) and segmental chromosomal aberrations (SCAs), respectively. Based on CGH data 
of 231 primary NB tumors, Vandesompele et al. demonstrated the existence of three clinicogenetic 
subgroups with distinct genomic aberration patterns and clinical variables. The first subgroup 
(subtype 1) represents predominantly near-triploid low-stage tumors with NCAs and favorable 
histology from infants with excellent outcome. The other two subgroups (subtype 2A and 2B) mainly 
contain near-diploid/tetraploid high-stage tumors with SCAs and unfavorable histology. Typically, 
subtype 2B is featured by MYCN amplification and 1p deletions (§1.2.1.5.2.1), while most of the 
tumors of subtype 2A have non-amplified MYCN and 11q loss (§1.2.1.5.2.2). Importantly, it was 
further shown that OS probabilities are worse for patients with subtype 2A or B tumors (with SCAs) 
compared to patients with subtype 1 tumors (without SCAs) [211]. Later on, several other studies 
confirmed that a genomic profile characterized by SCAs is associated with a higher risk of relapse 
[212–214]. In the study of Schleiermacher et al. analyses were focused on tumors of infants with 
MYCN non-amplified localized unresectable/disseminated NB, in order to determine whether 
profiling of SCAs is useful for therapeutic stratification in this specific patient group. As this study 
clearly showed that the presence of SCAs is associated with worse progression-free survival, it was 
decided to use SCA profiling results for therapy stratification in the SIOPEN Low and Intermediate 
Neuroblastoma European Study (LINES), in an attempt to lower treatment burden in this patient 
group [214]. 
 
1.2.1.5.2.1 Chromosome 1p 
 
One of the first discovered SCAs in NB is deletion of chromosome 1p [215]. In search of tumor 
suppressor genes, loss of heterozygosity (LOH) studies have mapped the smallest region of 
overlapping deletions (SRO) between tumors to 1p36 [216]. It occurs in approximately 25% of the 
cases and is associated with other adverse prognostic factors (age 12 months or older, INSS stage 4, 
MYCN amplification, unfavorable histology and diploidy). Attiyeh et al. showed that 1p36 LOH is 
highly associated with poor outcome and is independently predictive of worse EFS in patients 
without MYCN amplification [217].  
 
1.2.1.5.2.2 Chromosome 11q 
 
LOH of chromosome band 11q23 is detected in about 34% of NB tumors. These tumors are 
characterized by LOH of the entire chromosome 11 or by LOH of 11q with retention of 11p material 
(unbalanced 11q LOH). 11q23 LOH primarily occurs in tumors without MYCN amplification and 
chromosome 1p deletion, and is associated with the presence of INSS stage 4 and unfavorable 
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histology, as well as with the favorable prognostic factor of hyperdiploidy [217]. Of note, this 
aberration frequently appears with concurrent loss of 3p and gain of 17q [218]. Survival analyses 
indicate that 11q23 LOH is linked with a decreased probability of event-free survival (EFS). In patients 
without MYCN amplification, unbalanced 11q LOH leads to a decrease in both EFS and overall 
survival (OS) [217].  
 
1.2.1.5.2.3  Chromosome 17q 
 
Gain of material from chromosome 17 is the most frequent genetic abnormality of NB and may 
consist of an entire chromosome 17 or only the distal segment of 17q (17q21-qter; in approximately 
54% of NB tumors). The principal mechanism underlying gain of 17q is an unbalanced translocation 
with a variety of partner chromosomes (e.g. 1p). Gain of 17q is strongly associated with INSS stage 4, 
age of 12 months or more at diagnosis, 1p deletion, amplification of MYCN and diploidy or 
tetraploidy [219]. Vandesompele et al. have shown that patients with tumors with a normal 
chromosome 17 status (in conjunction with other defects) or with a 17q gain have a worse prognosis 
compared to patients whose tumors bear whole chromosome 17 gain [211]. 
 
 mRNA and miRNA-based prognostic markers 1.2.2
 
More recently, tumor mRNA expression profiling by microarray and qPCR analyses identified single 
gene prognostic markers (e.g. NTRK1 [220]), as well as prognostic multimarker mRNA signatures. For 
example, Oberthuer et al. designed a customized oligonucleotide microarray covering a high 
percentage of transcripts previously related to NB tumor behavior to profile 251 tumors, which 
allowed them to construct a prognostic 144-gene signature [221]. Vermeulen et al. developed a qPCR 
assay for 59 prognostic genes, identified by re-analysis of previously published studies, and showed 
that this signature is an accurate, independent predictor of outcome by profiling 579 NB tumors 
[222]. Additionally, also miRNAs, i.e. non-coding RNAs regulating mRNA expression, have been 
source of prognostic biomarker research and several miRNA-based signatures have been proposed 
[223, 224]. Importantly, these RNA-based prognostic signatures require independent validation and 
performance evaluation in prospective studies before they can be introduced into clinical settings.  
 
 DNA methylation-based prognostic markers 1.2.3
 
An overview of DNA methylation-based prognostic markers in NB is given in the following review 
paper, which summarizes the most important findings up until a few years ago.  
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Abstract 
 
Neuroblastoma (NB) is a childhood tumor originating from sympathetic nervous system cells. 
Although recently new insights into genes involved in NB have emerged, the molecular basis of NB 
development and progression still remains poorly understood. The best-characterized genetic 
alterations include amplification of the proto-oncogene MYCN, ALK activating mutations or 
amplification, gain of chromosome arm 17q and losses of 1p, 3p and 11q. Epigenetic alterations have 
been described as well: caspase 8 (CASP8) and RAS association domain family 1 isoform A (RASSF1A) 
DNA methylation are important events for the development and progression of NB. In total, about 75 
genes are described as epigenetically affected in NB cell lines and/or NB primary samples. These 
epigenetic alterations were either found using a candidate gene approach or based on the analysis of 
genome-wide screening techniques. This review gives an extensive overview of all epigenetic 
changes described in NB as of today, with a main focus on both prognostic use and the potential of 
genome-wide techniques to find epigenetic prognostic biomarkers in NB. We summarize the key 
findings so far and the state-of-the-art of the upcoming methods at a unique time frame in the 
transition towards combined genome-wide chromatin immunoprecipitation (ChIP) and DNA 
sequencing techniques. 
 
Keywords: epigenetics, apoptosis, DNA methylation, histone modifications, chromatin modification, 
neuroblastoma, review 
 
 
Introduction and background 
 
Neuroblastoma (NB) is a childhood tumor 
originating from sympathetic nervous system 
cells. The molecular basis of NB development 
and progression is still poorly understood. The 
best-characterized genetic alterations include 
amplification of the proto-oncogene MYCN, 
amplification and mutation of the ALK gene, gain 
of chromosome arm 17q and losses of 1p, 3p 
and 11q. Classical risk factors include the age at 
diagnosis, MYCN amplification status and stage 
of the disease. The last decade, DNA methylation 
research has been conducted in NB, revealing 
that silencing of caspase 8 (CASP8) and RAS 
association domain family 1 isoform A (RASSF1A) 
are important in the development and 
progression of the disease. Both genes are often 
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found to be methylated in primary NB samples 
and the methylation status of these genes is 
significantly associated with survival.  
The use of genome-wide screening techniques, 
such as re-expression analysis after treatment 
with 5-aza-2'-deoxycytidine (DAC), promoter 
assays after affinity-based capture (for instance 
using a 5-methylcytidine antibody), methylation 
microarrays after bisulfite treatment, and next-
generation techniques, has led to an immense 
increase in both throughput and genome 
coverage. In NB, as of today, about 75 different 
DNA methylation biomarkers are described in 
scientific literature using various detection 
techniques. A selection of these research papers 
has shown the potential to use epigenetic 
biomarkers for prognostic purposes (survival, 
risk classification). This review summarizes all 
available epigenetics data in NB, with a focus on 
the use of DNA methylation biomarkers in 
predicting prognosis. We present this review at a 
unique time frame in this post-genomic era 
where next-generation sequencing technologies 
have become feasible to be used for whole-
genome analysis at a reasonable cost. We will 
thus emphasize the potential of such genome-
wide detection technologies in the NB 
epigenetics perspective. 
 
DNA methylation markers in neuroblastoma: 
methodological approach 
 
A total of 61 publications on methylation in NB 
were included in this review. In these studies, 
DNA methylation is detected using (1) 
methylation-sensitive restriction enzymes or 
library enrichment towards methylated DNA 
using restriction enzymes recognizing CpG-rich 
sequences, (2) bisulfite treatment, converting 
unmethylated C to T or (3) affinity-based 
enrichment, using the 5-methylcytosine 
antibody (methylated DNA immunoprecipitation 
(MeDIP)) or proteins containing a methyl-CpG-
binding domain (MBD), such as MBD2 and 
MeCP2. In order to detect histone modifications, 
specific antibodies can be used. 
In addition, several studies make use of a 
pharmacologic unmasking strategy on NB cell 
lines. Using DAC, a cytosine analogue which will 
replace cytosine after several cell divisions, DNA 
methylation is inhibited, causing a 
demethylating effect. Combined with 
trichostatin-A (TSA), an inhibitor of histone 
deacetylases (HDACs) inhibiting the 
deacetylation of histone tails, this causes 
transcriptionally silenced genes (by DNA 
methylation and/or histone deacetylation) to 
become active again. These re-expression or 
reactivation events can be identified by 
comparing expression levels before and after 
treatment with DAC and/or TSA by making use 
of qPCR or expression microarrays. The latter 
approach can thus be used to identify possibly 
epigenetically silenced regions in NB cell lines in 
a genome-wide way. In contrast, most analyses 
on primary NB samples are candidate-based: the 
methylation status of the promoter regions of a 
rather limited number of genes (usually less than 
10-15) is tested. These candidates either arise 
based on the reactivation studies in NB cell lines 
or are chosen as they have shown to be involved 
in NB. The candidates are for instance reported 
as being significantly lower expressed in high-risk 
tumors versus low-risk tumors or are important 
in the NB biology. 
In total, about 75 different genes have been 
described as methylated (in varying degrees) in 
NB. These genes can be grouped based on their 
main function (cell cycle control, cell invasion 
and architecture, apoptosis-related genes, etc.). 
An overview of all reported genes and some 
summarizing information (range of methylation 
degree in cell lines and primary samples and 
associations with patient characteristics such as 
age at diagnosis, INSS stage and MYCN 
amplification status) is given in Supplemental 
Table 1. Very detailed information on each of 
these 75 genes, reported as being epigenetically 
modified in NB, is given in the supplements. All 
of these papers discuss DNA methylation; only 
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two papers describe histone modifications 
(PTGER2 and NSD1) as detected by ChIP [1,2]. 
 
Candidate gene case study: apoptosis and 
methylation in neuroblastoma 
 
As a case study to illustrate DNA methylation 
research in NB, the pathway of death receptors 
(DRs), decoy receptors (DcRs) and RASSF1A, and 
their relationship with apoptosis and caspases, is 
chosen and is depicted in Figure 1. Although 
methylation of caspase 8 (CASP8) in NB was first 
described in 2000 [3], only four years later it was 
already considered a key event in the biology of 
NB, next to MYCN amplification and other 
genetic factors [4]. From that first discovery on, 
other researchers soon started to investigate the 
methylation status of CASP8 and other genes 
implied in the apoptotic pathway in their NB 
sample sets. This so called candidate gene 
approach, where a limited number of genes are 
tested for their methylation status based on 
prior evidence, led to the further discovery of 
various methylated genes related to the extrinsic 
and intrinsic apoptotic route. In this perspective, 
methylation of RASSF1A was discovered and 
found to be frequently methylated in NB [5]. 
 
Caspase 8 pathway 
 
In most cases, the apoptotic process is 
characterized by the proteolytic activity of 
caspases. The two main apoptotic pathways in 
which caspase activation occurs, are the intrinsic 
mitochondrial pathway and the extrinsic 
receptor-mediated pathway [6]. 
The extrinsic pathway is initiated by binding of 
extracellular death signals with DRs on the 
surface of the target cells. These DRs belong to 
the tumor necrosis factor receptor (TNFR) 
superfamily and members of this family include 
TNFR1 (DR1, CD120a, p55 or p60), CD95 (DR2, 
APO1 or FASR), DR3 (also TNFRSF25, APO3, 
LARD, TRAMP or WSL1), TRAILR1 (DR4, APO2 or 
TNFRSF10A), TRAILR2 (DR5, KILLER, TRICK2 or 
TNFRSF10B), DR6 (TNFRSF21), ectodysplasin A 
receptor (EDAR) and nerve growth factor 
receptor (NGFR). These receptors are 
characterized by a specific cytoplasmatic domain 
of approximately 80 amino acids, the so called 
death domain (DD). By homotypic interaction, 
this DD recruits specific adaptor proteins 
depending on the type of the stimulated 
receptor. For CD95 for example, FAS-associated 
via death domain (FADD) is recruited. FADD 
carries a death effector domain (DED) which 
associates with the DED of procaspase 8. This 
clustering of proteins results in the formation of 
the death-inducing signaling complex (DISC), 
which leads to activation of procaspase 8. Once 
caspase 8 is activated, the execution phase of 
apoptosis is triggered. 
The intrinsic pathway is induced by cytotoxic 
signals such as DNA damage. These signals cause 
changes in the mitochondrial membrane, leading 
to an opening of the mitochondrial permeability 
transition pore (PTP), loss of the mitochondrial 
transmembrane potential and release of pro-
apoptotic proteins which are normally 
sequestered in the intermembrane space of the 
mitochondria such as cytochrome C. In the 
presence of (deoxy)adenosine triphosphate, the 
cytoplasmic cytochrome C clusters with the 
apoptotic protease activating factor 1 (APAF1). 
This adaptor protein contains a caspase 
recruitment domain (CARD) that allows binding 
with the CARD of procaspase 9. The formed 
apoptosome complex ultimately activates 
caspase 9, which then cleaves other targets. 
The extrinsic and intrinsic apoptotic pathways 
are also interlinked. Caspase 8 for example 
cleaves the BID protein, resulting in truncated 
BID (tBID) which inactivates BCL-2. This protein is 
an anti-apoptotic member of the B cell 
lymphoma 2 family which regulates the 
permeabilization of the mitochondria. Both 
pathways eventually merge into the same 
degrading execution phase. Here, execution 
caspases, such as caspase 3, are activated and 
cleave several cytoskeletal and nuclear proteins 
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Figure 1. Simplified schematic representation of the death receptors, decoy receptors and RASSF1A 
pathways related to apoptosis. Death receptor (DR) stimulation leads to the formation of the death-inducing 
signaling complex (DISC; indicated by the rectangle near the cell membrane). The intrinsic apoptotic pathway is 
characterized by the formation of the apoptosome (indicated by the rectangle near the mitochondrion). The 
genes coding for DcR1, DcR2, DR4, DR5, caspase 8 and RASSF1A are reported to be methylation biomarkers in 
neuroblastoma. APAF1: apoptotic protease activating factor 1; BAX: BCL-2 associated X-protein; BID: BH3 
interacting death domain; CNK1: connector enhancer of kinase suppressor of RAS; CytC: cytochrome C; DcR1: 
decoy receptor 1, TRAILR3, TNFRSF10C or TRID; DcR2: decoy receptor 2, TRAILR4, TNFRSF10D or TRUNDD; DD: 
death domain; DR4: TRAILR1, APO-2 or TNFRSF10A; DR5: TRAILR2, KILLER, TRICK2 or TNFRSF10B; FADD: FAS-
associated via death domain; MOAP-1: modulator of apoptosis-1; MST: mammalian sterile 20 like kinase; NFκβ: 
nuclear factor kappabeta; RASSF1A: RAS association domain family 1 isoform A; tBID: truncated BID; WW45: 
human Salvador homolog. 
 
 
 
 
mitogenic stimuli 
apoptosis 
survival 
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(structural and signaling proteins or kinases) like 
GDID4, PARP, GAS2 and Lamin-A, and thus cause 
apoptosis. 
Death ligands also interact with DcRs such as 
TRAILR3 (DcR1, TNFRSF10C or TRID), TRAILR4 
(DcR2, TNFRSF10D or TRUNDD), DcR3 
(TNFRSF6B, TR6 or M68) and osteoprotegerin 
(OPG). These receptors belong to the TNFR 
superfamily, but completely lack a DD or contain 
a truncated, non-functional DD. They can bind 
the extracellular death signals, but are unable to 
associate with the intercellular signaling 
molecules of apoptosis. They thus counteract 
the DRs. TRAILR3 and TRAILR4 compete with 
DR4 and DR5 for binding of APO2L/TRAIL. DcR3 
competes with CD95 for binding of FASL and 
with DR3 for binding of TL1A. DcR stimulation 
can activate the transcription factor NFκB that 
directs the transcription of anti-apoptotic genes, 
such as C-FLIP, BCL-XL and IAPs, promoting cell 
survival.  
In these pathways, the DRs TRAILR1 and 
TRAILR2, the DcRs TRAILR3 and TRAILR4, CASP8 
and APAF1 are described to be methylated in NB 
cell lines and primary tumors. Thus, DNA 
methylation affects the apoptotic pathways both 
at the receptor and downstream signaling level, 
and thereby inhibits apoptosis. The 
downregulation of the DcRs in NB is a puzzling 
feature, because it renders cancer cells more 
susceptible to TRAIL-induced apoptosis and, 
thus, would counteract tumorigenesis. According 
to van Noesel et al. this could be seen as a 
protective response against tumor formation or 
progression. In this view, TRAILR3 and TRAILR4 
downregulation represents a physiological 
response of the (pre)cancerous cell to a cellular 
state in which a higher level of apoptotic 
sensitivity is warranted [7]. Furthermore, in NB, 
increased levels of the anti-apoptotic BCL-2 and 
BCL-XL have been observed, and correlate with 
decreased apoptosis [8,9] and poor prognostic 
factors like MYCN amplification and unfavorable 
histology [10]. The methylation status of a 
selection of the reported genes is frequently 
described as being associated with prognostic 
factors (stage, survival, age, risk) and is 
described in prognostic methylation biomarker 
signatures. TRAILR2 is only described as being 
methylated in NB cell lines [7]. The fraction of 
NB patients that show methylation in specific 
regions of these genes and the relationship with 
methylation and clinical risk factors is given in 
Table 1. The gene coding for TMS1 (PYCARD), a 
member of a superfamily that mediates 
assembly of large signaling complexes in the 
inflammatory and apoptotic signaling pathways 
via the activation of caspases, is also reported 
methylated in NB and its methylation state is 
associated with MYCN amplification, stage and 
risk [11,12].  
 
RAS association domain family 1 isoform A 
pathway 
 
In addition to CASP8, another frequently 
methylated gene in NB is RASSF1A, a member of 
the RAS association domain family of proteins. 
Due to its interaction with multiple partners, 
RASSF1A influences a diversity of signaling 
pathways. Although this complex signaling 
network complicates unraveling the precise 
functional and biological relevance of RASSF1A, 
it is known to be implicated in the regulation of 
cell proliferation and apoptosis. As RASSF1A is 
characterized by a RAS association domain, one 
of the most obvious interaction partners of 
RASSF1A is the membrane-bound GTPase RAS. 
The interaction probably arises through 
heterodimerization of RASSF1A with RASSF5 
which directly binds activated RAS [23]. RASSF1A 
also interacts with the scaffold protein 
connector enhancer of kinase suppressor of RAS 
(CNK1) and the pro-apoptotic mammalian sterile 
20 like kinase (MST), through which these also 
contribute to the pro-apoptotic signaling 
initiated by activated RAS [24]. The MST kinases 
take part in a pro-apoptotic tumor suppressor 
kinase cascade via coupling with the adaptor 
protein WW45, which is also recruited by 
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Table 1. Methylation of death receptors, decoy receptors and CASP8 in neuroblastoma cell lines, primary and 
relapsed tumors. 
gene samples 
methylation 
clinical features reference 
number % 
CASP8 
cell lines 5/9 56  [7] 
cell lines 8/10 80  [11] 
cell lines 11/12 92  [13] 
primary tumor 24/60 40  [5] 
primary tumor 6/44 14  [14] 
primary tumor 25/41 60  [13] 
primary tumor 39/70 56 survival; signature with TNFRSF10D [15] 
primary tumor 17/45 38 stage [16] 
relapsed tumor 6/17 35  [16] 
primary tumor 20/36 56  [17] 
primary tumor 52/70 74 survival [18] 
primary tumor 10/11 91  [19] 
bone marrow 5/11 55  [19] 
primary tumor  52 
stage; infiltrated bone marrow; risk; 
survival; signature with other apoptotic 
genes 
[12] 
TNFRSF10D 
(DCR2) 
cell lines 6/9 67  [7] 
cell lines 10/10 100  [11] 
cell lines 14/14 100 signature with CASP8 [15] 
primary tumor 7/28 25  [7] 
primary tumor 13/31 42 
MYCN; signature with RASSF1A; SFN and 
TP73 
[20] 
primary tumor 31/70 44 survival [15] 
primary tumor 11/45 25  [16] 
relapsed tumor 5/17 29  [16] 
primary tumor 24/86 28 stage; MYCN; survival [21] 
TNFRSF10C 
(DCR1) 
cell lines 6/9 67  [7] 
cell lines 8/10 80  [11] 
primary tumor 6/28 21  [7] 
primary tumor 5/45 11  [16] 
relapsed tumor 3/17 18  [16] 
primary tumor 6/11 55  [19] 
bone marrow 4/11 36  [19] 
primary tumor  50 stage; age; risk [12] 
TNFRSF10A 
(DR4) 
cell lines 4/9 44  [7] 
cell lines 8/10 80  [11] 
cell lines 11/14 79  [15] 
primary tumor  51  [11] 
primary tumor 6/11 55  [19] 
bone marrow 4/11 36  [19] 
primary tumor  50 stage; age; risk [12] 
TNFRSF10B 
(DR5) 
cell lines 2/9 22  [7] 
APAF1 
primary tumor 6/11 55  [19] 
bone marrow 4/11 46  [19] 
primary tumor  29  [12] 
(continues) 
Note. The number and percentage of samples with methylation reported is given, next to the number of tested 
samples. Associations with clinical risk factors are given when reported significant. 
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Table 1. Methylation of death receptors, decoy receptors and CASP8 in neuroblastoma cell lines, primary and 
relapsed tumors. 
(continued) 
gene samples 
methylation 
clinical features reference 
number % 
PYCARD 
(TMS1) 
cell lines 8/10 80  [11] 
cell lines 13/14 93  [15] 
primary tumor  31 MYCN [11] 
primary tumor 32/70 46  [15] 
primary tumor 3/18 17  [22] 
primary tumor 3/11 27  [19] 
bone marrow 4/11 36  [19] 
primary tumor  25 stage; MYCN; risk [12] 
Note. The number and percentage of samples with methylation reported is given, next to the number of tested 
samples. Associations with clinical risk factors are given when reported significant. 
 
RASSF1A [25]. All these interactions are obvious 
examples that RASSF1A functions as a scaffold 
for assembly of an apoptotic complex. 
Furthermore, RASSF1A is also tightly linked with 
the extrinsic apoptotic pathway. Upon DR 
stimulation RASSF1A binds modulator of 
apoptosis 1 (MOAP1), which enables the 
association of MOAP1 with BAX, and subsequent 
BAX activation leads to permeabilization of the 
outer mitochondrial membrane and apoptosis 
[26]. 
RASSF1A is reported to be methylated in a very 
high fraction of NB patients. Table 2 shows the 
methylation status of RASSF1A in NB samples 
and the association of RASSF1A methylation with 
clinical risk factors. Only about 7 kb upstream of 
RASSF1A, another promoter region frequently 
reported to be methylated in NB is zinc finger, 
myeloid, nervy and DEAF1-type containing 10 
(ZMYND10 (BLU)), which is related to stage, age 
and risk [12,16,27]. 
 
Genome-wide DNA methylation profiling in 
neuroblastoma 
 
The candidate gene approach described in the 
above section is thus based on prior evidence: 
decreased expression in high-risk patients versus 
low-risk patients, reported methylation in other 
cancer types or involvement of the gene in NB 
biology. The number of promoter regions to be 
tested by such an approach is limited (usually 
less than 10-15). In order to identify DNA 
methylation biomarkers that can be used for 
better prognosis prediction, it may be needed to 
perform a whole-genome screening, followed by 
an analysis strategy to prioritize potential DNA 
methylation biomarkers and validation of the 
top-scoring candidates. 
During the last decades, a number of whole-
genome DNA methylation detection 
methodologies have been developed: on one 
hand re-expression analysis after a 
demethylating treatment using DAC, on the 
other hand promoter arrays or sequencing after 
affinity-based capture using MeDIP, and 
methylation-specific microarrays or deep-
sequencing after bisulfite treatment. So far, in 
NB research, whole-epigenome sequencing 
technologies have not been described. 
 
Re-expression experiments after treatment 
with DAC 
 
This pharmacologic unmasking strategy exists of 
expression profiling (using expression 
microarrays) before and after treatment with 
DAC. DAC is a cytosine analogue which cannot 
become methylated by the DNA 
methyltransferases (DNMTs). After several cell 
divisions, this causes a global demethylation of 
the genome. DAC can thus be considered a 
demethylating agent and an inhibitor of the 
DNMTs, which yields comparable results 
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compared to DNMT double knockout models, 
such as the DKO HCT-116 colorectal cancer cell 
line [30]. In addition, some studies use TSA in 
combination with DAC. TSA is an inhibitor of 
HDACs and will thus cause open chromatin 
structures. Genes that are highly re-expressed 
after treatment with DAC and/or TSA 
(reactivated) may be silenced due to DNA 
 
Table 2. Methylation of RASSF1A and ZMYND10 in neuroblastoma cell lines, primary and relapsed tumors, 
and serum. 
gene samples 
methylation 
clinical features reference 
number % 
RASSF1A 
cell lines 10/10 100  [11] 
cell lines 12/12 100  [13] 
primary tumor 37/67 55  [5] 
primary tumor 39/56 70 age; risk; survival [28] 
primary tumor 51/67 76  [5] 
primary tumor 26/31 84 
MYCN; signature with SFN; TP73; 
TNFRSF10D 
[20] 
primary tumor 34/41 83  [13] 
primary tumor 63/70 90  [15] 
primary tumor 42/45 93  [16] 
relapsed tumor 17/17 100  [16] 
primary tumor 29/41 71  [17] 
primary tumor 64/68 94  [29] 
serum 17/68 25 stage; MYCN [29] 
primary tumor 11/11 100  [19] 
bone marrow 8/11 73  [19] 
primary tumor  75 
stage; 1p deletion; infiltrated in bone 
marrow 
[12] 
ZMYND10 
cell lines 6/7 86  [27] 
cell lines 7/11 66  [13] 
cell lines 7/10 70  [11] 
cell lines 13/14 93  [15] 
primary tumor 20/49 41 stage [27] 
primary tumor 25/67 37  [7] 
primary tumor 3/35 8  [13] 
primary tumor 38/70 54  [15] 
primary tumor 15/45 34 stage [16] 
relapsed tumor 4/17 24  [16] 
primary tumor 6/40 15  [17] 
primary tumor 8/11 73  [19] 
bone marrow 10/11 91  [19] 
primary tumor  35 age; risk [12] 
Note. The number and percentage of samples with methylation reported is given, next to the number of tested 
samples. Associations with clinical risk factors are given when reported significant. 
 
methylation/histone modifications. This 
approach can only be applied on cell lines as 
demethylation occurs after several cell divisions. 
In NB, treatment with DAC and/or TSA is applied 
in more than half of the papers (over 30) 
describing epigenetics. However, only four 
publications perform a genome-wide expression 
study after a pharmacologic unmasking 
screening strategy [28,31,32,34]. In all four 
publications, this led to the discovery of 
previously undescribed DNA methylation 
biomarkers in NB. In all other research papers, 
reactivation is shown by (quantitative) PCR for a 
limited set of genes of interest, in order to 
demonstrate the link between DNA methylation 
and transcriptional silencing in NB cell lines. 
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MeDIP chip 
 
While the treatment with DAC and/or TSA leads 
to re-expression, this strategy is an indirect 
method to detect DNA methylation as the 
influence of the demethylating effect is 
measured at the transcriptional level. The last 
years, genome-wide detection techniques have 
been developed that are able to directly 
measure DNA methylation without the detour 
around (silenced) expression. 
One of these techniques is the use of the 5-
methylcytosine antibody (MeDIP) and combining 
this methylation-enriching immunoprecipitation 
with microarrays (MeDIP chip; tiling arrays or 
focused arrays such as promoter regions or CpG 
islands). This strategy is used by Murphy et al. 
[33] where the authors demonstrate that a large 
portion of methylated genes indeed shows 
reduced expression. In addition, the authors 
performed a ChIP experiment using MYCN and 
were able to define specific regions where 
MYCN-binding and DNA hypermethylation 
colocalize. 
 
Methylation-specific arrays 
 
Next to affinity-based methodologies to detect 
DNA methylation, bisulfite conversion has been 
used in all gold standard techniques such as 
methylation-specific PCR (MSP) and bisulfite 
sequencing. A frequently used high-throughput 
platform, making use of different probe types for 
methylated versus unmethylated bisulfite-
treated DNA is the Illumina Infinium 
HumanMethylation27 BeadChip. This technique 
with over 27,000 methylation-specific probes 
has recently been applied on NB primary 
samples [34] and has led to the identification of 
several novel methylation biomarkers that show 
potential for prognostic use. 
 
Next-generation sequencing techniques 
 
All three earlier described detection principles 
are also used in combination with next-
generation sequencing platforms (such as Roche 
454 and Illumina GAIIx) to detect DNA 
methylation in a genome-wide way. The 
complete honey bee and Arabidopsis thaliana 
methylomes have been determined by bisulfite 
sequencing [35,36]. As this technique would not 
be cost-efficient for larger genomes such as 
humans, one needs to decrease the fraction of 
the genome to be covered by sequencing. In 
order to enrich this limited library that is 
sequenced, restriction enzymes were used, 
making sure the retained fractions (based on 
sizing) cover the most dense CpG islands or 
regions, followed by deep bisulfite sequencing. 
Another methodology is to make use of the high 
affinity towards methylated cytosines of MBD-
containing proteins such as MBD2 and MeCP2 
[37,38] or by applying MeDIP [39], followed by 
(paired-end) sequencing.  
Some research groups, including our group, are 
at this moment in the process of using 
sequencing techniques to determine the 
methylome and/or to detect histone 
modifications in NB samples (cell lines and 
primary patients). The first results indicate the 
potential of epigenetic sequencing techniques: 
at a feasible cost, it becomes feasible to 
investigate the methylome or epigenome of a 
sample in great detail. Their findings will reveal 
the complexity of the epigenetic changes during 
development and progression of NB and 
eventually would allow assessment of the effect 
on the epigenome of diverse treatments, and 
which patients would be eligible for which type 
of treatment (prediction and personalized 
medicine). 
 
Epigenetics and neuroblastoma prognosis 
 
Despite advances in multimodal anticancer 
therapies, survival rates for children with NB 
remain disappointingly low. Although current 
risk assessment schemes have been significantly 
approved, inevitably undertreatment or 
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overtreatment will still occur for certain 
children. As a consequence, survival rates are 
suboptimal in the low-risk group, and a number 
of patients in the so-called high-risk group are 
unnecessarily put at risk for potential long term 
side effects of the toxic therapy. Clearly, a more 
objective and accurate classifier is needed for 
improved outcome prediction. Only then, 
 
Table 3. Overview of studies discussing DNA methylation biomarkers and their relationship with prognostic 
risk factors and survival. 
methylation biomarker 
(signature) 
risk factors survival 
reference 
age stage MYCN risk other overall 
event-
free 
RASSF1A        [40] 
TNFRSF10D        [21] 
HOXA9/RARB        [11] 
PCDHA/PCDHB/HLP/CYP26C1     
ploidy 
TrKA 
  [41] 
CASP8        [18] 
RASSF1A, SFN, TP73, 
TNFRSF10D 
       [20] 
EMP3        [42] 
PYCARD, MGMT, RARB        [19] 
CASP8, TNFRSF10D        [15] 
CASP8, ZMYND10        [16] 
NR1I2        [43] 
SFN, RASSF1A, CYP26C1, 
TNFRSF10D 
       [44] 
RASSF1A        [29] 
SCNN1A, PRKCDBP, KRT19        [34] 
apoptotic genes, such as 
TMS1, APAF1 and CASP8 
       [12] 
Note. Overall survival or event-free survival may be disease-free, relapse-free or progression-free. Only 
significant associations are reported (p-values according to the original publication). 
 
patients will receive the most appropriate 
therapy, can be monitored more intensively if 
needed, and become eligible for new 
experimental therapies. 
As briefly demonstrated in the death receptor 
pathway and for RASSF1A, several methylation 
biomarkers in NB are described to be associated 
with classical risk factors: MYCN amplification; 
age at diagnosis and stage. Several publications 
describe the use of (a combination of) DNA 
methylation biomarkers to show the effect of 
methylation on disease-free survival or overall 
survival. The power and potential of DNA 
methylation as non-invasive biomarkers is 
demonstrated by measuring DNA methylation of 
RASSF1A in serum of patients [40]. DNA 
methylation-based prognosis has the potential 
to be non-invasive, highly sensitive and specific. 
It can be detected using standard PCR or 
sequencing technologies. 
In many studies, the genes discussed in previous 
sections are used for prognostic purposes. 
However, more recently genome-wide screening 
methodologies are becoming more popular and 
feasible (re-expression analysis after treatment 
with DAC, promoter chips after capturing with 
MeDIP, methylation microarrays). This revealed 
a broader view on the NB methylome and 
allowed the identification of DNA methylation 
signatures that can be used for prognostic 
purposes. Table 3 lists all studies where the DNA 
methylation state demonstrates prognostic 
potential. The association with classical risk 
factors is indicated if significant, as well as the 
impact on survival. It can be noticed that, next to 
candidate genes previously described such as 
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CASP8 and RASSF1A, several novel methylation 
biomarkers that are related to prognosis, are 
described. 
 
Discussion and future perspectives 
 
As in other cancer types, it clearly has been 
shown that NB is a disease that is regulated by 
epigenetic mechanisms. Candidate gene 
approaches led to the discovery that frequently 
methylated regions in NB can be found in 
pathways related to apoptosis. Classical tumor 
suppressor genes do not show such a clear 
methylation signal in NB. 
Current technologies have the possibility to 
investigate the epigenetic changes in a genome-
wide way, and integrating these data with other 
data sources, such as mRNA and miRNA 
expression profiles and proteome data, would 
reveal the (epi)genomic landscape of NB. Such 
multidimensional and cross-species integrated 
information will be exploited using high-end 
bioinformatic tools and systems biology 
approaches in order to unravel the various 
implicated perturbed signaling pathways, 
complex interactions and cross-talk between 
critical nodes within these networks. 
Understanding such regulatory networks at play 
and in particular possible compensatory 
interactions may also be crucial for developing 
appropriate therapeutic strategies and to 
anticipate to and design strategies against new 
forms of therapy resistance. 
 
Supplemental materials  
 
Supplemental materials can be found at: 
www.tandfonline.com/doi/suppl/10.4161/epi.6.
8.16516?scroll=top  
 
Supplemental Table 1. DNA methylation in 
neuroblastoma cell lines and primary tumors. 
For each gene reported to be methylated in NB, 
the percentage of methylated samples is given 
(according to the original references) and 
associations with clinical risk factors are 
described. Below the table, detailed information 
(gene function and general information, features 
of the promoter region, and information related 
to DNA methylation analyses) on each of these 
genes can be found.  
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 Established prognostic markers are combined into a pretreatment risk classification system 1.2.4
 
Combinations of prognostic variables are used for risk group assignment and treatment stratification. 
Given the rare occurrence of NB, cooperative pediatric oncology groups have been established in the 
past to be able to conduct large-scale analyses and in this way to fully optimize the stratification 
procedures. These include both national and international groups, such as the Children’s Oncology 
Group (COG; North America and Australia), the German Pediatric Oncology and Hematology Group 
(GPOH), the Japanese Advanced Neuroblastoma Study Group (JANB), the Japanese Infantile 
Neuroblastoma Co-operative Study Group (JINCS) and the International Society of Pediatric Oncology 
Europe Neuroblastoma Group (SIOPEN). However, these cooperative groups initially selected 
different prognostic factors to tailor stratification, still complicating comparison of clinical trials 
performed throughout the world. In 2004, a task force of investigators from these cooperative 
groups, the so-called International Neuroblastoma Risk Group (INRG) Task Force, was set up to 
develop a consensus approach for pretreatment risk stratification of NB [154]. This effort led to the 
construction of the INRG classification system, next to the INRG Staging System (INRGSS; §1.2.1.3) 
and recommendation reports on the detection and evaluation of disseminated disease [143, 154, 
188, 197, 225]. 
 
In total, the statistical and clinical significance of 13 potential prognostic factors were analyzed in a 
cohort of 8,800 patients, and using survival tree regression analysis (Figure 13) the INRG classification 
system was built. Currently, this system includes seven criteria (the INRG stage (INRGSS), age of the 
patient at diagnosis, histologic category, grade of tumor differentiation, MYCN amplification status, 
presence/absence of 11q aberrations and tumor cell ploidy) to stratify patients into sixteen 
pretreatment risk groups (lettered A through R; Table 7). Based on arbitrary cutoffs on the EFS data 
in the survival tree regression analysis, these pretreatment risk groups were further clustered into 
four categories: very low-risk (5-year EFS > 85%), low-risk (5-year EFS > 75 to ≤ 85%), intermediate-
risk (5-year EFS ≥ 50 to ≤ 75%) and high-risk (5-year EFS < 50%). The proportion of patients grouped 
in these categories was 28.2%, 26.8%, 9.0% and 36.1%, respectively [154]. Of note, the survival tree 
regression analysis was performed using the INSS stage (§1.2.1.3), as the sample size of patients with 
known surgical risk factors (IDRFs that define INRGSS; §1.2.1.3) was too small relative to patients 
with known INSS stage [143]. However, the INSS stage is not suitable for pretreatment risk 
classification. For that reason, also posthoc analyses using the INRGSS were performed, which found 
both INSS stage and INRGSS highly prognostic of survival. This supports the translation of the survival 
tree regression analysis (in terms of INSS stage) into the INRG classification system (in terms of 
INRGSS) [143, 154]. To test the predictive ability of age, a consensus cutoff of 18 months was 
selected based on previous findings (§1.2.1.1). For patients with diploid, MYCN non-amplified stage 
M tumors, clinical justification was used to split patients younger than 12 months from 12 months 
and older to younger than 18 months of age [154]. 
 
Although the INRG Task Force recognized that genome-wide studies had identified powerful 
predictors of outcome, only MYCN amplification, chromosome 11q aberration and DNA ploidy status 
were included in the INRG pretreatment risk stratification, as microarray analyses of DNA copy 
number alterations and gene expression were not widely available at the time the classification was 
established. It is anticipated that the next-generation INRG classification system will incorporate 
profiles of the NB genome, transcriptome and epigenome to further improve prognostication [226]. 
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Table 7. Using the International Neuroblastoma Risk Group (INRG) consensus pretreatment classification, 
neuroblastoma patients are stratified into risk groups. 
INRG 
stage 
age 
(months) 
histologic 
category 
grade of tumor 
differentiation 
MYCN 
11q 
aberration 
ploidy 
pretreatment 
risk group 
L1/L2 
 
GN maturing; 
GNB 
intermixed 
    
A very low 
L1 
 
any, except 
GN maturing 
or GNB 
intermixed 
 
MYCN0 
  
B very low 
MYCN1 
  
K high 
L2 
< 18 
any, except 
GN maturing 
or GNB 
intermixed 
 
MYCN0 
no 
 
D low 
yes 
 
G intermediate 
≥ 18 
GNB nodular; 
NB 
differentiating MYCN0 
no 
 
E low 
yes 
 
H intermediate poorly 
differentiated or 
undifferentiated 
MYCN0 
 
 
MYCN1 
  
N high 
M 
< 18 
  
MYCN0 
 
hyper-
diploid 
F low 
< 12 
  
MYCN0 
 
diploid I intermediate 
12 to < 18 
  
MYCN0 
 
diploid J intermediate 
< 18 
  
MYCN1 
  
O high 
≥ 18 
     
P high 
MS < 18 
  
MYCN0 
no 
 
C very low 
yes 
 
Q high 
MYCN1 
  
R high 
Note. For INRG stage, see Table 6. 12 months: 365 days; 18 months: 547 days; blank field: any; diploid: DNA 
index ≤ 1.0; hyperdiploid: DNA index > 1.0 and includes near-triploid and near-tetraploid tumors; EFS: event-
free survival; GN: ganglioneuroma; GNB: ganglioneuroblastoma; MYCN1: MYCN amplified; MYCN0: MYCN non-
amplified; NB: neuroblastoma [154]. 
   
 
 
 
(continues) 
Figure 13. Using cutoffs on the event-free survival data in the survival tree regression analysis of the International Neuroblastoma Risk Group (INRG) cohort, four 
pretreatment risk group categories were determined: very low-risk, low-risk, intermediate-risk and high-risk. A split occurs for the most highly statistically significant 
factor as identified using a Cox proportional hazards regression model. A. Top levels of the overall tree. B. Subtree for NB and GNB-nodular, non-stage 4 MYCN0 patients. 
The split of stage 2, 3 from stage 4S patients was a clinical decision and not the result of statistical significance. EFS: 5-year event-free survival; GN: ganglioneuroma; GNB: 
ganglioneuroblastoma; INSS: International Neuroblastoma Staging System; MYCN0: MYCN non-amplified; MYCN1: MYCN amplified; NB: neuroblastoma; OS: overall survival. 
Based on [154].  
overall 
(n = 8800) 
EFS 63% ± 1% 
OS 70% ± 1% 
INSS stage 1, 2, 3, 4S 
(n = 5131) 
EFS 83% ± 1% 
OS 91% ± 1% 
INSS stage 4 
(n = 3425) 
EFS 35% ± 1% 
OS 42% ± 1% 
GN maturing;  
GNB intermixed 
(n = 162) 
EFS 97% ± 2% 
OS 98% ± 2% 
NB and GNB, nodular  
(n = 4970) 
EFS 83% ± 1% 
OS 90% ± 1% 
MYCN0 
(n = 3926) 
EFS 87% ± 1% 
OS 95% ± 1% 
MYCN1 
(n = 349) 
EFS 46% ± 4% 
OS 53% ± 4% 
MYCN0 
(n = 3926) 
EFS 87% ± 1% 
OS 95% ± 1% 
11q normal  
and diff-ing 
(n = 18) 
EFS 80% ± 16% 
OS 100% 
stage 2, 3 
(n = 1889) 
EFS 82% ± 1% 
OS 92% ± 1% 
1p normal 
(n = 457) 
EFS 94% ± 2% 
OS 99% ± 1% 
age < 547 days 
(n = 732) 
EFS 88% ± 1% 
OS 97% ± 1% 
age ≥ 547 days 
(n = 260) 
EFS 69% ± 3% 
OS 81% ± 2% 
11q normal 
(n = 62) 
EFS 87% ± 7% 
OS 97% ± 4% 
1p aberration 
(n = 38) 
EFS 78% ± 10% 
OS 100% 
11q aberration 
(n = 19) 
EFS 60% ± 20% 
OS 84% ± 14% 
11q aberration  
or p/u diff 
(n = 49) 
EFS 61% ± 11% 
OS 73% ± 11% 
11q normal 
(n = 176) 
EFS 83% ± 5% 
OS 98% ± 2% 
11q aberration 
(n = 8) 
EFS 38% ± 30% 
OS 63% ± 38% 
stage 1 
(n = 1556) 
EFS 93% ± 1% 
OS 98% ± 1% 
stage 4S 
(n = 481) 
EFS 82% ± 2% 
OS 91% ± 2% 
EFS 
intermediate risk 
high-risk 
low-risk 
very low-risk 
A. B. 
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Figure 13. Using cutoffs on the event-free survival data in the survival tree regression analysis of the International Neuroblastoma Risk Group (INRG) cohort, four 
pretreatment risk group categories were determined: very low-risk, low-risk, intermediate-risk and high-risk. A split occurs for the most highly statistically significant 
factor as identified using a Cox proportional hazards regression model. C. Subtree for NB and GNB-nodular, non-stage 4 MYCN1 patients. The split of stage 1 from stage 2, 3, 
4S patients was a clinical decision and not the result of statistical significance. LDH in U/l. D. Subtree for INSS stage 4 patients. The split of age 0 - < 365 days from age 365 - 
< 547 days was a clinical decision and not the result of statistical significance. Ferritin in ng/ml. DI: DNA index; EFS: 5-year event-free survival; LDH: lactate dehydrogenase; 
MYCN0: MYCN non-amplified; MYCN1: MYCN amplified; OS: overall survival. Based on [154]. 
  
MYCN1 
(n = 349) 
EFS 46% ± 4% 
OS 53% ± 4% 
stage 2, 3, 4S 
(n = 302) 
EFS 46% ± 4% 
OS 50% ± 4% 
LDH < 587 
(n = 44) 
EFS 67% ± 9% 
OS 72% ± 8% 
LDH ≥ 587 
(n = 10) 
EFS 40% ± 22% 
OS 58% ± 22% 
LDH ≥ 587 
(n = 169) 
EFS 43% ± 5% 
OS 47% ± 5% 
stage 4 
(n = 3425) 
EFS 35% ± 1% 
OS 42% ± 1% 
age < 547 days 
(n = 1019) 
EFS 63% ± 2% 
OS 68% ± 2% 
EFS 
intermediate-risk 
high-risk 
low-risk 
very low-risk 
C. D. 
stage 1 
(n = 47) 
EFS 49% ± 12% 
OS 75% ± 9% 
LDH < 587 
(n = 22) 
EFS 55% ± 15% 
OS 85% ± 10% 
MYCN0 
(n = 149) 
EFS 48% ± 5% 
OS 53% ± 5% 
MYCN0 
(n = 596) 
EFS 83% ± 2% 
OS 89% ± 2% 
MYCN1 
(n = 241) 
EFS 26% ± 4% 
OS 29% ± 4% 
ferritin < 92 
(n = 250) 
EFS 43% ± 4% 
OS 47% ± 4% 
ferritin ≥ 92 
(n = 1005) 
EFS 20% ± 2% 
OS 27% ± 2% 
DI > 1 
(n = 254) 
EFS 85% ± 3% 
OS 93% ± 2% 
age 365 -  
< 547 days 
(n = 14) 
EFS 75% ± 17% 
OS 82% ± 16% 
MYCN1 
(n = 43) 
EFS 28% ± 9% 
OS 27% ± 9% 
DI ≤ 1 
(n = 73) 
EFS 71% ± 10% 
OS 79% ± 9% 
MYCN0 
(n = 513) 
EFS 21% ± 2% 
OS 30% ± 2% 
age 0 -  
< 365 days 
(n = 59) 
EFS 71% ± 12% 
OS 80% ± 10% 
MYCN1 
(n = 232) 
EFS 19% ± 3% 
OS 22% ± 3% 
age ≥ 547 days 
(n = 2406) 
EFS 23% ± 1% 
OS 31% ± 1% 
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Unfortunately, the quest for prognostic NB markers has not yet come to an end, as accurate outcome 
prediction of patients remains challenging (§1.2.4). During the past years, the Center for Medical 
Genetics Ghent, which acts as the Belgian reference center for the genetic diagnosis and study of NB, 
has set up several projects to establish additional RNA- and DNA-based biomarkers, based on the 
study of copy number changes, and mRNA and miRNA tumor levels [211, 222, 224, 227]. In this 
setting, I have explored DNA methylation as an alternative target of prognostic biomarker research in 
NB.  
 
Up until a few years ago, the NB tumor DNA methylome was relatively unexplored and few 
prognostic DNA methylation biomarkers were described, as thus far most studies were candidate 
gene-based (§review paper; §1.2.3; [228]). Therefore, I started genome-wide screening efforts using 
methyl-CpG-binding domain (MBD) sequencing (§1.1.4.3) to identify new biomarkers.  
 
In a first discovery phase, the MBD sequencing workflow was optimized on 8 NB cell lines, whereby 
through data integration with mRNA expression, candidate biomarkers were selected. To evaluate 
these candidates, a high-throughput semi-automated methylation-specific PCR (MSP) pipeline was 
developed and used to test 43 biomarker MSP assays on an independent cohort of 89 primary 
tumors selected for risk classification and survival. This successfully led to the identification of 
putative prognostic methylation biomarkers (§paper 1; [229]). 
 
Subsequently, I set up a more extensive discovery by mapping the DNA methylome of 87 primary NB 
tumors using MBD sequencing. Differential methylation analyses between prognostic patient groups 
were applied to prioritize new candidate biomarkers. In total, 78 MSP assays were designed for top-
ranking differentially methylated regions and tested on two independent cohorts of 132 and 177 
primary tumors, respectively. Further, a new statistical framework was developed to identify a robust 
set of MSP assays of which the percentage of methylated assays allows accurate outcome prediction. 
As such, multiple prognostic single-gene methylation biomarkers were identified and validated, as 
well as a prognostic 58-marker methylation signature, predicting overall and event-free survival. This 
study encompasses the largest DNA methylation biomarker study in NB so far (§paper 2; [230] and 
§paper 3; [110]). 
 
Along with the 87 primary tumors (stage 1, 2, 3 and 4) of our biomarker validation study, also 15 
stage 4S tumors were profiled by MBD sequencing, creating DNA methylation maps of 102 
heterogeneous primary NB tumors. This unique resource of methylation information was shared with 
the NB research community through an open access data descriptor, making the MBD sequencing 
data easily reusable (§paper 3; [110]).  
 
Finally, I characterized the promoter DNA methylation portrait of stage 4S NB (§1.2.1.3), by 
performing differential methylation analyses between MYCN non-amplified stage 4S, stage 4 and 
stage 1/2 tumors, using the MBD sequencing data of 41 primary tumors. I showed that specific 
chromosomal locations are enriched for stage 4S differentially methylated promoters and that stage 
4S tumors show characteristic hypermethylation of specific subtelomeric promoters. Additionally, 
our MBD sequencing data illustrated that important oncogenic pathways, neural crest development 
and differentiation, and epigenetic processes are differentially regulated in stage 4S tumors. These 
findings open new avenues for further research, to gain more insights in the NB pathology in general 
and stage 4S specifically (§paper 4; [231]). 
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biomarker methylation and NB risk factors and survival analyses), and analyzing the mRNA 
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Abstract 
 
Accurate outcome prediction in neuroblastoma, which is necessary to enable the optimal choice of 
risk-related therapy, remains a challenge. To improve neuroblastoma patient stratification, this study 
aimed to identify prognostic tumor DNA methylation biomarkers. To identify genes silenced by 
promoter methylation, we first applied two independent genome-wide methylation screening 
methodologies to eight neuroblastoma cell lines. Specifically, we used re-expression profiling upon 5-
aza-2’-deoxycytidine (DAC) treatment and massively parallel sequencing after capturing with a 
methyl-CpG-binding domain (MBD sequencing). Putative methylation markers were selected from 
DAC-upregulated genes through a literature search and an upfront methylation-specific PCR on 20 
primary neuroblastoma tumors, as well as through MBD sequencing in combination with publicly 
available neuroblastoma tumor gene expression data. This yielded 43 candidate biomarkers that 
were subsequently tested by high-throughput methylation-specific PCR on an independent cohort of 
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89 primary neuroblastoma tumors that had been selected for risk classification and survival. Based 
on this analysis, methylation of KRT19, FAS, PRPH, CNR1, QPCT, HIST1H3C, ACSS3 and GRB10 was 
found to be associated with at least one of the classical risk factors, namely age, stage or MYCN 
status. Importantly, HIST1H3C and GNAS methylation was associated with overall and/or event-free 
survival. This study combines two genome-wide methylation discovery methodologies and is the 
most extensive validation study in neuroblastoma performed thus far. We identified several novel 
prognostic DNA methylation markers and provide a basis for the development of a DNA methylation-
based prognostic classifier in neuroblastoma. 
 
Keywords: DNA methylation, neuroblastoma, biomarker, prognosis, MBD sequencing, methylation-
specific PCR (MSP), 5-aza-2'-deoxycytidine (DAC) 
 
 
Background  
 
Neuroblastoma (NB) is a neuroectodermal tumor 
that originates from precursor cells of the 
sympathetic nervous system and represents the 
most common extra-cranial solid tumor of early 
childhood. NB displays a highly variable clinical 
course, ranging from spontaneous regression to 
life-threatening disease [1].  
Despite advances in multimodal anticancer 
therapies, survival rates for children with 
aggressive NB remain disappointingly low. 
Survival rates vary widely, depending on clinical 
features, such as age at diagnosis and tumor 
stage, as well as biological characteristics of the 
tumor. Amongst the latter, MYCN amplification 
has been used for many years as a genetic 
marker for therapy stratification [1]. More 
recently, a subset of high-risk tumors with non-
amplified MYCN and 11q deletions was 
identified, while absence of segmental 
aberrations upon genome-wide DNA copy 
number analysis was found to be associated with 
excellent survival [2,3]. In order to facilitate the 
comparison of risk-based clinical trials, a new 
consensus approach for pretreatment risk 
classification has been designed including 
genetic parameters [1,4]. Despite this progress, 
additional markers for therapeutic stratification 
are warranted in order to avoid under- or 
overtreatment and to improve selection of ultra-
high-risk patients for new experimental 
therapies. Recently, prognostic mRNA and 
microRNA (miRNA) signatures were developed 
to accommodate this need [5–7]. Here, we 
propose that the use of DNA methylation 
markers is a new and promising method for 
prognostic classification. 
DNA methylation is the addition of a methyl 
group to carbon 5 of the cytosine within the CpG 
dinucleotide. Dense clusters of CpG 
dinucleotides, termed CpG islands, are often 
present in gene promoters and methylation of 
those regions typically results in transcriptional 
silencing of the gene. As such, abnormal DNA 
methylation in cancer cells leads to aberrant 
expression patterns [8]. In NB, the most 
described epigenetic alterations are DNA 
methylation of CASP8 [9] and RASSF1A [10], both 
associated with risk factors, such as MYCN 
amplification, age at diagnosis and tumor stage 
[11–15]. Recently, a few genome-wide 
methylation screening methodologies have been 
applied in NB, including re-expression analysis 
after treatment with 5-aza-2’-deoxycytidine 
(DAC), DNA methylation promoter arrays after 
capturing with methylated DNA 
immunoprecipitation (MeDIP) and methylation 
microarrays. These studies indicate that aberrant 
DNA methylation makes an important 
contribution towards NB tumor biology by 
downregulating specific genes and show the 
potential of using DNA methylation in future 
patient therapy stratification protocols [16–18]. 
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Furthermore, the power of DNA methylation as a 
non-invasive, sensitive and specific biomarker 
has been demonstrated by measuring DNA 
methylation of RASSF1A in serum of primary NB 
patients [15] (for a detailed review see [19]). In 
order to improve the outcome prediction of NB 
patients, this study aims at establishing robust 
DNA methylation biomarkers that can identify 
patients with unfavorable prognosis.  
 
Results  
 
Discovery and integrated analysis: genome-
wide methylation screening for selection of 
candidate biomarkers  
 
The experimental setup of the study is 
summarized in Figure 1. In order to identify DNA 
methylation biomarkers in NB, we first applied 
two genome-wide methylation screening 
methodologies on eight NB cell lines: microarray 
after re-expression analysis and massively 
parallel sequencing after capturing with a 
methyl-CpG-binding domain (MBD sequencing). 
The genome-wide assessment of gene 
expression reactivation upon DAC treatment is 
an indirect method to detect DNA methylation 
as the influence of the demethylating effect is 
measured at the transcriptional level using 
oligonucleotide chips. Out of 54,675 probes, a 
total of 3,624 were upregulated after DAC 
treatment compared to untreated controls 
(RankProd false discovery rate (FDR) < 5%), of 
which 1,665 were upregulated at least twofold in 
at least one cell line. Using a cutoff of at least a 
twofold difference between the DAC-treated 
and the untreated sample, 989 probes were re-
expressed in at least 2 cell lines. In order to 
select specific and sensitive methylation 
biomarkers from this high number of reactivated 
probes, an integrated bioinformatics approach 
was applied. The 1,665 upregulated probes 
identified by RankProd analysis were further 
filtered using a genome-wide promoter 
alignment strategy, referred to as the ‘broad 
approach’ in Hoque et al. [20]. This strategy 
consists of a genome-wide multiple alignment of 
promoter regions, where similar sequence 
regions thus cluster together and where the 
‘distance’ (the number of nodes in the 
hierarchical alignment model) is shown to be 
able to predict novel biomarkers. Such 
approaches using DAC re-expression data have 
previously been successfully applied to enrich 
towards truly methylated genes [20,21]. We 
selected 150 genes that were either in the 
‘neighborhood’ (less than 8 nodes away) of a 
known methylation marker or that clustered 
together in the promoter sequence alignment 
with a high number of reactivation events (at 
least two genes in the cluster showed at least 
three reactivation events). Integration with (NB) 
literature, using an in-house developed text-
mining-based approach (using NCBI E-Utils to 
query PubMed, using all known gene aliases in 
combination with either DNA methylation-
related or NB-related search terms), and 
selection for genes located in genomic regions 
reported as recurrently affected by DNA copy 
number changes in NB, eventually led to the 
selection of 120 candidate biomarkers, 
comprising 30 novel candidate markers and 90 
known methylation markers in other tumor 
types. To obtain direct evidence for DNA 
methylation and to further select prognostic 
biomarkers, the selected 120 candidate 
biomarkers were tested on the DAC-treated and 
untreated NB cell lines CLB-GA, LAN-2, N206, SH-
SY5Y and SJNB-1, and primary NB samples (9 
low-risk survivors (LR-SURV) and 11 high-risk 
deceased (HR-DOD) patients; for details see 
Material and methods), using high-throughput 
methylation-specific PCR (MSP). In the NB cell 
lines, the DAC-treated samples show less 
methylation calls in comparison to untreated 
samples (130 MSP assays (64%) are more 
frequently methylated in the untreated 
samples), and taking all MSP assays into account 
the average number of methylated samples per 
assay is 0.39 for the DAC-treated cell lines versus 
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Figure 1. Combining genome-wide methylation discovery and validation, several novel prognostic DNA 
methylation markers were identified in neuroblastoma (NB). Starting points are a microarray based re-
expression study after treatment with 5-aza-2’-deoxycytidine (DAC) and a next-generation sequencing 
experiment using an enrichment strategy towards methylated DNA (methyl-CpG-binding domain (MBD) 
capture). Both were performed on the same panel of eight NB cell lines. Applying a bioinformatics and text-
mining-based approach on the re-expression data, 120 candidate genes were selected and tested using an 
initial high-throughput methylation-specific PCR (MSP) screen. The MBD sequencing data were combined with 
public mRNA expression studies to enrich for potential prognostic biomarkers. Using a rank-based scoring 
system, a final selection of 43 candidates was made, which were then tested using MSP on 89 primary NB 
samples (in the following subgroups: HR-DOD: high-risk patients that die of disease; HR-SURV: high-risk 
patients with long follow-up; LR-SURV: low-risk patients with long follow-up). Finally, mRNA expression levels 
of seven DNA methylation biomarkers were determined. qPCR: quantitative polymerase chain reaction. 
 
1.47 for the untreated cell lines (p = 0.0002), 
revealing dense methylation in genes 
upregulated upon DAC treatment and efficient 
demethylation by DAC (data not shown). The 
complete results of the initial high-throughput 
MSP screening on the primary NB samples can 
be found in Additional file 1.  
The second genome-wide DNA methylation 
screening methodology we applied, to the same 
eight NB cell lines, was MBD sequencing: 
massively parallel sequencing of methylation-
enriched DNA fragments, whereby the 
discovery and integrated analysis 
enrichment 
methylated 
genes 
enrichment                
prognostic 
genes 
6 available mRNA expression studies 
 
microarray platforms 
380 primary NB tumors 
initial high-throughput MSP 
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54675 microarray probes 
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mRNA expression profiling 
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2 genes (2 qPCR mRNA assays) 
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enrichment is based on the capture of 
methylated sheared DNA using the high affinity 
of the methyl-CpG-binding domain (MBD) of the 
protein MBD2 towards methylated cytosines. 
Sequencing yielded 4.4 to 8.6 million paired-end 
reads, depending on the cell line, and after peak 
calling 70,816 to 112,412 peaks were detected, 
representing genomic regions methylated in the 
corresponding cell line. Between 7,612 and 
11,178 of these peaks (around 10% of all 
identified peaks) are located in promoter regions 
of annotated genes (-1,500 bp to +1,000 bp 
around the transcription start site (TSS)). These 
‘methylation peaks’ were visualized in the 
Integrative Genomic Viewer [22], showing that 
promoter regions that are well known to be 
heavily methylated in NB were confirmed - for 
example, the protocadherin β (PCDHB) family 
cluster (Additional file 2) [23,24]. In some 
regions (for example, in the promoter regions of 
HIST1H3C and ACSS3) it was also possible to 
distinguish different DNA methylation profiles 
between MYCN amplified (IMR-32, LAN-2 and 
N206) and MYCN non-amplified (SH-SY5Y, SK-N-
AS, CLB-GA and SJNB-1) NB cell lines (Additional 
file 2). Using the R/BioC package DESeq [25], 510 
regions were identified as differentially 
methylated between MYCN amplified and non-
amplified cell lines, of which 95 are in close 
proximity to an annotated TSS (-1,500 bp to 
+1,000 bp). Also, some miRNAs appeared to be 
methylated in their promoter region.  
After peak calling, we also performed gene set 
enrichment analysis [26], using a custom, ranked 
list of genes with at least one MBD peak present 
in a region -1,500 bp to +500 bp around its TSS, 
in order to explore whether promoter regions 
that are enriched after MBD capture are often 
re-expressed as well upon DAC treatment. This 
analysis clearly showed a high enrichment score 
for each cell line (enrichment scores from 0.32 
to 0.36; FDR q-value < 0.01), demonstrating that 
a large portion of methylated regions (captured 
by MBD) are indeed reactivated upon DAC 
treatment. The overlap between the two 
genome-wide datasets can be further explored 
by intersecting them. In total, 183 genes are 
both reactivated upon DAC treatment (at least 1 
log2 difference after and before treatment) and 
have an MBD peak in their promoter regions (-
1,500 bp to +1,000 bp around the TSS) in at least 
2 of the 8 investigated NB cell lines. Of these 183 
genes, 46 are both re-expressed and methylated 
in 3 cell lines, 9 in 4 cell lines and 5 in at least 5 
cell lines.  
As we feared that only using cell lines in the 
selection phase of potential prognostic DNA 
methylation biomarkers would lead to the 
identification of methylated markers not 
necessarily related to prognosis, six publicly 
available mRNA expression studies [27–34] were 
included in the analysis. In these studies, which 
comprise mRNA expression data of 380 primary 
NB tumors, identifying differentially expressed 
probes (genes) between prognostic groups 
would allow us to pinpoint potential prognostic 
methylated promoter regions in our methylome 
maps. Finally, a rank-based scoring system was 
used to prioritize genes that show methylation, 
re-expression after DAC treatment and 
differential expression (related to risk) across the 
prognostic groups. This score scheme uses the 
individual ranks of each analysis. In brief, DAC 
reactivation is ranked according to FDR rate (as 
determined by RankProd analysis), MBD 
sequencing data are ranked according to peak p-
values and expression data are ranked according 
to FDR (determined by RankProd analysis). Each 
data source is given the same weight and a 
combined rank is calculated (for details, see 
Materials and methods). This scoring system 
combined all generated data and allowed us to 
select 43 top-ranking and thus strong prognostic 
methylation candidate genes without the need 
to use rather artificial threshold values for the 
different datasets.  
 
Validation: determining the prognostic power 
of DNA methylation biomarkers 
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For these 43 genes, 48 MSP assays were 
designed and tested on 3 NB cell lines (IMR-32, 
SK-N-AS and SH-SY5Y) and the HCT-116 DKO cell 
lines, along with an independent cohort of 89 
primary NB samples. Within the 89 primary NB 
sample set all three prognostic groups (LR-SURV, 
HR-DOD and high-risk survivors (HR-SURV); for 
details see Material and methods) were 
approximately equally represented. The 
complete matrix with all MSP results of all 
samples and a global overview of the MSP 
results per assay can be found in Additional file 
3. Over 60% of the designed assays indeed 
detected methylation for the respective marker 
in at least 10% of the selected NB tumors. Ten 
MSP assays (COL6A3, miR-1225, miR-3177, 
PCDHA6, PLXNC1, ANKRD43, ADRB2, APOE, miR-
671 and QPCT) revealed methylation in at least 
75% of the patient samples, and the MSP assays 
for KCND2, PRPH, KRT19 (assay 83159) and 
TNFRSF10D were methylated in 50% to 75% of 
the patient samples. We could also detect DNA 
methylation in the promoter region of miR-1225, 
miR-3177, miR-671 and miR-663, methylated in 
99%, 99%, 79% and 4% of the patient samples, 
respectively.  
Unique in this study is the use of three discrete 
prognostic patient groups, which allowed us to 
assess differential methylation across all these 
prognostic groups. Therefore, we performed 
hierarchical cluster analysis on the methylation 
data of all 48 MSP assays on the entire NB tumor 
cohort, revealing two clusters with a separation 
between high-risk (HR) and low-risk (LR) patients 
(heatmap in Additional file 3). Furthermore, the 
overall methylation pattern in the primary NB 
tumor samples was compared by calculating the 
number of methylation events for each sample. 
This indicates that HR patients show, on average, 
more methylation events compared to LR 
patients (p < 0.001; HR-DOD, 17.21 methylation 
events (95% confidence interval (CI) 15.62 to 
18.81); HR-SURV, 17.13 methylation events (95% 
CI 15.81 to 18.46); LR-SURV, 13.00 methylation 
events (95% CI 11.86 to 14.14)). Also on the 
individual marker level, some MSP assays are 
differentially methylated across the prognostic 
patient groups: KRT19 and ACSS3.These genes 
are more frequently methylated in HR patients 
compared to LR patients (Table 1). Within the HR 
group, HIST1H3C shows a tendency to be more 
frequently methylated in HR-DOD compared to 
HR-SURV samples (21% in HR-DOD versus 7% in 
HR-SURV), while KRT19 (32% versus 48%) and 
ACSS3 (25% versus 47%) show the inverse 
pattern. 
Some individual MSP assays were also associated 
with one or more NB risk factors (stage, MYCN 
status and age at diagnosis), and are thus 
potential prognostic biomarkers in NB (Table 1). 
In this analysis, the age at diagnosis was tested 
using two different age cutoffs. The 12 months 
cutoff was chosen as it was used for therapy 
stratification and as a criterion in the sample 
selection. The more recently established cutoff 
of 18 months [1,35,36] was also taken into 
account. Newly discovered methylated markers 
are FAS, PRPH, CNR1, QPCT, HIST1H3C, ACSS3 
and GRB10, methylation of which is associated 
with at least one of the NB risk factors. Table 1 
further indicates that the difference in the 
methylation status of HIST1H3C and ACSS3 
between MYCN non-amplified and amplified NB 
cell lines as detected by MBD sequencing is 
reflected in the MSP results of the primary 
tumors as well, as HIST1H3C and ACSS3 are 
almost exclusively methylated in MYCN 
amplified samples. 
Survival analysis using the complete MSP data 
set indicates that patients with less methylation 
events showed better survival rates than 
patients with a high number of methylation 
events (p = 0.01; Additional file 3), as this 
analysis principally discriminates HR and LR 
patients. In order to assess to what extent our 
MSP data set is able to predict overall survival 
(OS) in HR-SURV versus HR-DOD patients, leave-
one-out decision tree analysis was performed 
and repeated 58 times (the number of HR 
patients). For this analysis, we only included the 
   
 
 
Table 1. Several individual markers are differentially methylated between the prognostic groups and neuroblastoma risk factors. 
type subtype 
KRT19 FAS PRPH CNR1 QPCT HIST1H3C ACSS3 GRB10 
number % number % number % number % number % number % number % number % 
prognostic 
group 
LR-SURV 0/31 0 1/31 3 14/31 45 2/31 6 18/31 58 0/31 0 0/31 0 6/31 19 
HR-SURV 14/30 48 8/30 27 24/30 80 10/30 33 25/30 83 2/30 7 14/30 47 13/30 43 
HR-DOD 9/28 32 6/28 21 19/28 68 10/28 36 24/28 86 6/28 21 7/28 25 11/28 39 
INSS stage 
stage 1 0/21 0 0/21 0 8/21 38 1/21 5 13/21 62 0/21 0 0/21 0 4/21 19 
stage 2 1/12 8 2/12 17 8/12 67 2/12 17 8/12 67 0/12 0 1/12 8 3/12 25 
stage 3 9/17 53 4/17 24 13/17 77 9/17 53 15/17 88 3/17 18 9/17 58 8/17 47 
stage 4 13/39 33 9/39 15 28/39 72 10/39 26 31/39 80 5/39 18 11/39 28 15/39 39 
MYCN 
amplification 
status 
MYCN  
non-amplified 
7/50 14 2/50 4 24/50 48 5/50 10 31/50 62 0/50 0 2/50 4 14/50 28 
MYCN 
amplified 
16/39 41 13/39 33 33/39 85 17/39 44 36/39 92 8/39 21 19/39 49 16/39 41 
age at 
diagnosis 
> 12 months 21/53 40 14/53 26 37/53 69 18/53 34 46/53 87 8/53 15 21/53 40 24/53 45 
< 12 months 2/36 6 1/36 3 20/36 56 4/36 11 21/36 58 0/36 0 0/36 0 6/36 17 
> 18 months 20/45 44 13/45 29 33/45 73 17/45 38 40/45 89 8/45 18 19/45 49 23/45 51 
< 18 months 3/44 7 2/44 5 24/44 55 5/44 11 27/44 61 0/44 0 2/44 5 7/44 16 
overall total  23/89 26 15/89 17 57/89 64 22/89 25 67/89 75 8/89 9 21/89 24 30/89 34 
statistics on type (Fisher’s exact p-value) 
 KRT19 FAS PRPH CNR1 QPCT HIST1H3C ACSS3 GRB10 
prognostic group <0.001 0.151 0.112 0.068 0.165 0.0624 <0.001 0.405 
MYCN amplification status 0.0594 0.008 0.008 0.008 0.017 0.0146 <0.001 0.708 
INSS stage 0.007 0.287 0.221 0.059 0.683 0.448 0.008 0.700 
age cutoff 12 months 0.008 0.045 0.579 0.138 0.059 0.123 <0.001 0.059 
age cutoff 18 months 0.002 0.045 0.326 0.059 0.045 0.0594 0.0015 0.012 
Note. The number (percentage) of methylated samples in each stratum is given. P-values according to Fisher’s exact test, corrected for multiple testing (Benjamini-
Hochberg). HR-DOD: high-risk deceased patients; HR-SURV: high-risk patients alive for at least 1,000 days follow-up; INSS: International Neuroblastoma Staging System; LR-
SURV: low-risk patients alive for at least 1,000 days follow-up. P-values in bold indicate significant associations. 
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data from MSP assays (un)methylated in at least 
three samples. Comparison of the 58 generate 
decision trees showed that 4 DNA methylation 
biomarkers (CNR1, ACSS3, HIST1H3C and PRPH) 
are included in at least 50% of the resulting 
classifiers. Then, leave-one-out decision tree 
analysis was redone, but this time using only the 
methylation data of CNR1, ACSS3, HIST1H3C and 
PRPH. Afterwards, the predictions for all 58 HR 
samples were visualized in a Kaplan-Meier plot 
(Figure 2). This analysis indicates that the 
combined methylation status of CNR1, ACSS3, 
HIST1H3C and PRPH has the potential to 
discriminate between HR-SURV and HR-DOD 
patients (p = 0.058). 
 
 
 
Figure 2. The combined methylation status of CNR1, ACSS3, HIST1H3C and PRPH can potentially discriminate 
high-risk patients. The Kaplan-Meier plot shows overall survival in the high-risk samples of the high-throughput 
MSP screening according to their predicted overall survival status based on leave-on-out decision tree analysis 
using the methylation data of CNR1, ACSS3, HIST1H3C and PRPH. Group 1 is predicted to survive, group 2 to die 
of disease. The p-value is determined using log-rank test (Mantel-Cox). 
 
Survival analysis was also performed on the 
individual marker level. We first tested 
differences between the HR-DOD and LR-SURV 
groups using the univariate log-rank test (with 
multiple testing correction). This first analysis 
indicates that six genes (KRT19, FAS, CNR1, 
HIST1H3C, ACSS3 and GNAS) are significantly 
related to survival when comparing these 
patient groups. As we also want to discriminate 
the HR patient groups (HR-DOD and HR-SURV), 
we then used the entire dataset (all samples) to 
assess which of these six genes were associated 
with survival (in a specific stratum only, such as 
only in MYCN non-amplified samples). These 
results are shown in Table 2. According to log-
rank tests, HIST1H3C methylation is associated 
with both OS and event-free survival (EFS), while 
GNAS methylation is associated with EFS. As NB 
is a heterogeneous disease, these biomarkers 
may be suited to a specific subgroup of patients 
for predicting survival. For example, HIST1H3C 
methylation only occurs in high-stage tumors 
with MYCN amplification (6/17 (35%) in HR-DOD 
patients versus 2/22 (9%) in HR-SURV patients). 
Figure 3 shows the Kaplan-Meier plots for 
HIST1H3C and GNAS methylation (OS or EFS and 
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OS in specific strata related to one of the risk 
factors).  
 
mRNA expression profiling: determining 
transcriptional silencing of DNA methylation 
biomarkers 
 
As it is known that promoter methylation may 
cause transcriptional silencing of the gene, we 
further measured the mRNA expression levels of 
five promising DNA methylation biomarkers that 
were methylated in a substantial fraction of HR 
patients (CNR1, GRB10, KRT19, PRPH and QPCT). 
Quantitative RT-PCR assays were developed and 
tested on 366 primary NB tumor samples. Table 
3 displays the results of the comparisons of the 
expression levels of each DNA methylation 
biomarker between the different NB tumor 
stages, MYCN non-amplified and amplified 
tumors, the two age groups (using both the 12 
and 18 months cutoff), and surviving and 
deceased patients. As an example, the mRNA 
expression levels of these genes across the NB 
tumor stages are depicted in Additional file 4. 
Out of the 366 primary NB tumors, 245 could be 
assigned to one of the prognostic groups defined 
in this study (Additional file 4), which allowed us 
to asses differential mRNA expression between 
these groups as well. For all genes mRNA 
expression levels were significantly higher in the 
LR group compared to the HR groups. As 
methylation of these genes was mainly detected 
in the HR groups, this suggests that methylation 
may contribute to the transcriptional silencing of 
these genes. 
 
Table 2. Several individual DNA methylation markers are associated with survival.  
statistics KRT19 FAS CNR1 HIST1H3C ACSS3 GNAS 
HR-DOD versus LR-SURV (p-value OS) 0.037 0.028 0.043 0.002 0.002 0.012 
HR-DOD versus LR-SURV (p-value EFS) 0.039 0.049 0.039 0.039 0.079 0.039 
HR-DOD versus LR-SURV and  
HR-SURV (p-value OS) 
0.687 0.639 0.423 0.039 0.691 0.221 
HR-DOD versus LR-SURV and  
HR-SURV (p-value EFS) 
0.665 0.467 0.414 0.041 0.939 0.041 
HR-DOD versus LR-SURV and  
HR-SURV (p-value OS (stratum)) 
  
age < 12 
months 
0.035 
stage 4 
0.033 
 
MYCN0 
0.033 
HR-DOD versus LR-SURV and  
HR-SURV (p-value EFS (stratum)) 
 
age < 12 
months 
0.014 
   
MYCN0 
0.001 
Note. Log-rank test statistics (Mantel-Cox) are given (multiple testing correction by Benjamini-Hochberg) for 
comparison between the ultra-high-risk group (HR-DOD) versus the low-risk group (LR-SURV), and between the 
ultra-high-risk group (HR-DOD) and all survivors (LR-SURV and HR-SURV). If a significant association (p < 0.05) 
was found in a particular stratum (associated with risk factors), this stratum is shown (multiple testing 
correction for the different comparisons by Benjamini-Hochberg). EFS: event-free survival; MYCN0: MYCN non-
amplified; OS: overall survival. P-values in bold indicate significant associations. 
 
Table 3. The mRNA expression level of several markers associates with neuroblastoma risk factors, 
prognostic groups and survival. 
grouping variable statistics CNR1 GRB10 KRT19 PRPH QPCT 
stage Kruskal-Wallis p-value <0.001 0.008 0.118 0.010 <0.001 
MYCN amplification status Mann-Whitney p-value <0.001 <0.001 <0.001 <0.001 <0.001 
age cutoff 12 months Mann-Whitney p-value <0.001 0.609 <0.001 0.005 <0.001 
age cutoff 18 months Mann-Whitney p-value <0.001 0.810 <0.001 0.003 0.006 
overall survival status Mann-Whitney p-value <0.001 0.003 0.023 <0.001 <0.001 
prognostic group Kruskal-Wallis p-value <0.001 0.002 0.005 <0.001 <0.001 
The statistical test used is shown and p-values (corrected for multiple testing using Benjamini-Hochberg) are 
indicated. P-values in bold indicate significant associations. 
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Figure 3. Methylation of HIST1H3C and GNAS is associated with worse survival outcome. Kaplan-Meier plots 
on the left show overall survival or event-free survival for all 89 primary neuroblastoma samples, those on the 
right overall survival in a specific stratum based on one of the risk factors only. Survival curves indicated with 
‘M’ are the methylated samples, survival curves associated with the unmethylated assay are indicated with ‘U’. 
The numbers of patients are indicated (n) and p-values are determined using log-rank test (Mantel-Cox; 
multiple testing correction by Benjamini-Hochberg). Time is censored to 2,000 days. MYCN0: MYCN non-
amplified. 
Survival analysis using Cox proportional hazards 
further shows that low mRNA expression levels 
of CNR1 (hazard ratio 0.768; 95% CI 0.619 to 
0.953; p = 0.028), GRB10 (hazard ratio 0.613; 
95% CI 0.433 to 0.866; p = 0.015) and PRPH 
(hazard ratio 0.714; 95% CI 0.566 to 0.922; p = 
0.015) were significantly associated with poor 
survival. After dichotomization of the mRNA 
expression data, using the median relative 
mRNA expression value as a cutoff, Kaplan-
Meier survival curves were plotted (log-rank 
test; Additional file 4).  
An interesting observation in our MBD 
sequencing and MSP data is the fact that 
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HIST1H3C and ACSS3 are differentially 
methylated between MYCN non-amplified and 
amplified NB cell lines and primary tumors 
(Table 1; Additional file 2). To further explore 
this finding, the HIST1H3C and ACSS3 MSP assays 
were tested on 31 NB cell lines, of which 10 
were MYCN non-amplified and 21 MYCN 
amplified (Additional file 5). In addition, we also 
profiled HIST1H3C and ACSS3 mRNA expression 
levels in these cell lines, in order to assess the 
direct relationship between promoter 
methylation and mRNA expression and to 
compare this relationship between MYCN non-
amplified and amplified cell lines. The significant 
differential methylation status of HIST1H3C and 
ACSS3 between MYCN non-amplified and 
amplified samples was confirmed in the NB cell 
lines (HIST1H3C, methylated in 15/21 (71%) 
MYCN amplified cell lines and in 2/10 (20%) 
MYCN non-amplified cell lines, p = 0.018; ACSS3, 
methylated in 20/21 (95%) MYCN amplified cell 
lines and in 3/10 (30%) MYCN non-amplified cell 
lines, p < 0.001). Moreover, expression of 
HIST1H3C mRNA was significantly lower in 
methylated samples compared to unmethylated 
samples, both in MYCN amplified (p = 0.005) and 
MYCN non-amplified (p = 0.044) cell lines (Figure 
4). These data support the idea that HIST1H3C 
promoter methylation contributes to 
transcriptional silencing of the gene. Figure 4 
further indicates that the MYCN status itself is 
not significantly associated with HIST1H3C mRNA 
expression levels (p = 0.204). As ACSS3 is 
expressed at very low mRNA levels, we could not 
correlate its mRNA expression data with the 
methylation data (data not shown).  
 
 
 
Figure 4. HIST1H3C has lower mRNA expression levels in neuroblastoma cell lines in which the HIST1H3C 
promoter is methylated. Thirty-one neuroblastoma cell lines were categorized according to their MYCN 
amplification and HIST1H3C methylation status. The relative HIST1H3C mRNA expression level of each of these 
cell lines is indicated. P-values according to Mann-Whitney test are also indicated. MYCN0: MYCN non-
amplified; MYCN1: MYCN amplified. 
Discussion  
 
Thus far, most of the studies analyzing DNA 
methylation patterns in NB have been candidate 
gene-based, with the methylation status of the 
promoter region for only a limited number of 
genes being tested. These candidate genes were 
selected based either on prior knowledge of NB 
tumor biology or on the fact of being methylated 
in other tumor types. As a consequence, only 
few DNA methylation biomarkers, such as 
KRT19, TNFRSF10D, CASP8, ZMYND10 and 
RASSF1A, were previously related to NB risk 
factors or survival [11,13–15,18,37–41]. In order 
to identify new DNA methylation biomarkers in 
NB, we applied a multilevel experimental 
approach. In the discovery phase we established 
a genome-wide methylome map of eight NB cell 
lines. These cell lines were profiled using gene 
expression microarrays before and after DAC 
treatment, and using MBD capture followed by 
next-generation sequencing (NGS). The 
combination of both methodologies enabled the 
identification of regions that are both 
methylated and undergo re-expression upon 
DAC treatment. So far, only MeDIP chips were 
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used in whole promoter profiling studies on NB 
[9], making this study the first one using NGS for 
unbiased and more sensitive assessment of 
genome-wide DNA methylation patterns in NB. 
Our results emphasize the potential of this 
epigenetic sequencing technique, as it enables 
the investigation of the methylome or 
epigenome of a sample in great detail at a 
feasible cost.  
Integration of these methylome maps with 
genome-wide gene expression profiles led to a 
selection of 43 candidate biomarkers that were 
tested on 89 primary NB patient samples. All 
samples were assigned to one of three discrete 
prognostic patient groups (low-risk survivors (LR-
SURV), high-risk deceased (HR-DOD) and high-
risk survivors (HR-SURV)). While most NB 
methylation studies did not discriminate 
between HR-SURV and HR-DOD patients, we 
believe this is an important clinical question, as 
both prognostic groups are currently considered 
high-risk and uniformly treated, making the 
present study unique in its concept. As we make 
use of amplified bisulfite-converted DNA, only 
limited amounts (100 to 200 ng) of tumor DNA 
are required to test over 100 MSP assays. The 
MBD sequencing results greatly help in designing 
the assays in the most informative regions, 
which is important as the assay location is 
critically important, again confirmed in this study 
for a number of genes for which multiple assays 
were designed (for example, TGFBI and KRT19). 
The combination of the number of samples and 
assays used in this study further makes it the 
most comprehensive methylation study in NB. 
Furthermore, the high-throughput validation 
pipeline allows fast and accurate follow-up 
validation of potential candidate DNA 
methylation biomarkers for large numbers of 
patients. Indeed, PCR-based detection 
methodologies are robust and can thus be used 
in a wide range of laboratory settings for a low 
price without the need of special equipment 
other than for qPCR and (microfluidic) 
electrophoresis, both present in most molecular 
laboratories. The presented DNA methylation 
screening and validation methodology can thus 
easily be adapted by (cancer) researchers 
addressing similar questions in other research 
fields.  
In this study, several novel biomarkers were 
established in addition to known DNA 
methylation biomarkers in NB, such as KRT19, 
TGFBI, TNFRSF10D and TNFRSF10A 
[14,18,37,42,43]. Interestingly, some of these 
novel genes were previously reported to be 
important in NB biology (without reference to 
their epigenetically altered status) or were 
described as epigenetic biomarkers in other 
tumor entities, such as FAS, which encodes a 
member of the tumor necrosis factor receptor 
(TNFR) superfamily [44–50]. Several other novel 
methylation biomarkers were also shown to be 
differentially methylated between HR and LR 
patients, and many of these were associated 
with NB risk factors or with survival. However, 
discriminating HR-DOD and HR-SURV patients is 
challenging. While only a few individual MSP 
designs (HIST1H3C, KRT19 and ACSS3) were 
moderately discriminatory between these two 
HR subgroups, the combined methylation data 
analysis of CNR1, ACSS3, HIST1H3C and PRPH 
indicates the potential of DNA methylation 
biomarkers in stratifying HR NB patients. In this 
study, the difficulty of identifying individual 
biomarkers that differentiate between HR-DOD 
and HR-SURV patients may be explained by the 
fact that NB cell lines were used in the discovery 
phase, thus enriching for genes discriminating 
between HR and LR patients as NB cell lines can 
be considered models for aggressive HR tumors. 
To accommodate this, we plan to perform a 
large-scale discovery using MBD capture 
followed by NGS on primary NB tumors equally 
distributed over the three prognostic groups 
used here.  
PRPH is one of the novel biomarkers identified 
and is differentially methylated across the 
prognostic patient groups. This gene encodes 
the cytoskeletal protein peripherin found in 
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neurons of the peripheral nervous system, and is 
probably associated with maturation of the 
neural phenotype and hence serves as a 
differentiation marker for tumors derived from 
the neural crest [51]. In our study, PRPH 
methylation was mainly detected in more 
advanced tumor stages. Since promoter 
methylation may cause transcriptional silencing 
of the gene and advanced NB tumor stages are 
less differentiated [52], this is in line with the 
idea that high levels of peripherin contribute to 
more differentiated tumor stages. As 
demonstrated in this study, this idea is further 
strengthened by the fact that PRPH mRNA 
expression levels gradually decreased with 
increasing aggressiveness of the tumor. As whole 
genome sequence analysis recently showed that 
genes involved in neuritogenesis are recurrently 
affected in high-stage NB [53], the identification 
of PRPH methylation opens new research 
perspectives regarding NB therapy. 
Next to protein-coding genes, some MSP assays 
were designed in the promoter region of 
miRNAs. Aberrant miRNA expression contributes 
majorly to NB tumor biology and has been 
extensively studied during the past few years. 
Most of these studies used miRNA microarrays 
or high-throughput RT-qPCR to analyze the 
miRNA expression patterns in primary NB tumor 
samples [54–56]. Although a broad deregulation 
of the miRNA expression profile in NB has been 
described, miRNA promoter hypermethylation is 
relatively unexplored. Up until now, the only 
miRNA for which the promoter region is known 
to be methylated in NB is miR-200b [57]. 
Interestingly, miR-1225, miR-3177 and miR-671 
were found to be methylated in their promoter 
region in more than 75% of the NB tumors in our 
study. Currently, little is known about the 
putative function of these miRNAs, as they are 
not well described or not described at all in the 
literature [58,59]. 
Another interesting finding is that MYCN non-
amplified and amplified samples show 
differential promoter methylation of HIST1H3C 
and ACSS3. Currently, little is known about the 
association between MYCN and DNA 
methylation of certain genes in NB, nor about 
the underlying molecular mechanisms. 
Previously, Teitz et al. [9,60] showed that DNA 
methylation of CASP8 is almost exclusively 
associated with MYCN amplification in both NB 
cell lines and primary tumors. They further 
noticed that CASP8 was hemimethylated (only 
one allele) in stage 1, 2 and 3 NB, which may 
indicate that complete methylation of CASP8 
may be coupled to another event, such as 
amplification of the MYCN gene. While this 
suggests that MYCN amplification is functionally 
linked to complete methylation of both CASP8 
alleles, it is not clear if these two events occur 
concurrently, or if one event leads to the other. 
Obviously, genes differentially methylated 
between MYCN non-amplified and amplified 
samples need to be further functionally 
characterized, as this may lead to new insights 
into NB biology.  
 
Conclusions  
 
Although international collaboration in the field 
of NB has invested tremendous effort in 
optimizing patient stratification and therapy 
protocols, OS rates remain low. This study shows 
that DNA methylation biomarkers have the 
potential to refine current risk assessment 
schemes. In contrast to most NB methylation 
studies that are candidate gene-based, we 
applied two genome-wide detection 
methodologies to discover hypermethylated 
regions in NB: re-expression analysis after 
demethylating DAC treatment and NGS after 
MBD capture. Furthermore, we present a high-
throughput and semi-automated MSP pipeline, 
which was used to test the candidate DNA 
methylation markers on a large patient tumor 
cohort. We have identified novel aberrant 
promoter hypermethylation of protein coding 
genes and miRNAs in NB. Some of these DNA 
methylation biomarkers are associated with NB 
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risk factors and/or survival, emphasizing the 
prognostic value of these markers and their 
potential to be used in a DNA methylation-based 
prognostic classifier in NB. The use of such a 
DNA methylation signature, discriminating HR 
patients, is demonstrated here by the combined 
methylation data analysis of CNR1, ACSS3, 
HIST1H3C and PRPH. Furthermore, some DNA 
methylation biomarkers showed low levels of 
mRNA expression in patient groups with high 
methylation levels. This suggests that promoter 
methylation may contribute to transcriptional 
silencing of these genes, which may be 
important in the pathogenesis of NB. 
Encouraged by these results, we will now 
extensively further validate these DNA 
methylation biomarkers and refine the 
methylome map of different prognostic NB 
patient groups.  
 
Materials and methods  
 
Neuroblastoma cell lines and primary tumors  
 
In total, 33 well-characterized NB cell lines, 
authenticated using array comparative genomic 
hybridization and short tandem repeat 
genotyping, were included in this study 
(Additional files 2 and 5). DNA was isolated using 
the QIAamp DNA Mini Kit (Qiagen, Venlo, The 
Netherlands). In addition, 109 primary tumor 
samples of NB patients were collected prior to 
therapy at the Ghent University Hospital (Ghent, 
Belgium), the University Children’s Hospital 
Essen (Essen, Germany), Our Lady’s Children’s 
Hospital Dublin (Dublin, Ireland) or the Hospital 
Clínico Universitario (Valencia, Spain). Informed 
consent was obtained from each patient’s 
guardian and the study was approved by the 
ethical committee of the Ghent University 
Hospital (approval number B67020109912). 
Clinical characteristics of the patients are shown 
in Additional files 1 and 3. All NB patient samples 
were assigned to one of three defined risk 
groups based on risk parameters (tumor stage, 
MYCN status and age at diagnosis) and disease 
outcome. First, HR patients that died of disease 
(HR-DOD) as defined by stage 2/3, MYCN 
amplified, DOD; stage 4, age at diagnosis < 12 
months, MYCN amplified, DOD; or stage 4, age at 
diagnosis > 12 months, DOD (n = 39). Second, HR 
patients alive (HR-SURV) after follow-up time > 
1,000 days (n = 30). Third, LR patients alive (LR-
SURV) defined by stage 1/2, MYCN non-
amplified, follow-up time > 1,000 days; stage 3, 
MYCN non-amplified, age < 12 months, follow-
up time > 1,000 days (status at last known 
follow-up is alive; n = 40). The clinical data of the 
366 primary NB tumors (SIOPEN/GPOH cDNA 
library [6]), used to test the mRNA expression 
levels of the most promising DNA methylation 
biomarkers, can be found in Additional file 4. 
 
Microarray after re-expression analysis  
 
Eight NB cell lines (CHP-902R, CLB-GA, IMR-32, 
LAN-2, N206, SH-SY5Y, SK-N-AS and SJNB-1) 
were grown in the presence of 3 µM DAC (Sigma, 
Bornem, Belgium)) for 3 days, as previously 
described, and untreated controls were also 
prepared [61]. After harvesting, RNA was 
extracted with the RNeasy Mini kit (Qiagen), 
accompanied by RNase free DNase treatment on 
column (Qiagen). After RNA quality check on the 
Experion (Bio-Rad, Nazareth, Belgium), sample 
preparation, hybridization to Affymetrix Human 
Genome U133 Plus 2.0 oligonucleotide chips and 
scanning were carried out according to the 
manufacturer’s protocol at the VIB MicroArray 
Facility. Standard quality metrics (simpleaffy 
BioC package [62] boxplots, visual inspection of 
the slides, 5’-3’ degradation plot) demonstrated 
that the oligonucleotide chip data were of good 
quality. The BioC affy package was used to 
normalize (gc-RMA normalization) the 
expression levels and to obtain present/absent 
(expression/no expression) MAS 5.0 calls for 
each probe set. For all cell lines and for each 
probe set, the number of reactivation events 
was counted (absent in untreated cells and 
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present in treated cells). Expression data (before 
and after DAC treatment) have been deposited 
into the Gene Expression Omnibus [GEO: 
GSE31229], according to the MIAME guidelines.  
 
MBD sequencing  
 
DNA samples (1 µg DNA) of the eight NB cell 
lines were sheared (Covaris S2) to an average 
length of 200 bp. Fragment distribution was 
determined by the Agilent 2100 Bioanalyzer and 
the concentration was determined using the 
Quant-iT PicoGreen dsDNA HS Assay Kit 
(Invitrogen, Ghent, Belgium). Starting from 200 
ng sheared DNA, the MethylCollector Kit 
(ActiveMotif, La Hulpe, Belgium) was used to 
enrich for methylated fragments. Library 
preparation for multiplex Illumina sequencing 
was done by combining the DNA Sample Prep 
Master Mix Set 1 (New England Biolabs, 
Frankfurt am Main, Germany) and the 
Multiplexing Sample Preparation Oligo Kit 
(Illumina). Size selection of the library was done 
on a 2% agarose gel. Fragments of around 300 
bp (±50 bp) were excised and purified. Illumina 
library amplification (21 cycles) was performed 
and concentration was determined. Paired-end 
sequencing was used for high confidence 
mapping of captured fragments (2 × 45 bp 
sequencing - Illumina GAIIx, NXTGNT). Paired-
end reads were mapped on the human 
reference genome (GRCh37) using Bowtie 0.12.7 
and peaks were called using MACS 1.4beta. For 
differential methylation analysis, PCR duplicates 
were removed and sequence tags counted by 
using the BioC packages Short-Read and 
rtracklayer [63,64]. Sequence tag counts per 
sample were used to compose a count matrix 
that could be processed by the BioC package 
DESeq [25]. Sequencing data (raw sequence files, 
WIG files for visualization of the mapping results 
and the BED peak files as determined by MACS) 
have been deposited into GEO [GEO:GSE31353].  
 
Selection of candidate biomarkers  
Initial high-throughput MSP  
In total, 212 MSP assays (Additional file 1) were 
designed in the promoter region of 120 
corresponding genes re-expressed after DAC 
treatment, and tested on both the DAC-treated 
and untreated NB cell lines, 9 LR-SURV patients 
and 11 HR-DOD patients (Additional file 1). A 
total of 500 to 1,000 ng DNA of these samples 
was bisulfite-treated (EZ DNA Methylation Kit, 
Zymo Research, Irvine, CA, USA), eluted in 30 µl 
elution buffer and then tested on the BioTrove 
OpenArray (Life Technologies, Ghent, Belgium). 
Beta actin (ACTB) was used as a control and to 
normalize samples. The in vitro methylated HCT-
116 DKO cell line (treated with SssI, Zymo 
Research) was used as a positive control. The 
methylation status for each MSP assay was 
determined, and called methylated if the melting 
temperature (Tm) of the amplicon was within a 
specific interval as defined by the positive 
control sample. These methylation calls were 
further analyzed by determining specificity and 
sensitivity of the HR-DOD samples versus LR-
SURV samples.  
 
Publicly available mRNA expression studies  
Six publicly available mRNA expression studies 
[27–34] [GEO:GSE19274, GEO:GSE16237, 
GEO:GSE14880, GEO: GSE12460, GEO:GSE13136, 
GEO:GSE3960] were analyzed using RankProd 
analysis (BioC package [18]), to identify 
differentially expressed probes between 
prognostic groups (high-risk versus low-risk, 
high-stage versus low-stage, and MYCN 
amplified versus MYCN non-amplified).  
 
Scoring system  
Each analysis score of a promoter region (for 
example, RankProd FDR-value and p-value for 
differential expression between risk groups, and 
p-values of the peak after MBD sequencing) was 
ranked and given a score, ranging from tan (1) to 
0 according to their rank. These individual scores 
were then summed and 43 top-ranking genes 
were selected for further analysis.  
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High-throughput MSP  
 
MSP assays were designed to only amplify the 
bisulfite-converted target region of interest and 
do not anneal to genomic DNA. As each primer 
contains at least two CpG sites, this means that a 
PCR product will only be generated if the 
template is methylated. We choose not to 
design the according U primers (that would 
amplify the non-methylated bisulfite-converted 
DNA) as we do not assess methylation in a 
quantitative way. After in silico assay evaluation, 
48 selected MSP primers (including the ACTB 
control; Additional file 3) were empirically 
validated on the Roche LightCycler 480 (LC480) 
using the in vitro methylated HCT-116 DKO 
(positive control), the HCT-116 DKO (negative 
control) and NB cell lines. Based on melting 
curve and amplicon size analysis, all assays were 
considered amplicon-specific. The MSP assays 
were tested on 89 samples, selected from the 
previously described patient groups (31 LR-SURV 
patients, 28 HR-DOD patients and 30 HR-SURV 
patients; Additional file 3). A no template control 
(NTC) sample was loaded as well. For all 
samples, 500 to 1,000 ng DNA was bisulfite-
treated (EZ DNA Methylation Kit, Zymo 
Research) and eluted in 40 µl elution buffer. 
Prior to MSP, bisulfite-treated DNA (BT-DNA) 
was amplified using the EpiTect Whole 
Bisulfitome Kit (Qiagen), starting from 100 ng BT-
DNA. After amplification, the yield was 
determined by the Qubit 2.0 fluorometer in 
combination with the Quant-iT PicoGreen dsDNA 
BR Assay Kit (Invitrogen). The MSP was 
performed on the LC480 and plates were 
prepared using the Tecan freedom Evo robot, 
using a design that assures that all samples were 
tested for the same assay in the same run [65]. 
MSP amplifications were performed in 10 µl 
containing 5 µl LC480 SYBR Green I Master Mix 
(2×; Roche, Vilvoorde, Belgium), 1 mg/ml bovine 
serum albumin (Roche), 1 mM MgCl2 (Roche), 
125 nM forward and reverse primer (IDT, 
Leuven, Belgium), sample (20 ng amplified BT-
DNA) and nuclease-free water (Sigma). MSP 
conditions were as follows: activation for 10 
minutes at 95°C, 45 amplification cycles (10 s at 
95°C, 30 s at 60°C and 5 s at 72°C), followed by 
melting curve analysis (5 s at 95°C - melting 
curve from 60 to 95°C) and cool down to 45°C. 
Afterwards, the size of the amplicons was 
determined using the Caliper LabChip GX. A MSP 
assay was considered methylated if (1) its Cq-
value < 35 (calculated by the LC480 software 
using the second derivative maximum method), 
(2) its melting temperature (Tm) differed no 
more than 2°C from that of the positive control 
sample, and (3) the amplicon length differed no 
more than 10 bp from the band size of the 
positive control sample. In addition, the band 
height, as determined by the LabChip GX 
software, was required to be higher than 20.  
 
mRNA expression profiling  
 
The mRNA expression levels of CNR1, GRB10, 
KRT19, PRPH and QPCT were profiled on the NB 
SIOPEN/ GPOH cDNA library generated from 366 
primary NB tumor samples (Additional file 4) [6]. 
For each DNA methylation marker a qPCR mRNA 
assay was designed and validated in silico and in 
vitro (Additional file 4) [66]. PCR plates were 
prepared as described in the previous section 
and RT-qPCR was performed on the LC480 as 
described in [6]. Relative gene expression levels 
were then normalized using the geometric mean 
of five reference sequences (HPRT1, SDHA, UBC, 
HMBS and AluSq) [67]. For HIST1H3C and ACSS3, 
a qPCR mRNA assay (Additional file 5) was 
designed and tested on 31 NB cell lines on which 
the corresponding MSP assay was tested as well. 
Here, qPCR amplifications were performed in 5 
µl containing 2.5 µl SsoAdvanced SYBR Green 
Supermix (2×; Bio-Rad), 0.25 µl forward and 
reverse primer (5 µM each) and 2 µl cDNA 
sample (corresponding to 5 ng cDNA). Relative 
gene expression levels were normalized using 
the geometric mean of the reference sequences 
SDHA, UBC and AluSq. All RT-qPCR data analysis 
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was done in qbase-PLUS version 2.0 (Biogazelle, 
Ghent, Belgium) [65]. Logged and normalized 
qPCR data can be found in Additional file 4 and 
5. 
 
Statistical analysis  
 
Statistical analyses were performed using IBM 
SPSS software version 19.0. All statistical tests 
were two-sided and p-values < 0.05 were 
considered statistically significant. Differential 
methylation across the prognostic groups was 
determined by the Chi square test. The 
relationship between the methylation status and 
NB risk factors was determined using Fisher’s 
exact test. Univariate survival analysis was 
performed with the Kaplan-Meier method and 
log-rank statistics (Mantel-Cox) to determine the 
impact of methylation status on EFS and OS. EFS 
was defined as the time between initial 
diagnosis and relapse or death of disease, or 
time between diagnosis and last follow-up if no 
event had occurred. OS is the time to disease-
related death or last follow-up. Hierarchical 
clustering and leave-one-out decision tree 
analysis were performed using R 2.13.0 (rpart 
package). The relationship between logged 
mRNA expression levels and the prognostic 
groups, OS status and NB risk factors was 
determined using the non-parametric Kruskal-
Wallis test or Mann-Whitney test. Hazard ratios 
between logged mRNA expression data and 
survival were estimated using the Cox 
proportional hazard model. Kaplan-Meier curves 
were created by dichotomizing the logged mRNA 
expression data, using the median mRNA 
expression value as a cutoff. For HIST1H3C, the 
relationship between logged mRNA expression 
levels and the methylation status of the gene, 
and the MYCN status, was determined using the 
Mann-Whitney test. For all the above mentioned 
statistical tests, multiple hypothesis testing 
correction was performed (Benjamini-Hochberg 
method by using the R function p.adjust). 
 
Additional materials  
 
Additional files can be found at: 
http://genomebiology.biomedcentral.com/articl
es/10.1186/gb-2012-13-10-r95 
 
Additional File 1. Clinical patient annotation, 
MSP assays and results on the BioTrove 
discovery platform. Part BioTrove clinical 
annotation. Patient characteristics of the 
samples used for the initial high-throughput MSP 
screening on the BioTrove OpenArray. PatientID 
is a unique patient number, the group indicates 
the risk. Clinical characteristics given are the age 
at diagnosis in months, International 
Neuroblastoma Staging System (INSS) stage, 
MYCN amplification status (0 is non-amplified 
and 1 is amplified), follow-up time (FU) in days 
after diagnosis, and overall survival (OS) and 
event-free survival (EFS) time in days after 
diagnosis. OS indicates whether the patient was 
alive (0) at the last known FU or died of disese 
(1). Similar for EFS, indicating events, such as 
relapse or progression. Empty cells represent 
missing values. Part BioTrove assays. MSP 
assays used in the initial high-throughput MSP 
screening on the BioTrove OpenArray. For each 
tested gene, the assay name(s) and 
corresponding forward and reverse primer(s) (5’ 
to 3’) are indicated, as well as the genomic 
location of the amplicon on the hg19 reference 
genome. Part BioTrove results. Results of the 
initial high-throughput MSP screening on the 
BioTrove OpenArray. For each assay and sample, 
the methylation call (dark blue is methylated, 
green unmethylated) is given. Samples are 
subdivided into two prognostic groups (HR-DOD 
and LR-SURV). The specificity and sensitivity of 
the assays is indicated as well. Assyas selected 
for further testing are indicated in yellow. HR-
DOD: high-risk deceased patients and LR-SURV: 
low-risk patients alive for at least 1000 days 
follow-up. 
 
Additional File 2. Visualization of the 
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protocadherin beta gene cluster and the 
HIST1H3C promoter region in the Integrative 
Genomic Viewer. First panel. Visualization of a 
part of the protocadherin β (PCDHB) gene family 
cluster in IGV. For each NB cell line (SK-N-AS, 
CLB-GA, SH-SY5Y, SJNB-1, CHP-902R, IMR-32, 
LAN-2 and N206), the number of sequencing 
tags at each position is shown and the location 
of detected peaks is indicated with a red bar. 
The captured sequences clearly overlap with 
CpG islands in each individual member of this 
gene cluster. Second panel. Visualization of the 
promoter region of HIST1H3C in IGV. The four 
NB cell lines at the bottom (CHP-902R, IMR-32, 
LAN-2 and N206) are MYCN amplified. Three of 
these cell lines clearly show sequence tags in the 
CpG island, while the four NB cell lines on top 
(SK-N-AS, CLB-GA, SH-SY5Y and SJNB-1), which 
are MYCN non-amplified cell lines, do not show 
any signal.  
 
Additional File 3. Clinical patient annotation, 
summary of clinical characteristics, MSP assays, 
results and summarized results (per clinical 
parameter) on the LC480 platform for 89 NB 
patient samples. Assays differentially 
methylated between prognostic groups and 
between NB risk factors are discussed in detail, 
as well as extended analyses on the MSP data 
(hierarchical clustering (heatmap) and survival 
analysis according to the number of methylation 
events (Kaplan-Meier plot)). Part LC480 clinical 
annotation. Patient characteristics of the 
samples used for the high-throughput MSP 
screening on the Roche LC480. PatientID is a 
unique patient number, the group indicates the 
risk. Clinical characteristics given are the age at 
diagnosis in months, International 
Neuroblastoma Staging System (INSS) stage, 
MYCN amplification status (0 is non-amplified 
and 1 is amplified), follow-up time (FU) in days 
after diagnosis, and overall survival (OS) and 
event-free survival (EFS) time in days after 
diagnosis. OS indicates whether the patient was 
alive (0) at the last known FU or died of disease 
(1). Similar for EFS, indicating events such as 
relapse or progression. Segmental aberrations 
for chromosome 1p, 11q and 17q are indicated 
with normal, partial loss (PL), whole loss (WL), 
partial gain (PG) or whole gain (WG). Empty cells 
represent missing values. Part LC480 overview 
annotation. Summary of the clinical 
characteristics of the 89 primary NB samples 
used in the high-throughput MSP screening. Part 
LC480 assays. MSP assays used in the high-
throughput MSP screening on the Roche LC480. 
For each tested gene, the assay name(s) and 
corresponding forward and reverse primer(s) (5’ 
to 3’) are indicated, as well as the genomic 
location of the amplicon on the hg19 reference 
genome. Part LC480 results. Results of the high-
throughput MSP screening on the Roche LC480. 
For each assay and for each sample, the 
methylation call (dark blue is methylated, green 
unmethylated) is given. The patient samples are 
subdivided into three prognostic groups (LR-
SURV, HR-DOD and HR-SURV). CL: cell line; Neg: 
negative control (HCT-116 DKO cell line); NTC: 
no template control. Part LC480 overview 
results. Summary of the MSP results of the high-
throughput study. The number of methylated 
samples for a particular MSP assay within each 
prognostic group and for the entire sample set is 
given (percentage of methylated samples 
between brackets). Assays are ranked 
descending on the number of overall methylated 
samples. Assays discussed in more detail in the 
results section are indicated in grey. Part Group 
associations. Detailed information on a selection 
of assays, differentially methylated between 
prognostic groups (per prognostic group and per 
combination of risk factors). The number 
(percentage) of methylated samples in each 
stratum is given. Part Risk factor associations. 
Detailed information on a selection of assays, 
differentially methylated between NB risk 
factors (per (combination of) risk factors). The 
number (percentage) of methylated samples in 
each stratum is given. Part Heatmap. 
Hierarchical clustering based on the MSP data of 
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the 89 primary NB tumor samples. This analysis 
reveals two clusters, indicated with group 1 and 
group 2, which predominantly distinguish high-
risk and low-risk NB patient samples. Each 
sample is assigned to a prognostic group (LR-
SURV, HR-DOD and HR-SURV). Part KM number. 
Kaplan-Meier plot: overall survival in the 
samples of the high-throughput MSP screening 
according to the number of methylation events. 
The purple line indicates patients with 0 to 16 
methylation events, the red line patients with 16 
to 27 methylation events. This 16 methylation 
events cutoff was used, as the average number 
of methylation events in one sample is 16. The p-
value is determined using a log-rank test 
(Mantel-Cox). Time is indicated in days, starting 
from diagnosis. HR-DOD: high-risk deceased 
patients; HR-SURV: high-risk patients alive for at 
least 1000 days follow-up; INSS: International 
Neuroblastoma Staging System; LR-SURV: low-
risk patients alive for at least 1000 days follow-
up. 
 
Additional File 4. Clinical annotation, summary 
of clinical characteristics, qPCR assays and 
results of qPCR experiments on 366 NB patient 
samples (SIOPEN/GPOH cDNA library). Boxplots 
of the expression levels for CNR1, GRB10, KRT19, 
PRPH and QPCT in each of the five different NB 
stages (stages 1, 2, 3, 4 and 4S). A Kaplan-Meier 
plot shows overall survival according to the 
relative mRNA expression levels of CNR1, GRB10, 
KRT19, PRPH and QPCT. Part SIOPEN clinical 
annotation. Patient characteristics of the 
samples of the NB SIOPEN/GPOH cDNA library. 
PatientID is a unique patient number, the group 
indicates the risk. Clinical characteristics given 
are the age at diagnosis in months, International 
Neuroblastoma Staging System (INSS) stage, 
MYCN amplification status (0 is non-amplified 
and 1 is amplified), overall survival (OS) and 
event-free survival (EFS) time in days and 
months after diagnosis, respectively. OS 
indicates whether the patient was alive (0) at the 
last known follow-up or died of disease (1). 
Similar for EFS, indicating events, such as relapse 
or progression. Empty cells represent missing 
values. Part SIOPEN overview annotation. 
Summary of the clinical characteristics of the 
366 primary NB samples of the SIOPEN/GPOH 
cDNA library. Part SIOPEN assays. qPCR mRNA 
assays used in the mRNA expression profiling of 
the DNA-methylation biomarkers CNR1, GRB10, 
KRT19, PRPH and QPCT. For each tested gene, 
the assay name and corresponding forward and 
reverse primer (5’ to 3’) are indicated, as well as 
the genomic location of the amplicon on the 
hg19 reference genome. Part SIOPEN results. 
Results of the mRNA expression measurement of 
the DNA-methylation biomarkers CNR1, GRB10, 
KRT19, PRPH and QPCT. The Cq values were 
converted to relative quantities and log2 values. 
Relative gene expression levels were then 
normalized using the geometric mean of five 
reference sequences (HPRT1, SDHA, UBC, HMBS 
and AluSq). These logged and normalized qPCR 
data are given. Part Expression. Relative mRNA 
expression distribution of CNR1, GRB10, KRT19, 
PRPH and QPCT in each of the five different NB 
tumor stages (stage 1, 2, 3, 4 and 4S). In the box 
plots, the right and left hinge of the boxes 
represents the 75th percentile and 25th 
percentile, respectively. Whiskers, lines that 
extend from the box to the highest and lowest 
values, indicate the data range. Significant p-
values according to the Kruskal-Wallis test 
(corrected for multiple testing using Benjamini-
Hochberg) are indicated. Part Survival. Kaplan-
Meier plots: overall survival in the NB 
SIOPEN/GPOH samples according to the relative 
mRNA expression levels of CNR1, GRB10, KRT19, 
PRPH and QPCT. Survival curves indicated with 
‘High’ and ‘Low’ are the samples assigned to the 
high and low mRNA expression group, 
respectively, using the median relative mRNA 
expression value as a cutoff to create the 
groups. Significant p-values according to the log-
rank test (Mantel-Cox; corrected for multiple 
testing using Benjamini-Hochberg) are indicated. 
Time is indicated in days, starting from diagnosis 
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and censored to 4000 days (censored samples 
are indicated with vertical lines crossing the 
overall survival curves). HR-DOD: high-risk 
deceased patients; HR-SURV: high-risk patients 
alive for at least 1000 days follow-up; INSS: 
International Neuroblastoma Staging System; LR-
SURV: low-risk patients alive for at least 1000 
days follow-up. 
 
Additional File 5. Quantitative PCR and MSP 
assays for HIST1H3C and ACSS3 and matched 
results (expression levels - methylation call) for 
a panel of 31 NB cell lines. Part HIST1H3C and 
ACSS3 qPCR mRNA assay. qPCR mRNA assays 
used in the mRNA expression profiling of the 
DNA-methylation biomarkers HIST1H3C and 
ACSS3. For each gene, the assay name and 
corresponding forward and reverse primer (5’ to 
3’) are indicated. Part HIST1H3C - ACSS3 MSP 
cell lines. Results of the HIST1H3C and ACSS3 
MSP screen on 31 NB cell lines. The methylation 
call (dark blue is methylated, green 
unmethylated) of each cell line is indicated, as 
well as the MYCN amplification status. Part 
HIST1H3C qPCR cell lines. Results of the mRNA 
expression measurement of the DNA-
methylation biomarker HIST1H3C. The Cq values 
were converted to relative quantities and 
converted to log2 values. Relative gene 
expression levels were then normalized using 
the geometric mean of the reference sequences 
SDHA, UBC and AluSq. These logged and 
normalized qPCR data are given. 
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Abstract 
 
Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this 
study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total, 396 low- 
and high-risk primary tumors were analyzed, of which 87 were profiled using methyl-CpG-binding 
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domain (MBD) sequencing for differential methylation analysis between prognostic patient groups. 
Subsequently, methylation-specific PCR (MSP) assays were developed for 78 top-ranking 
differentially methylated regions and tested on two independent cohorts of 132 and 177 samples, 
respectively. Further, a new statistical framework was used to identify a robust set of MSP assays of 
which the methylation score (i.e. the percentage of methylated assays) allows accurate outcome 
prediction. Survival analyses were performed on the individual target level, as well as on the 
combined multimarker signature. As a result of the differential DNA methylation assessment by MBD 
sequencing, 58 of the 78 MSP assays were designed in regions previously unexplored in 
neuroblastoma, and 36 are located in non-promoter or non-coding regions. In total, 5 individual MSP 
assays (located in CCDC177, NXPH1, lnc-MRPL3-2, lnc-TREX1-1 and one on a region from 
chromosome 8 with no further annotation) predict event-free survival and 4 additional assays 
(located in SPRED3, TNFAIP2, NPM2 and CYYR1) also predict overall survival. Furthermore, a robust 
58-marker methylation signature predicting overall and event-free survival was established. In 
conclusion, this study encompasses the largest DNA methylation biomarker study in neuroblastoma 
so far. We identified and independently validated several novel prognostic biomarkers, as well as a 
prognostic 58-marker methylation signature. 
 
Keywords: neuroblastoma, prognosis, DNA methylation, biomarker, biomarker signature 
 
 
Introduction 
 
Neuroblastoma (NB), a childhood tumor that 
originates from precursor cells of the 
sympathetic nervous system, is a heterogeneous 
disease with prognosis ranging from excellent 
long-term survival to high-risk with fatal 
outcome. In order to determine the most 
appropriate treatment modalities for each 
patient, patients are stratified into risk groups at 
the time of diagnosis, based on combinations of 
clinical (age of the patient, stage of the tumor) 
and biological (MYCN amplification status, DNA 
index, histopathology) parameters [1]. Use of 
this risk classification system has shown that 
patients characterized by the same 
clinicobiological parameters can have different 
disease outcomes, indicating that accurate 
assessment of prognosis of NB patients still 
remains difficult [2–4]. Therefore, additional 
prognostic markers are warranted, allowing a 
more accurate risk estimation and more rapid 
identification of those patients who will not 
benefit from current treatments. 
Molecular alterations of the epigenome, 
especially DNA methylation, have emerged as 
alternative targets of biomarker research. DNA 
methylation biomarkers potentially have great 
clinical value due to the stable nature of DNA. 
For this reason, there are many relevant 
applications of DNA methylation biomarkers in 
cancer. For example, they could be used for 
early tumor detection, tumor classification, 
stratification of treatment, tumor recurrence 
and patient prognosis, as well as predicting and 
monitoring a patient’s response to treatment 
(detailed review in reference [5]). In NB, several 
prognostic single-gene methylation biomarkers 
have been reported, e.g. promoter methylation 
of TNFRSF10D, CASP8, ZMYND10, RASSF1A, 
KRT19, GNAS, HIST1H3C, RB1 and TDGF1 [6–11]. 
Furthermore, a CpG island methylator 
phenotype (CIMP), described as the aberrant 
and concordant methylation of multiple 
promoter CpG islands, has been shown to be of 
prognostic significance [12–16].  
In this study, we aim to assess the primary NB 
tumor methylome in a genome-wide manner to 
identify differentially methylated regions (DMRs) 
between the prognostic patient groups, and to 
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use these DMRs to establish and validate new 
and valuable biomarkers. 
 
Results 
 
Methyl-CpG-binding domain (MBD) sequencing 
of primary tumors prioritizes differentially 
methylated regions (DMRs) between patient 
subgroups 
 
The study design is schematically represented in 
Figure 1. In the discovery phase, two 
independent cohorts of 42 (MBD cohort I) and 
45 (MBD cohort II) primary NB tumors, selected 
for risk classification and survival (low-risk 
survivors (LR-SURV), high-risk survivors (HR-
SURV) and high-risk deceased (HR-DOD)), were 
analyzed by methyl-CpG-binding domain (MBD) 
sequencing (Supplemental Table 1A and B). 
Sheared input DNA was enriched towards 
methylated fragments using the high affinity of 
the MBD of the MeCP2 protein towards 
methylated cytosines. These methylation-
enriched fractions, as well as the input (non-
MBD-enriched) DNA of MBD cohort II were then 
further studied by next-generation sequencing. 
After raw data analyses, differentially 
methylated regions (DMRs) between patient 
subgroups were detected using DESeq, which 
uses count data as input. The following patient 
subgroups were compared: HR-SURV versus HR-
DOD (on the entire cohorts, as well as on the 
high-risk MYCN amplified (HR-MYCN1) and non-
amplified (HR-MYCN0) cohorts only), LR-SURV 
versus HR-DOD, and HR-MYCN0 versus HR-
MYCN1 (Supplemental Table 2). The same 
analyses were performed on the input sample 
data in order to estimate the background signal 
and exclude falsely identified DMRs. The DESeq 
analyses yield for each region of interest the 
mean normalized counts per patient group, as 
well as the log2 fold change and p-value for the 
statistical significance of the difference. By 
calculating the π-value (π = -ln p-val * log2 fold 
change [17]) for each of these regions, a new 
significance score was defined, which was then 
used to rank the candidate prognostic DMRs. 
Hierarchical cluster analysis using normalized 
counts of the top-ranking DMRs yielded two 
sample clusters which mainly correspond to the 
patient groups used in the differential 
methylation analysis, highlighting the capability 
of our MBD sequencing analysis strategy in 
identifying biomarker candidates (examples 
shown in Supplemental Figure 1). 
 
Methylation-specific PCR (MSP) assays are 
designed and tested on two independent 
cohorts 
 
MBD sequencing data of the top-ranking DMRs 
(promoter regions and 5 kb windows) from the 
different prognostic comparisons were visualized 
in the Integrative Genomics Viewer (IGV; [18]) in 
order to locate the most informative 
(discriminative) region for MSP primer design 
(Figure 1). The importance of this step is 
illustrated by the promoter region of HNRNPH1, 
which was identified as differentially methylated 
between HR-SURV and HR-DOD patients, and LR-
SURV and HR-DOD patients (Supplemental 
Figure 2). MBD regions for which no clear 
discriminative region could be identified were 
excluded from further analyses and only DMRs 
hypermethylated in HR-DOD or HR-MYCN1 
samples were considered for further evaluation. 
In total, 78 MSP assays (Supplemental Table 2) 
were designed, analytically validated and tested 
on 19 NB cell lines (Supplemental Table 3), 
positive and negative controls (the (in vitro 
methylated) HCT-116 DKO cell line), along with 
two independent cohorts of 148 (MSP cohort I) 
and 202 (MSP cohort II) primary NB samples 
assigned to one of the three defined prognostic 
patient groups (Supplemental Table 4). Also the 
ACTB primer pair, a control assay that does not 
contain CpG sites and thus should always 
generate a PCR product, was tested on these 
samples to confirm successful DNA preparation 
(bisulfite treatment and amplification). In total, 
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Figure 1. Schematic representation of the study design. Differentially methylated regions (DMRs) between the 
prognostic patient groups are identified by methyl-CpG-binding domain (MBD) sequencing on MBD cohort I 
and II. For the top candidate prognostic DMRs, the MBD sequencing data were visualized in order to locate the 
most informative region for methylation-specific PCR (MSP) assay design. These assays were subsequently 
tested on MSP cohort I and II. By applying specific methylation calling criteria [10], a binary dataset for each of 
these cohorts was constructed, which was subsequently used for survival analyses. Cq: quantification cycle; h: 
height; Sz: size; Tm: melting temperature. The subscript pos refers to the data of the positive control sample. 
 
16 samples of MSP cohort I and 25 samples of 
MSP cohort II failed for this assay, probably due 
to low DNA quality, and were therefore excluded 
from the study. 
 
MSP confirms the validity of MBD sequencing in 
identifying candidate methylation biomarkers 
 
In both MSP cohort I and II, primary tumor 
samples of HR-DOD and HR-MYCN1 patients 
show more methylation events compared to 
either survivors (p = 0.001 for both cohorts; 
Supplemental Figure 3A and 3B) and HR-MYCN0 
patients (p < 0.001 for both cohorts; 
Supplemental Figure 3C and 3D), respectively. 
This again confirms the validity of MBD 
sequencing data in identifying candidate 
markers, as all MSP assays were designed in 
regions identified in the MBD sequencing data as 
being hypermethylated in HR-DOD or HR-MYCN1 
patients. To further strengthen MBD sequencing 
as a powerful technology for identification of 
genome-wide differential methylation, the 
genomic locations of the in-house designed MSP 
assays were compared to the genomic locations 
of the cytosines interrogated on the Infinium 
HumanMethylation450 BeadChip Kit (HM450 
array; Illumina). Of note, 58 MSP assays (74.36%) 
do not overlap with an interrogated cytosine on 
the HM450 array, and would thus not have been 
identified using this array technology (e.g. 
promoter region of UHRF2 in Supplemental
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Table 1. Survival analyses on the individual MSP assay level identify new biomarkers for overall and event-
free survival. 
 MSP cohort I MSP cohort II 
overall 
survival 
log-
rank 
univariable logistic regression 
log-
rank 
univariable logistic regression 
variable p p OR 95% CI p p OR 95% CI 
assay006  
(SPRED3) 
0.005 0.043 2.26 1.03 - 4.96 0.014 0.030 2.08 1.08 - 4.04 
assay008  
(TNFAIP2) 
0.008 0.009 3.13 1.33 - 7.40 0.025 0.020 2.28 1.14 - 4.57 
assay011 0.002 0.001 3.56 1.64 - 7.75 < 0.001 < 0.001 3.82 1.81 - 8.08 
assay062  
(NPM2) 
0.021 0.010 4.19 1.41 - 12.46 0.038 0.036 2.38 1.06 - 5.33 
assay087  
(NXPH1) 
0.014 0.043 2.26 1.03 - 4.96 0.003 0.004 2.60 1.37 - 4.95 
assay108  
(CYYR1) 
0.024 0.004 3.46 1.48 - 8.13 0.046 0.040 1.93 1.03 - 3.61 
assay111 
(CCDC177) 
0.002 < 0.001 3.68 1.71 - 7.89 0.020 0.022 2.11 1.11 - 3.99 
assay113  
(lnc-MRPL3-2) 
0.002 0.004 3.03 1.43 - 6.43 0.034 0.056 1.84 0.98 - 3.45 
assay116  
(lnc-TREX1-1) 
0.008 0.056 3.27 0.97 - 10.98 0.004 0.021 2.87 1.18 - 7.01 
event-free 
survival 
log-
rank 
univariable logistic regression 
log-
rank 
univariable logistic regression 
variable p p OR 95% CI p p OR 95% CI 
assay011 0.007 0.006 2.77 1.35 - 5.70 < 0.001 < 0.001 4.18 2.02 - 8.67 
assay087 
(NXPH1) 
0.018 0.017 2.58 1.19 - 5.62 0.003 0.004 2.56 1.35 - 4.83 
assay111 
(CCDC177) 
< 0.001 < 0.001 4.94 2.33 - 10.48 0.007 0.004 2.52 1.34 - 4.74 
assay113 
(lnc-MRPL3-2) 
0.035 0.040 2.12 1.04 - 4.32 0.038 0.030 1.98 1.07 - 3.67 
assay116 
(lnc-TREX1-1) 
0.022 0.060 3.33 0.95 - 11.70 0.019 0.055 2.38 0.98 - 5.80 
Note. For each individual MSP assay, the log-rank p-values, and the p-value, odds ratio (OR) and 95% 
confidence interval (CI) of the univariable logistic regression analyses are shown. Methylation of the individual 
markers is associated with worse overall and event-free survival. 
 
Figure 4). Also, 36 MSP assays (46.15%) are 
located in non-promoter or non-coding regions. 
 
Survival analyses on the individual MSP assay 
level identify new prognostic biomarkers 
 
Overall, the percentage of methylated samples 
per MSP assay ranges from 96.97% to 2.27% in 
MSP cohort I, and from 97.18% to 1.70% in MSP 
cohort II, and variable percentages between the 
prognostic patient groups are detected 
(Supplemental Table 4). The results of the 
survival analyses (log-rank test) on each 
individual MSP assay and the different patient 
(sub)cohorts are indicated in Supplemental Table 
2. Although the survival analyses on the high-risk 
subgroups did not yield significant results, 
analyses on the entire cohorts identified 9 
individual prognostic MSP assays for overall 
survival (OS) and 5 assays for event-free survival 
(EFS) that were significantly detected in both 
MSP cohort I and II (Table 1). For EFS, these 
assays are located in the promoter region or 
gene body of CCDC177 and NXPH1, and the long 
non-coding RNAs lnc-MRPL3-2 and lnc-TREX1-1. 
The additional prognostic assays for OS are
   
 
 
Table 2. The nine individual prognostic MSP assays are differentially methylated between patient groups with distinct neuroblastoma risk factors (MSP cohort I). 
MSP cohort I 
factor - number (percentage) 
assay006 
(SPRED3) 
assay008 
(TNFAIP2) 
assay011 
assay062 
(NPM2) 
assay087 
(NXPH1) 
assay108 
(CYYR1) 
assay111 
(CCDC177) 
assay113 
(lnc-MRPL3-2) 
assay116 
(lnc-TREX1-1) 
INSS stage 
stage 1  
(n =27) 
3 (11.11) 0 (0.00) 6 (22.22) 0 (0.00) 2 (7.41) 1 (3.70) 2 (7.41) 8 (29.63) 1 (3.70) 
stage 2  
(n = 18) 
1 (5.56) 1 (5.56) 7 (38.89) 1 (5.56) 1 (5.56) 0 (0.00) 5 (27.78) 4 (22.22) 0 (0.00) 
stage 3  
(n = 33) 
15 (45.45) 10 (30.30) 17 (51.52) 5 (15.15) 16 (48.48) 11 (33.33) 16 (48.48) 13 (39.39) 4 (12.12) 
stage 4  
(n = 54) 
18 (33.33) 17 (31.48) 35 (64.81) 10 (18.52) 18 (33.33) 17 (31.48) 32 (59.26) 28 (51.85) 7 (12.96) 
MYCN 
amplification 
status 
MYCN0  
(n = 96) 
11 (11.46) 11 (11.46) 39 (40.63) 5 (5.21) 12 (12.50) 13 (13.54) 29 (30.21) 28 (29.17) 2 (2.08) 
MYCN1  
(n = 36) 
26 (72.22) 17 (47.22) 26 (72.22) 11 (30.56) 25 (69.44) 16 (44.44) 26 (72.22) 25 (69.44) 10 (27.78) 
age at diagnosis 
≤ 12 months  
(n = 54) 
6 (11.11) 1 (1.85) 17 (31.48) 1 (1.85) 9 (16.67) 1 (1.85) 11 (20.37) 11 (20.37) 1 (1.85) 
> 12 months  
(n = 78) 
31 (39.74) 27 (34.62) 48 (61.54) 15 (19.23) 28 (35.90) 28 (35.90) 44 (56.41) 42 (53.85) 11 (14.10) 
≤ 18 months  
(n = 63) 
10 (15.87) 5 (7.94) 22 (34.92) 1 (1.59) 10 (15.87) 2 (3.17) 14 (22.22) 16 (25.40) 1 (1.59) 
> 18 months  
(n = 39) 
27 (39.13) 23 (33.33) 43 (62.32) 15 (21.74) 27 (39.13) 27 (39.13) 41 (59.42) 37 (53.62) 11 (15.94) 
factor - statistics (p) 
assay006 
(SPRED3) 
assay008 
(TNFAIP2) 
assay011 
assay062 
(NPM2) 
assay087 
(NXPH1) 
assay108 
(CYYR1) 
assay111 
(CCDC177) 
assay113 
(lnc-MRPL3-2) 
assay116 
(lnc-TREX1-1) 
INSS stage 0.002 < 0.001 0.003 0.056 < 0.001 < 0.001 < 0.001 0.085 0.302 
MYCN amplification status < 0.001 < 0.001 0.002 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
age at diagnosis (cutoff 12 months) < 0.001 < 0.001 0.001 0.002 0.018 < 0.001 < 0.001 < 0.001 0.027 
age at diagnosis (cutoff 18 months) 0.004 < 0.001 0.002 < 0.001 0.004 < 0.001 < 0.001 0.001 0.005 
(continues) 
Note. For each of the nine individual prognostic MSP assays the number (percentage) of methylated samples in each stratum of MSP cohort I is given. P-values are 
according to the Fisher’s exact test. INSS: International Neuroblastoma Staging System; MYCN0: MYCN non-amplified; MYCN1: MYCN amplified.  
   
 
 
Table 2. The nine individual prognostic MSP assays are differentially methylated between patient groups with distinct neuroblastoma risk factors (MSP cohort II). 
(continued) 
MSP cohort II 
factor - number (percentage) 
assay006 
(SPRED3) 
assay008 
(TNFAIP2) 
assay011 
assay062 
(NPM2) 
assay087 
(NXPH1) 
assay108 
(CYYR1) 
assay111 
(CCDC177) 
assay113 
(lnc-MRPL3-2) 
assay116 
(lnc-TREX1-1) 
INSS stage 
stage 1  
(n =27) 
2 (7.41) 1 (3.70) 7 (25.93) 0 (0.00) 3 (11.11) 10 (37.04) 11 (40.74) 10 (37.04) 1 (3.70) 
stage 2  
(n = 17) 
4 (23.53) 3 (17.65) 8 (47.06) 0 (0.00) 4 (23.53) 5 (29.41) 6 (35.29) 4 (23.53) 0 (0.00) 
stage 3  
(n = 27) 
7 (25.93) 6 (22.22) 14 (51.85) 5 (18.52) 9 (33.33) 12 (44.44) 9 (33.33) 14 (51.85) 6 (22.22) 
stage 4  
(n = 103) 
41 (39.81) 35 (33.98) 83 (80.58) 24 (23.30) 48 (46.60) 50 (48.54) 66 (64.08) 56 (54.37) 16 (15.53) 
MYCN 
amplification 
status 
MYCN0  
(n = 115) 
11 (9.57) 14 (12.17) 63 (54.78) 11 (9.57) 22 (19.13) 39 (33.91) 47 (40.87) 43 (37.39) 7 (6.09) 
MYCN1  
(n = 60) 
43 (71.67) 30 (50.00) 48 (80.00) 18 (30.00) 40 (66.67) 37 (61.67) 43 (71.67) 40 (66.67) 16 (26.67) 
age at diagnosis 
≤ 12 months  
(n = 53) 
1 (1.89) 1 (1.89) 14 (26.42) 0 (0.00) 8 (15.09) 12 (22.64) 10 (18.87) 11 (20.75) 3 (5.66) 
> 12 months  
(n = 124) 
53 (42.74) 44 (35.48) 99 (79.84) 29 (23.39) 56 (45.16) 65 (52.42) 82 (66.13) 73 (58.87) 20 (16.13) 
≤ 18 months  
(n = 74) 
10 (13.51) 4 (5.41) 27 (36.49) 2 (2.70) 14 (18.92) 23 (31.08) 22 (29.73) 22 (29.73) 8 (10.81) 
> 18 months  
(n = 103) 
44 (42.72) 41 (39.81) 86 (83.50) 27 (26.21) 50 (48.54) 54 (52.43) 70 (67.96) 62 (60.19) 15 (14.56) 
factor - statistics (p) 
assay006 
(SPRED3) 
assay008 
(TNFAIP2) 
assay011 
assay062 
(NPM2) 
assay087 
(NXPH1) 
assay108 
(CYYR1) 
assay111 
(CCDC177) 
assay113 
(lnc-MRPL3-2) 
assay116 
(lnc-TREX1-1) 
INSS stage 0.006 0.005 < 0.001 0.002 0.003 0.439 0.004 0.066 0.066 
MYCN amplification status < 0.001 < 0.001 0.001 0.001 < 0.001 0.001 < 0.001 < 0.001 < 0.001 
age at diagnosis (cutoff 12 months) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.085 
age at diagnosis (cutoff 18 months) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.006 < 0.001 < 0.001 0.505 
Note. For each of the nine individual prognostic MSP assays the number (percentage) of methylated samples in each stratum of MSP cohort II is given. P-values are 
according to the Fisher’s exact test. INSS: International Neuroblastoma Staging System; MYCN0: MYCN non-amplified; MYCN1: MYCN amplified. 
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located in the promoter region of SPRED3, 
TNFAIP2, NPM2 and CYYR1. For MSP assay011, 
which has prognostic value for both OS and EFS, 
the amplicon is located on chr8:143 498 349 - 
143 498 469 (flanking genes are TSNARE1 
(downstream on ± 14 kb) and BAI1 (upstream on 
± 47 kb on opposite strand)). The corresponding 
results of the univariable logistic regression 
analyses are also shown in Table 1, and 
associations between the prognostic DNA 
methylation biomarkers and established 
prognostic NB risk factors (MYCN amplification, 
age at diagnosis (both 12 and 18 month cutoff) 
and International Neuroblastoma Staging System 
(INSS) stage [19]) are shown in Table 2. 
 
A 58-marker methylation signature with 
accompanying methylation score cutoff of 25% 
predicts overall and event-free survival 
 
As all MSP assays were designed in regions 
identified as hypermethylated in HR-DOD or HR-
MYCN1 samples and as the MSP data show 
association with outcome (Supplemental Figure 
3A-3D), the possibility of establishing a robust 
and accurate multimarker signature for OS and 
EFS based on the number of methylation events 
was explored. To this purpose, a new statistical 
framework was developed, which allows 
identification of a robust set of MSP assays of 
which the methylation scores (i.e. the 
percentage of methylated assays in each sample) 
allow accurate outcome prediction (details in 
Materials and Methods and Figure 2). The 
signature was trained on MSP cohort I and 
tested on MSP cohort II. For the high-risk 
subgroups, the resulting signature was not 
prognostic, but using the entire sample cohorts, 
a set of 58 MSP assays (Supplemental Table 4) 
with a methylation score cutoff of 25% was put 
forward and shown to significantly predict OS (p 
< 0.001 for both cohorts, log-rank test) and EFS 
(p = 0.001 for MSP cohort I and p < 0.001 for 
MSP cohort II). For MSP cohort I, OS at 5 years of 
follow-up is 80.14% (95% confidence interval (CI) 
72.06 - 89.11) for the group of patients at 
methylation low-risk, compared to 47.74% 
(34.43 - 66.18) for the group of patients at 
methylation high-risk. The 5-year EFS is 80.54% 
(72.40 - 89.61) and 55.22% (40.92 - 74.51) in the 
methylation low- and high-risk groups, 
respectively. For MSP cohort II, OS at 5 years of 
follow-up is 86.67% (79.92 - 93.98) for the 
methylation low-risk group, compared to 44.20% 
(34.14 - 57.23) for the methylation high-risk 
group. Here, the 5-year EFS is 86.86% (79.86 - 
94.47) and 53.34% (42.06 - 67.65) in the 
methylation low- and high-risk groups, 
respectively. The corresponding Kaplan-Meier 
curves are depicted in Figure 3. Power analyses 
using these survival rates illustrate that the MSP 
cohorts contain sufficient numbers of samples to 
obtain 90% power at 5% significance level. The 
signature has a balanced accuracy (BAC) of 
70.12% for OS and 65.71% for EFS on MSP 
cohort I. On MSP cohort II, these values are 
71.28% and 67.97%, respectively. Univariable 
logistic regression analyses also illustrate that 
the signature predicts OS and EFS, and 
multivariable logistic regression analyses show 
that the signature is a significantly independent 
predictor of OS in MSP cohort II after controlling 
for known risk factors (Supplemental Table 5). 
Associations between the signature predictions 
and established NB risk factors are shown in 
Table 3. 
 
Discussion 
 
MYCN amplification was identified as first 
genetic prognostic marker, in addition to age at 
diagnosis and tumor stage, which is still used 
today in therapeutic stratification [1]. Further 
studies have attempted to explore additional 
parameters to improve prognostic classification. 
Most notably, these include large chromosomal 
imbalances as well as transcriptome-based gene 
signatures. Given the low mutation burden,
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Figure 2. A new statistical framework was developed to identify a robust multimarker signature for accurate 
outcome prediction. The framework consists of three major steps: (1) signatures construction, (2) evaluation of 
the performance and robustness of the constructed signatures and (3) the selection of the final signature. 
Details of every step are described in the materials and methods section. a: assay; BAC: balanced accuracy; 
s:sample; TNR: true negative rate (specificity); TPR: true positive rate (sensitivity).  
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Figure 3. A robust 58-marker methylation signature and methylation score of 25% predicts overall and event-
free survival. Kaplan-Meier curves and log-rank p-values for overall survival (MSP cohort I in A. and MSP cohort 
II in B.) and event-free survival (MSP cohort I in C. and MSP cohort II in D.) are shown. The numbers of patients 
at methylation low- and high-risk as predicted by the 58-marker signature are indicated. The numbers in 
parentheses in the plots refer to the number of patients that experienced an event (deceased of disease for 
overall survival, and relapse, progression or deceased of disease for event-free survival). *Missing follow-up 
time for two methylation low-risk patients and three methylation high-risk patients. **Missing follow-up time 
for five methylation high-risk patients, and event status and follow-up time for one patient. 
 
more recent sequencing efforts did not deliver 
significant novel tools for prognostic 
stratification [20], although ALK mutation status 
is of importance for including patients for 
targeted therapy with ALK inhibitors. Recent 
studies have shown that NB biology is also 
strongly determined by the epigenetic profile of 
the tumor, which has paved the way for 
prognostic DNA methylation biomarker research. 
During the past years, multiple prognostic single-
gene methylation biomarkers have been 
described in NB; also a so-called CpG island 
methylator phenotype (CIMP) was found to be 
of prognostic value [6–16]. Here, we studied the 
NB methylome in a genome-wide manner to 
establish and validate novel prognostic 
biomarkers for OS and EFS.  
Several features contribute to the novel and 
comprehensive aspect of our study. A first 
important feature is the number of analyzed 
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tumor samples. In total, 396 primary tumors 
were included, which is the largest series studied 
to date. Most reported studies only rely on NB 
cell lines or on a relatively limited number of 
tumors in the discovery phase and thus fall short 
in covering the NB heterogeneity, or lack 
independent validation on large sample cohorts. 
Of note, previous studies on mRNAs and 
microRNAs in NB have emphasized that 
biomarkers are of little or no utility if they are 
not validated on an independent patient cohort 
[21,22]. Here, MBD sequencing was applied to 
87 primary tumors, carefully selected for risk 
classification, allowing optimal biomarker 
discovery, and two independent cohorts of 132 
and 177 primary tumors were used to test the 
selected candidate biomarkers. Power analyses 
further emphasize that these large sample 
collections result in adequate power of the 
study. 
 
Table 3. The 58-marker signature predictions are associated with established neuroblastoma risk factors. 
MSP cohort I 
factor - number (percentage) OS signature prediction EFS signature prediction 
INSS stage 
stage 1 (n =27) 0 (0.00) 0 (0.00) 
stage 2 (n = 18) 1 (5.56) 1 (5.56) 
stage 3 (n = 33) 15 (45.45) 15 (45.45) 
stage 4 (n = 54) 28 (51.85) 28 (51.85) 
MYCN amplification 
status 
MYCN0 (n = 96) 17 (17.71) 17 (17.71) 
MYCN1 (n = 36) 27 (75.00) 27 (75.00) 
age at diagnosis 
≤ 12 months (n = 54) 5 (9.26) 5 (9.26) 
> 12 months (n = 78) 39 (50.00) 39 (50.00) 
≤ 18 months (n = 63) 8 (12.70) 8 (12.70) 
> 18 months (n = 69) 36 (52.17) 36 (52.17) 
MSP cohort II 
factor - number (percentage) OS signature prediction EFS signature prediction 
INSS stage 
stage 1 (n =27) 4 (14.81) 4 (14.81) 
stage 2 (n = 17) 4 (23.53) 4 (23.53) 
stage 3 (n = 27) 7 (25.93) 7 (25.93) 
stage 4 (n = 103*) 72 (69.90) 71 (69.61) 
MYCN amplification 
status 
MYCN0 (n = 115) 38 (33.04) 38 (33.04) 
MYCN1 (n = 60)* 47 (78.33) 46 (77.97) 
age at diagnosis 
≤ 12 months (n = 53) 1 (1.89) 1 (1.89) 
> 12 months (n = 124*) 86 (69.35) 85 (69.11) 
≤ 18 months (n = 74) 9 (12.16) 9 (12.16) 
> 18 months (n = 103*) 78 (75.73) 77 (75.49) 
Note. For both OS and EFS, the number (percentage) of methylation high-risk samples in each stratum of MSP 
cohort I and II is given. All associations are statistically significant (p < 0.001; Fisher’s exact test). *Missing EFS 
status for one patient. EFS: event-free survival; INSS: International Neuroblastoma Staging System; MYCN0: 
MYCN non-amplified; MYCN1: MYCN amplified; OS: overall survival.  
 
Another important feature is that we made use 
of MBD sequencing of primary NB tumors in the 
discovery phase to identify novel biomarker 
candidates. Compared to the Illumina 
methylation arrays, which were previously 
applied to NB tumors, MBD sequencing 
interrogates more CpGs (approximately 18% of 
all CpGs versus < 2% for the arrays [23]) and thus 
allows extension of the biomarker discovery 
phase to previously unexplored regions. MBD 
sequencing also has higher genomic coverage 
than methodologies based on antibodies 
(methylated DNA immunoprecipitation (MeDIP)) 
[24]. This genome-wide assessment of the DNA 
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methylation pattern is reflected in the final 
selection of MSP assays, as we have shown that 
most of the assays would not have been 
identified using the HM450 array and that a 
substantial part of the assays is located in non-
promoter or non-coding regions. These findings 
support previous studies in other cancer types 
that show that it is important to extend the 
search for potentially clinical applicable DNA 
methylation biomarker to the entire methylome 
rather than focusing on promoter CpG islands of 
which methylation is in most cases inversely 
correlated to their transcriptional activity [5].  
The prognostic relevance of the selected 
candidate biomarkers was further analyzed in 
two large independent cohorts using our 
previously established high-throughput and 
semi-automated MSP pipeline [10]. As these 
cohorts include a considerable number of both 
high-risk survivors and non-survivors, the 
candidates could not only be tested on the 
entire sample cohorts, but also on the high-risk 
cohorts only. This analysis is very valuable, for 
the reason that the need for prognostic 
biomarkers is the highest within this group of 
patients. However, although differential 
methylation analyses and hierarchical clustering 
on the MBD sequencing data illustrate that high-
risk survivors and high-risk non-survivors show 
different methylation patterns, the MSP screens 
did not identify markers that were significantly 
prognostic in both MSP high-risk cohort I and II. 
Importantly, this does not mean that high-risk 
DNA methylation biomarkers cannot be found. It 
only indicates that the methylation differences 
in the DMRs (of 2 kb or 5 kb) in the MBD 
sequencing data between these high-risk groups 
are too subtle to be easily translated in an MSP 
assay which only interrogates a few CpGs. 
Therefore, the possibility of establishing high-
risk methylation biomarkers based on genome-
wide bisulfite sequencing, which allows analysis 
of the methylome at the single CpG level, should 
be addressed in the future. These future studies 
might also benefit from focusing on more 
homogeneous high-risk patient groups, for 
example by only studying MYCN amplified or 
non-amplified samples, as the heterogeneity 
within our high-risk cohort might also have 
counteracted the possibility of establishing high-
risk DNA methylation biomarkers.  
Nevertheless, our validation efforts allowed 
robust identification of prognostic assays on the 
entire patient cohorts. Newly discovered 
individual prognostic methylation biomarkers for 
event-free survival (EFS) are CCDC177 and 
NXPH1, and SPRED3, TNFAIP2, NPM2 and CYYR1 
for overall survival (OS). Interestingly, some of 
these biomarkers are linked with neural 
processes and/or have already been described in 
other tumor types. For example, NXPH1 encodes 
the neurexophilin 1 protein that forms a very 
tight complex with alpha neurexins, a group of 
proteins that promote adhesion between 
dendrites and axons, and methylation of this 
gene was previously described as potential 
diagnostic biomarker for breast cancer [26]. 
TNFAIP2 (tumor necrosis factor, alpha-induced 
protein 2) was also found to be hypermethylated 
in colorectal cancer [27] and NPM2 
(nucleophosmin/ nucleoplasmin 2) in melanoma 
[28] and acute myeloid leukemia [29]. 
Alterations of sequence and expression of CYYR1 
(cysteine/tyrosine-rich 1) were previously 
observed in neuroendocrine tumors [30]. 
Remarkably, also three non-coding methylation 
biomarkers for OS and EFS were identified (lnc-
MRPL3-2, lnc-TREX1-1 and assay011). Assay011 
is located on chr8:143 498 349 - 143 498 469, 
but further annotation is not available for this 
region. These findings again underscore the 
importance of screening the entire methylome 
for biomarker discovery. Of note, the role of 
methylation of these non-promoter CpGs in NB 
is currently unclear and should also be topic of 
further investigation, as it has been shown that 
DNA methylation outside promoters may also be 
crucial for gene regulation [25]. Clearly, this 
might reveal new aspects of NB tumorigenesis.  
Finally, a new statistical framework was applied 
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to identify a robust set of MSP assays of which 
the methylation scores of the samples allow 
accurate outcome prediction. Both for OS and 
EFS, a 58-marker signature with a methylation 
score cutoff of 25% was selected based on the 
data of MSP cohort I. Survival analyses on both 
MSP cohort I and II indicate that the signature 
displays prognostic value for OS and EFS, and is a 
significant independent predictor of OS in MSP 
cohort II after controlling for established NB risk 
factors. All newly discovered individual 
prognostic methylation biomarkers are part of 
the signature and further inspection of the other 
assays included in the signature shows 
biomarkers previously described in other tumor 
types, as well as genes previously linked to NB, 
such as NAV2, which functions in axonal 
elongation and is required for all-trans retinoic 
acid to induce neurite outgrowth in human NB 
cells [31]. Also in this regard, the present study is 
unique, since combining multiple individual 
methylation assays into a single biomarker 
signature is not previously reported in NB, with 
the exception of testing the CpG island 
methylator phenotype (CIMP), but this assay 
panel was simply adopted from the colorectal 
cancer research field. Yet, it should be tested 
whether these established DNA methylation 
biomarkers can further improve the 
performance of our 58-marker signature.  
In conclusion, the applications of DNA 
methylation biomarkers in cancer management 
are versatile and these should definitely be 
further explored in the context of NB. During the 
past decades, many efforts have been made to 
identify prognostic DNA methylation biomarkers 
for NB, but currently no such biomarkers have 
made it to the clinic, as they lack comprehensive 
validation. In our study, we performed genome-
wide methylation profiling of primary NB tumors 
using MBD sequencing to discover novel 
prognostic methylation biomarkers and 
subsequently tested top candidates in two 
independent cohorts using MSP. As such, we 
comprised 396 patients in total, which greatly 
increases the validity of the study and makes it 
the largest DNA methylation biomarker study in 
NB to date. We robustly identified several novel 
individual biomarkers for OS and EFS, and could 
develop a prognostic 58-marker signature of 
which a methylation score cutoff of 25% allows 
accurate outcome prediction in the total patient 
cohorts. Furthermore, on the validation cohort, 
this signature was an independent predictor of 
OS after controlling for known NB risk factors, 
clearly indicating its clinical relevance. As such, 
this study forms a solid basis for further 
investigation of our biomarkers and signature in 
NB subgroups which could not be robustly 
examined in our cohorts (low-risk non-survivors 
and more homogeneous high-risk subgroups). 
Ideally, also the integration with other DNA 
methylation biomarkers and -omic data should 
be further explored to fully optimize the 
assessment of NB prognosis and appropriate 
stratification of patient treatment. 
 
Materials and methods 
 
Neuroblastoma cell lines and primary tumors 
 
In total, 437 primary NB tumor samples were 
used to establish four independent sample 
cohorts: MBD cohort I (n = 42), MBD cohort II (n 
= 45), MSP cohort I (n = 148) and MSP cohort II 
(n = 202). Also 19 NB cell lines (Supplemental 
Table 3) were included in the study. All primary 
tumor samples were assigned to one of three 
previously defined [10] risk groups based on NB 
risk parameters (INSS stage, MYCN amplification 
status and age of the patient at diagnosis) and 
disease outcome: (1) high-risk patients that died 
of disease (HR-DOD), (2) high-risk survivors (HR-
SURV), or (3) low-risk survivors (LR-SURV). 
Samples were collected at the Centre Léon 
Bérard (n = 125, Lyon, France), the Hospital 
Clínico Universitario (n = 86; Valencia, Spain), the 
Ghent University Hospital (n = 80; Ghent, 
Belgium), the Sydney Children’s Hospital (n = 48; 
Sydney, Australia), the Institut Curie (n = 37, 
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Paris, France), the Children’s Cancer and 
Leukemia Group (n = 29, Leicester, UK), the Our 
Lady’s Children’s Hospital Dublin (n = 13; Dublin, 
Ireland), the University Hospital Brno (n = 11, 
Brno, Czech Republic) and the University 
Children’s Hospital Essen (n = 8; Essen, 
Germany). Detailed clinical characteristics of the 
patients and a summary across the different 
subcohorts are given in Supplemental Table 1. 
The study was approved by the ethical 
committee of the Ghent University Hospital 
(approval number: B67020109912). 
 
Methyl-CpG-binding domain sequencing 
 
DNA fragmentation and MBD-based capturing of 
42 (MBD cohort I) and 45 (MBD cohort II) 
samples were performed as described in [32] 
and Decock et al., in preparation. Briefly, 200-
500 ng sheared DNA was used to enrich for 
methylated fragments using the MethylCap kit 
(MBD from MeCP2; Diagenode). For each 
captured fraction of the samples of MBD cohort 
I, DNA library preparation was performed using 
the NEBNext DNA Library Prep Master Mix Set 
for Illumina (New England Biolabs) in 
combination with the Multiplexing Sample 
Preparation Oligonucleotide Kit (Illumina) for 
paired-end adapter ligation. For the input and 
enriched fractions of the samples of MBD cohort 
II, library preparation was automated on an 
Apollo 324 Next Generation Sequencing Library 
Preparation System (IntegenX), making use of 
the PrepX ILM DNA Library Kit (IntegenX) in 
combination with the Multiplexing Sample 
Preparation Oligonucleotide Kit. Paired-end 
sequencing was performed on an Illumina GAIIx 
(MBD cohort I; PE 2 x 45 bp) and HiSeq2000 
(MBD cohort II; PE 2 x 51 bp). 
 
Methylation-specific PCR 
Experimental MSP conditions and methylation 
calling were done as previously described [10] 
and are shown in Figure 1. Here, 78 technically 
validated MSP primer pairs (and the 
methylation-independent ACTB control assay; 
Supplemental Table 2) were tested on amplified 
bisulfite-treated DNA from 19 NB cell lines and 
two independent cohorts of 148 (MSP cohort I) 
and 202 (MSP cohort II) patients, selected from 
the previously defined prognostic patient 
groups. 
 
Bioinformatics and statistical analyses 
 
Methyl-CpG-binding domain sequencing 
Raw MBD sequencing data were demultiplexed 
and converted to FASTQ files. Quality control 
was performed by FastQC, followed by paired-
end read mapping to the human reference 
genome (hg19) using Bowtie2 [33] and SAMtools 
[34]. PCR duplicates were marked by Picard and 
mapping quality control was done by SAMStat 
[35] and bamUtil. Peaks were called using MACS 
[36]. Data have been deposited into the Gene 
Expression Omnibus (GEO; GSE69224 and 
GSE69243). Count matrices for differential 
methylation analyses between the prognostic 
patient subgroups in DESeq [37] were 
constructed using the R ShortRead [38] and 
rtracklayer [39] packages. Here, for both MBD 
cohorts, two count datasets were constructed. 
The first one represents a table that reports for 
each MBD-enriched sample the number of 
mapped reads that are assigned to the promoter 
region (-1,500 bp to +500 bp around 
transcription start site (TSS)) of the different 
Ensembl Transcripts (release 68), and the second 
one to 5 kb genomic windows (2.5 kb 
overlapping moving windows). Hierarchical 
clustering was performed using the R gplots and 
RColorBrewer packages. 
 
Methylation-specific PCR 
For survival analyses on the MSP data, the 
Kaplan- Meier method was used to estimate 
overall and event-free survival (OS and EFS) 
probabilities, and survival functions were 
compared with the log-rank test (R survival 
package). OS time was defined as the time 
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between diagnosis and disease-related death or 
last follow-up. EFS time is the time between 
diagnosis and first occurrence of relapse, 
progression or death of disease, or last follow-
up. P-values < 0.05 were considered statistically 
significant. All individual assays were tested, as 
well as a multimarker signature that was 
established on MSP cohort I using a new 
statistical framework (Figure 2 and Cannoodt et 
al., in preparation). This framework involves 
three major steps: (1) the construction of 
signatures, (2) the evaluation of the 
performance and robustness of each 
constructed signature, and (3) the signature 
selection. The construction of signatures (step 1) 
is based on the performance of the individual 
assays, which is evaluated by determining the 
following statistical metrics: sensitivity (true 
positive rate (TPR)), specificity (true negative 
rate (TNR)) and balanced accuracy (BAC). Each of 
these metrics was subsequently used to rank the 
assays (from highest to lowest value) and a 
cutoff, defined by percentiles of the ranked list 
(from 0% to 100% with 5% increment; 21 
possible cutoffs), was applied to select a specific 
assay set. Then, the methylation score (i.e. the 
percentage of methylated assays) for each of the 
samples is calculated and used to rank the 
samples (from lowest to highest value). Again, a 
percentage cutoff is applied on the ranked list, 
which allows making risk predictions for each 
sample. Samples with a methylation score above 
the cutoff have a high risk. Samples with a 
methylation score below the cutoff have a low 
risk. Given the number of tested metrics to 
evaluate the individual assay performance (3 
possibilities), the number of possible cutoffs to 
select a specific assay set (21 possibilities), and 
the number of possible methylation score 
cutoffs (21 possibilities), 1,323 signatures were 
constructed and further evaluated on their 
performance and robustness (step 2). The 
performance of the constructed signatures was 
examined by determining the BAC, as well as a 
score that reflects how well the percentage of 
predicted samples with an event equals the true 
percentage of samples with an event (score of % 
event samples in Figure 2). The robustness of the 
constructed signatures was tested by performing 
100 bootstraps, creating a subcohort containing 
half of the samples. For each of these 100 
subcohorts, signatures were constructed as 
described above and for each combination of 
parameters the Jaccard similarity index [40] 
between the selected assay set on the entire 
cohort and the bootstrap cohort was computed. 
The robustness of the signature is then reflected 
in the mean Jaccard similarity of the 100 
bootstraps (R caret package). In order to select a 
final signature (step 3), the performance and 
robustness metrics are combined in a weighted 
harmonic mean, and the signature with the 
highest value is retained. Also power analyses 
(SAS Power and Sample Size), and univariable 
and multivariable logistic regression analyses (R 
survival package) were performed. Included 
factors in the multivariable analyses are: the 
MYCN amplification status (MYCN amplified 
versus non-amplified as reference), age of the 
patient at diagnosis (> 18 months versus ≤ 18 
months as reference [41]), INSS stage (stage 4 
versus not stage 4 as reference) and the 
signature prediction (methylation high-risk 
versus methylation low-risk as reference). 
Associations between the prognostic DNA 
methylation biomarkers and established NB risk 
factors (MYCN amplification, age at diagnosis 
(cutoff of 12 months and 18 months) and INSS 
stage) were determined using Fisher’s exact test. 
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Supplemental Figure 1. Hierarchical cluster 
analyses highlight the capability of the methyl-
CpG-binding domain (MBD) sequencing analysis 
strategy in identifying candidate biomarkers. A. 
Clustering using the top 500 hyper- and 
hypomethylated promoter regions in high-risk 
non-survivors (HR-DOD) compared to low-risk 
survivors (LR-SURV) in MBD cohort II. B. 
Clustering using the top 500 hyper- and 
hypomethylated promoter regions in high-risk 
non-survivors compared to high-risk survivors 
(HR-SURV) in MBD cohort II. C. Clustering using 
the top 500 hyper- and hypomethylated 
promoter regions in high-risk MYCN amplified 
(HR-MYCN1) samples compared to high-risk 
MYCN non-amplified samples (HR-MYCN0). 
 
Supplemental Figure 2. Visualization of the 
MBD sequencing data of the HNRNPH1 
promoter region allows identification of the 
most informative (discriminative) region for 
MSP assay design. The location of three 
different MSP assays in the HNRNPH1 promoter 
region is shown (blue bars in the upper panel), 
as well as the number of sequencing tags at each 
position for each primary tumor of MBD cohort II 
(lower panel). Assay 1 is located in the region 
that is most discriminative between high-risk 
non-survivors (red) and high-risk survivors 
(orange)/low-risk survivors (green), while assay 2 
and 3 are located in less informative regions 
(with fuzzy methylation patterns). 
 
Supplemental Figure 3. Methylation-specific 
PCR confirms the validity of methyl-CpG-
binding domain sequencing in identifying 
candidate methylation markers. Number of 
methylation events of 68 MSP assays (designed 
in regions identified in the MBD sequencing data 
as being hypermethylated in non-survivors) in 
survivors (LR-SURV and HR-SURV) and non-
survivors of MSP cohort I (A.; Mann-Whitney, p = 
0.001) and MSP cohort II (B.; Mann-Whitney, p = 
0.001). Number of methylation events of 23 MSP 
assays (designed in regions identified in the MBD 
sequencing data as being hypermethylated in 
high-risk MYCN amplified samples) in high-risk 
MYCN non-amplified and amplified samples of 
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MSP cohort I (C.; Mann-Whitney, p < 0.001) and 
MSP cohort II (D.; Mann-Whitney, p < 0.001). 
 
Supplemental Figure 4. Visualization of the 
MBD sequencing data of the promoter region of 
UHRF2 shows that the corresponding MSP 
assay would not have been identified using the 
HM450 array. The location of the in-house 
designed MSP assay (large blue bar in upper 
panel) and probes of the HM450 array (small 
blue bars in the upper panel) are shown, as well 
as the number of sequencing tags at each 
position for each primary tumor of MBD cohort II 
(lower panel). High-risk non-survivors are 
indicated in red, high-risk survivors in orange 
and low-risk survivors in green. 
 
Supplemental Table 1. In total, 437 annotated 
primary neuroblastoma DNA samples were 
collected and assigned to a specific study 
subcohort. A. Detailed characteristics. Each 
sample is characterized by a unique patientID 
and is assigned to a prognostic risk group (LR-
SURV, HR-SURV or HR-DOD) and subcohort 
(MBD cohort I, MBD cohort II, MSP cohort I or 
MSP cohort II). Clinical characteristics given are 
the age at diagnosis in months, International 
Neuroblastoma Staging System (INSS) stage, 
MYCN amplification status (0 is non-amplified 
and 1 is amplified), and overall survival (OS) and 
event-free survival (EFS) status and time after 
diagnosis in days. The OS status indicates 
whether the patient was alive (0) at the last 
known follow-up or died of disease (1). Similarly, 
the EFS status indicates events such as relapse, 
progression or death. NAs represent missing 
values. LR-SURV: low-risk survivors, HR-DOD: 
high-risk deceased patients, HR-SURV: high-risk 
survivors. B. Summary. Per subcohort an 
overview of the clinical characteristics is given. 
*Only samples with a positive ACTB call were 
included, as only these were used in the 
analyses. 
 
Supplemental Table 2. Seventy-eight MSP 
assays were designed, technically validated and 
tested for overall and event-free survival 
prediction. For each assay, if available, the gene 
annotation is shown, as well as the forward and 
reverse primer (5’ to 3’), and the genomic 
location of the amplicon on the hg19 reference 
genome. The corresponding region of interest in 
the methyl-CpG-binding domain sequencing data 
and the comparisons in which the region was 
identified as differentially methylated (indicated 
by yes, followed by the group that is 
hypermethylated) are indicated, as well as log-
rank p-values for overall and event-free survival 
in the corresponding test cohort. Furthermore, it 
is shown whether the assay is part of the 58-
marker signature or not. 
 
Supplemental Table 3. Nineteen neuroblastoma 
cell lines are included in the study. For each cell 
line, the MYCN amplification status is shown, as 
well as its corresponding number in the MSP 
screen. 
 
Supplemental Table 4. The LabChip GX size and 
height, and LC480 Cq and Tm value were 
combined to construct a dichotomous calling 
matrix. A. Results on MSP cohort I. For each 
assay and sample, the methylation call (dark 
blue (1) is methylated, yellow (0) unmethylated) 
is given. The patient samples are subdivided into 
three prognostic groups (LR-SURV, HR-DOD and 
HR-SURV). LR-SURV: low-risk survivors, HR-DOD: 
high-risk deceased patients, HR-SURV: high-risk 
survivors, CL: cell line, U-HCT: negative control 
(HCT-116 DKO cell line), M-HCT: positive control 
(in vitro methylated HCT-116 DKO cell line) and 
NTC: no template control. B. Results on MSP 
cohort II. C. Summary on MSP cohort I and MSP 
cohort II (only ACTB positive samples are taken 
into account). The number and percentage of 
methylated samples for a particular MSP assay 
within each prognostic group and for the entire 
sample cohorts is given. 
 
Supplemental Table 5. The 58-marker 
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methylation signature is an independent 
prognostic predictor of overall survival in MSP 
cohort II. For each variable, the p-value, odds 
ratio (OR) and 95% confidence interval (CI) of the 
univariable and multivariable logistic regression 
analyses are shown. The age at diagnosis cutoff 
is 18 months. 
 
Editorial note 
 
This paper has been accepted based in part on 
peer-review conducted by another journal and 
the authors’ response and revisions as well as 
expedited peer-review in Oncotarget. 
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Abstract 
 
Comprehensive genome-wide DNA methylation studies in neuroblastoma (NB), a childhood tumor 
that originates from precursor cells of the sympathetic nervous system, are scarce. Recently, we 
profiled the DNA methylome of 102 well-annotated primary NB tumors by methyl-CpG-binding 
domain (MBD) sequencing, in order to identify prognostic biomarker candidates. In this data 
descriptor, we give details on how this data set was generated and which bioinformatics analyses 
were applied during data processing. Through a series of technical validations, we illustrate that the 
data are of high quality and that the sequenced fragments represent methylated genomic regions. 
Furthermore, genes previously described to be methylated in NB are confirmed. As such, these MBD 
sequencing data are a valuable resource to further study the association of NB risk factors with the 
NB methylome, and offer the opportunity to integrate methylome data with other -omic data sets on 
the same tumor samples such as gene copy number and gene expression, also publically available. 
 
Subject categories: DNA methylation, pediatric cancer, next-generation sequencing 
 
 
Background and summary 
 
Neuroblastoma (NB), a neuro-ectodermal tumor 
that originates from precursor cells of the 
sympathetic nervous system, represents the 
most common extra-cranial solid tumor of early 
childhood and is considered a heterogeneous 
disease driven by genetic aberrations, as during 
the past decades mainly genetic factors have 
been described to influence the pathogenesis 
and disease course (including MYCN 
amplification, ALK amplification and mutation, 
hyperdiploidy, and gains and losses of specific 
chromosome arms (1p, 3p, 11q and 17q)) [1]. 
Also, recent comprehensive whole-genome 
sequencing studies of primary NB tumors 
pinpointed chromothripsis and defects in 
neuritogenesis genes as important tumor-driving 
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events in a subset of NB [2], and indicated that 
MYCN, TERT and ATRX alterations define major 
subgroups of high-risk NB [3,4]. However, also 
epigenetic mechanisms, such as DNA 
methylation alterations, seem to contribute to 
the NB biology and clinical behavior.  
As reviewed in Decock et al. [5], multiple DNA 
methylation alterations have been described in 
NB, but given the rare occurrence of the disease, 
the number of comprehensive genome-wide 
DNA methylation studies analyzing primary 
tumor samples is limited. Hence, most studies 
initially make use of NB cell lines and only 
validate the most obvious methylation 
alterations in primary NB tumors. For example, a 
frequently applied methodology to NB cell lines 
is assessment of gene expression reactivation 
upon 5’-aza-2’-deoxycytidine (DAC) treatment, a 
cytosine analogue that cannot be methylated, 
leading to progressive DNA demethylation upon 
cell division. However, major drawbacks of these 
studies are that their discovery phases fall short 
in covering the NB heterogeneity, as NB cell lines 
are considered models for aggressive high-risk 
tumors, and that DNA methylation detection is 
indirectly assessed, as the influence of the 
demethylating effect is measured at the 
transcriptional level [6–8]. To accommodate this, 
the Illumina 27 and 450 K methylation arrays, 
directly interrogating the status of 
approximately 27,000 and 485,000 methylation 
sites, respectively, recently were applied to 
primary NB tumors [6,9–12]. Yet, also this 
technology has important limitations: the design 
of the arrays is heavily biased to interrogation of 
CpG sites previously described in literature and 
covers less than 2% of all CpG sites in the human 
genome [13].  
Therefore, we generated a data set comprising 
of 102 primary NB tumors in which DNA 
methylation is assessed by massively parallel 
sequencing of methylation enriched DNA 
fragments. The applied method is based on the 
use of MeCP2, a member of the methyl-CpG-
binding domain (MBD) protein family which 
specifically binds to methylated cytosines and 
enables precipitation of methylated DNA 
fragments. This data set is unique in the NB 
research field, as it is the first sample cohort in 
which the full tumor heterogeneity is being 
assessed by genome-wide methylation analysis 
using next-generation sequencing (NGS); it was 
originally collected for the identification of 
prognostic biomarker candidates. Selected 
candidates were validated in independent 
cohorts using methylation-specific PCR and we 
showed that MBD sequencing allowed selection 
of valuable markers which would not have been 
identified using the Illumina methylation arrays 
[14]. 
Here, we provide a detailed description of the 
methodological approach and bioinformatics 
analyses, as well as easy access to the (analyzed) 
MBD sequencing data and analysis tools, 
allowing other researchers (inexperienced with 
MBD sequencing) to reuse it. Importantly, the 
analyzed samples are well annotated; besides 
overall and event-free survival data, also 
following NB characteristics are available: age of 
the patient at diagnosis, tumor stage according 
to the International Neuroblastoma Staging 
System (INSS) [15] and MYCN amplification 
status. As such, these data offer the opportunity 
to further explore the association of these risk 
factors with the NB methylome. Furthermore, 
integration of methylome data with other -omic 
data sets should be examined in order to fully 
map the NB biology on a genome-wide level. The 
present MBD sequencing data greatly facilitate 
these integration analyses, considering that for 
part of the profiled samples matching expression 
and array comparative genomic hybridization 
(aCGH) data are available [16–18] (see Methods 
for details). 
In summary, this data descriptor outlines details 
on the generation and analysis of MBD 
sequencing data of 102 primary NB tumors 
(Figure 1). As NB is a rare disease and 
comprehensive DNA methylation studies scarce, 
these MBD sequencing data are very valuable 
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Figure 1. The MBD sequencing data of 102 primary neuroblastoma tumors are processed using different 
analysis tools. Depicted are the available methyl-CpG-binding domain (MBD) sequencing data sets and 
downstream data processing and technical validation steps. These steps are represented as arrows and circles, 
respectively. For each step, the applied tool or analysis is indicated. For the technical validation steps, also the 
corresponding data descriptor figures and tables are indicated. DMA: differential methylation analysis; IGV: 
Integrative Genomics Viewer; PE: paired-end; RPKM: reads per kilobase CpG island per million. 
 
and permit further unravelling the role of DNA 
methylation in the NB biology. 
 
Methods  
 
DNA sample collection 
 
Two independent cohorts of 42 and 60 primary 
tumor DNA samples, respectively annotated as 
MBD cohort I and II, were sequenced. Samples 
of fresh frozen tumors were collected at the 
Ghent University Hospital (n =49; Ghent, 
Belgium), the Hospital Clínico Universitario 
(n=42; Valencia, Spain), the University Children’s 
Hospital Essen (n =8; Essen, Germany) and the 
Our Lady’s Children’s Hospital Dublin (n=3; 
Dublin, Ireland), according to previously 
published criteria [7,14], and stage 4S tumors 
were also included. Detailed clinical 
characteristics of the patients are given in Table 
1 (available online only). For samples 809 and 
912, DNA was extracted from different parts of 
the same primary tumor. Informed consent was 
obtained from each patient’s guardian and the 
study was approved by the ethical committee of 
the Ghent University Hospital (approval number 
B67020109912). Matching expression data 
[16,17] of 38 tumors are available through the 
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NCBI Gene Expression Omnibus (GEO) database 
(GSE21713 and GSE32664; sample IDs in Table 1 
(available online only)). Matching aCGH data [18] 
of 38 tumors are available through ViVar [19] 
(https://www.cmgg.be/vivar/; login: review, 
password: review, project: Kumps et al. 2013; 
sample IDs in Table 1 (available online only)). 
 
Methyl-CpG-binding domain (MBD) sequencing 
 
DNA fragmentation  
For each sample, between 400 to 1,000 ng DNA 
was sheared to obtain DNA fragments with an 
average length of 200 bp. The DNA was loaded 
in 120 μl TE buffer (1:5), transferred to a Snap 
Cap microTUBE (Covaris) and exposed to Covaris 
S2 Adaptive Focused Acoustics. Fragment 
distribution and concentration was determined 
on a High Sensitivity DNA chip (Agilent 
Technologies).  
 
Methylated DNA capturing  
Subsequently, capturing of methylated DNA 
fragments was done according to the MethylCap 
kit protocol of Diagenode using 200-500 ng DNA. 
Elution of the captured fraction was performed 
in 150 μl High Elution Buffer and DNA was 
purified using the MinElute PCR purification kit 
(Qiagen). For MBD cohort II, also input samples 
(10%) were prepared.  
 
Library preparation  
As MBD cohort I and II were profiled in a 
different time frame and NGS methodologies 
evolve at rapid pace, a different library 
preparation protocol and sequencing technology 
was applied to each of them. For MBD cohort I, 
DNA library preparation was performed using 
the NEBNext DNA Library Prep Master Mix Set 
for Illumina (New England Biolabs) in 
combination with the Multiplexing Sample 
Preparation Oligonucleotide Kit (Illumina) for 
paired-end adapter ligation. Size selection of the 
library is done on a 2% agarose gel (Bio-Rad). 
Fragments between 250 and 350 bp were 
excised and purified using a Qiagen Gel 
Extraction Kit. For MBD cohort II, library 
preparation was automated on an Apollo 324 
Next Generation Sequencing Library Preparation 
System (IntegenX), making use of the PrepX ILM 
DNA Library Kit (IntegenX). For paired-end 
adapter ligation the Multiplexing Sample 
Preparation Oligonucleotide Kit was used. Size 
selection was done with 1X AMPure XP beads 
(Agencourt) and PEG-Bead Solution. 
 
Library amplification  
PCR library amplification with appropriate Index 
Primers for each sample was performed using 
the Multiplexing Sample Preparation 
Oligonucleotide Kit and following PCR 
conditions: 30 s at 98 °C, 21 amplification cycles 
(10 s at 98 °C, 30 s at 65 °C and 30 s at 72 °C), 5 
min at 72 °C, and held at 4 °C. PCR product 
purification was done using the High Pure PCR 
Purification Kit (Roche). QC was performed on a 
DNA 1000 chip (Agilent) and concentration was 
determined by qPCR according to the qPCR 
Quantification Protocol Guide of Illumina. 
Samples were pooled and profiled on an Illumina 
GAIIx (PE 2 × 45 bp) for MBD cohort I and on an 
Illumina HiSeq2000 (PE 2 × 51 bp) for MBD 
cohort II. 
 
Data processing and analysis 
 
Sequencing data  
All crucial steps in the processing and analysis of 
the MBD sequencing data are summarized in 
Figure 1. Raw sequencing data were 
demultiplexed and converted to FASTQ files 
(with sequencing reads and quality scores). 
Quality control on the raw data was performed 
by FASTQC (version 0.9.2; 
http://www.bioinformatics.babraham.ac.uk/proj
ects/fastqc/).  
 
Read mapping  
Next, the sequencing reads were 
mapped/aligned to the human reference 
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genome (hg19), using the Bowtie2 [20] mapper 
(version 2.0.0 beta7) and FASTQ files as input. 
For each sample, two paired FASTQ files are 
available (as we performed paired-end 
sequencing), in which the data lines correspond 
to each other. To improve the mapping quality, 
reads were only taken into account if the 
sequences in both files could be mapped to the 
reference genome (maximum 500 bp between 
both paired ends). Also sequencing quality 
scores were used in the mapping process. The 
BAM format was used as output file type. PCR 
duplicates were marked with Picard (version 
1.79; http://broadinstitute.github.io/picard/) 
and the BAM files were sorted and indexed using 
SAMtools [21] (version 0.1.18) and index 
commands. These files have been deposited as 
raw data files in the NCBI Gene Expression 
Omnibus (GEO) database (Data Citation 1 for 
MBD cohort I; Data Citation 2 and Data Citation 
3 for MBD cohort II). FASTQ records can be 
extracted from the sequence alignments in the 
BAM files using the BEDTools bamtofastq 
conversion utility [22]. Starting from the SRA 
files, the NCBI SRA Toolkit (fastq-dump) can be 
used to generate the FASTQ files. Mapping 
quality was evaluated using SAMStat [23] 
(version 1.08) and BamUtil (version 1.0.2; 
http://genome.sph.umich.edu/wiki/BamUtil). 
Technical validation of MBD enrichment is 
performed by fragment CpG plot analysis [24] 
and by plotting the densities of the median 
numbers of mapped reads per kilobase per 
million (RPKM [25]) in all CpG islands (n=28,691) 
across the different subcohorts. 
 
Peak calling  
The process of converting mapped sequencing 
reads to coverage vectors and the detection of 
enriched regions (peaks) is referred to as peak 
detection or peak calling. Here, peak calling was 
done using the MACS [26] software tool (version 
1.4.0 beta) and BAM files as input. BED files 
were generated (Data Citation 1 for MBD cohort 
I; Data Citation 2 and Data Citation 3 for MBD 
cohort II), indicating the location and score 
(linked to the p-value) of the identified peaks. 
 
Visualization 
MACS is also used to output WIG files (Data 
Citation 1 for MBD cohort I; Data Citation 2 and 
Data Citation 3 for MBD cohort II), which are 
transformed to a binary format (TDF file; Data 
Citation 1 for MBD cohort I; Data Citation 2 and 
Data Citation 3 for MBD cohort II) by igvtools 
(https://www.broadinstitute.org/igv/igvtools) 
for visualization in the Integrative Genomics 
Viewer (IGV) [27]. An example IGV XML-session 
file for MBD cohort II and instructions on how to 
make use of this file are included in the GitHub 
repository (see Code availability). 
 
Differential methylation analyses 
Differential methylation analyses between 
sample groups are described in detail in Decock 
et al. [14]. Briefly, for each subcohort, two count 
data sets were constructed, in which for each 
sample the numbers of mapped reads in the 
promoter region of the different Ensembl 
Transcripts or 5 kb genomic windows are 
indicated. Here, we provide access to these 
count data sets (Supplementary Tables 3-8), 
which can directly be used for differential 
methylation analyses in DESeq [14,28]. 
 
Code availability 
All tools and code that are necessary to generate 
the described file types are provided in a Docker 
container (Docker Hub; 
https://hub.docker.com/r/mateongenaert/mbdt
oolbox/). More advanced analysis scripts can be 
found in the GitHub repository 
(https://github.com/mateongenaert/MBDToolB
ox). 
 
Data records 
 
An overview of the sample annotation and data 
outputs is given in Table 1 (available online 
only). The outputs of each step in the data 
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processing (read mapping: BAM files, peak 
calling: BED files, and visualization: WIG and TDF 
files) have been deposited in the GEO database. 
For MBD cohort I, the accession number is 
GSE69224 (Data Citation 1), for MBD cohort II, 
GSE69243 (Data Citation 2) and GSE69268 (Data 
Citation 3). In GEO, these data sets were 
submitted as SubSeries of the SuperSeries 
GSE69279 (Data Citation 4). We also provide a 
Docker container, made available through 
Docker Hub, that embeds all necessary tools to 
generate the data files and illustrates the 
analysis pipeline. More advanced analysis scripts 
are given in the GitHub repository (see Code 
availability). 
 
Table 2. Using BamUtil, basic sequencing statistics of MBD cohort I and II are computed.  
statistic 
MBD cohort I 
enriched samples 
MBD cohort II 
enriched samples 
MBD cohort II 
input samples 
range mean median range mean median range mean median 
total read 
number (e6) 
4.65 - 
18.20 
13.38 14.17 
29.74 - 
66.59 
45.09 44.41 
20.86 - 
59.51 
36.00 33.19 
duplicate reads 
(%) 
0.70 - 
72.00 
6.46 3.39 
2.55 - 
79.69 
31.04 19.89 
2.24 - 
10.47 
4.17 3.68 
properly paired 
reads (%) 
48.29 - 
94.51 
85.64 89.29 
86.86 - 
97.57 
95.33 95.72 
94.78 - 
97.55 
96.50 96.59 
Note. Total read number: the total number of reads in the two paired FASTQ files of a sample; duplicate reads 
as a percentage of the total read number; properly paired reads as a percentage of the total read number. 
 
Technical validation 
 
Validation of raw and mapped sequencing data 
 
The total read number and percentage of 
duplicate and properly paired reads in each 
sample are given in Supplementary Table 1, and 
a summary of these sequencing statistics across 
the different sample cohorts can be found in 
Table 2. 
To ensure raw data quality, FASTQC analyses 
were performed to determine the per base 
sequence quality which reflects the probability 
that a base has been called incorrectly [29]. 
Quality scores between 41 and 28, 28 and 20, 
and below 20 are considered base calls of very 
good quality, calls of reasonable quality and calls 
of poor quality, respectively. In order to obtain a 
general overview of the range of quality values 
across all bases at each position, the median 
quality score for each position in each FASTQ file 
was determined. Figure 2 shows the distribution 
of these median per base quality scores across 
the different sample cohorts. In general, the 
quality scores of both MBD cohort I and II are of 
reasonable to very good quality. Given the 
different sequencing technologies that were 
used for MBD cohort I (Illumina GAIIx) and II 
(Illumina HiSeq2000), it is expected that the read 
quality of MBD cohort II is higher than that of 
MBD cohort I. The steadily increase and 
subsequent decrease in quality along the read is 
also expected for Illumina-based experiments 
[29,30]. 
Mapping quality is ensured by analyzing the 
mapping quality scores of the alignments in each 
sample (Supplementary Table 2). In Figure 3, the 
distributions of the percentages of mapped 
reads across the different mapping quality 
ranges are shown. For all subcohorts, the reads 
are clearly mapped with high accuracy, as almost 
for every sample, more than half of the mapped 
reads has a MAPQ ≥ 30 [23]. 
 
Validation of MBD-based enrichment 
 
Over the past years several companies 
developed commercial kits for MBD-based
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Figure 2. The per base sequence quality scores indicate that the raw sequencing data are of good quality.  
Shown are the distributions of the median per base quality score (determined by FASTQC) of the enriched 
samples of MBD cohort I (A.), and of the enriched (B.) and input (C.) samples of MBD cohort II. In the boxplots, 
the lower and upper hinge of the boxes represents the 25th and 75th percentile, respectively. The whiskers 
extend to the lowest and highest value that is within 1.5 times the interquartile range. Data beyond the end of 
the whiskers are outliers and plotted as dots. 
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Figure 3. The mapping quality scores illustrate high mapping accuracy. Shown are the distributions of the 
percentages of mapped reads across the different mapping quality ranges, as determined by SAMStat (A. 
enriched samples of MBD cohort I, B. enriched samples of MBD cohort II and C. input samples of MBD cohort 
II). In the boxplots, the lower and upper hinge of the boxes represents the 25th and 75th percentile, 
respectively. The whiskers extend to the lowest and highest value that is within 1.5 times the interquartile 
range. Data beyond the end of the whiskers are outliers and plotted as dots.  
 
capturing of methylated fragments. Although all 
of them claim to be of high quality, differences 
in performance exist. Careful kit selection is thus 
of utmost importance [24]. Here, sheared tumor 
DNA was enriched towards methylated 
fragments using the MethylCap kit of Diagenode, 
that makes use of the methylCap protein, 
consisting of the MBD of human MeCP2 fused 
with gluthatione-S-transferase (GST) containing 
an N-terminal His6-tag. A previous evaluation 
assessed the quality of this kit for combination 
with NGS by comparison with four other 
commercially available kits [24]. This study also 
compared the MBD sequencing data with 
reduced representation bisulfite sequencing 
(RRBS) and Illumina 27 K methylation array data 
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of the same samples. Together, these analyses 
showed that the MethylCap kit outperforms the 
others, due to a consistent combination of high 
yield, sensitivity and specificity [24]. In order to 
demonstrate that the samples of MBD cohort I 
and II were enriched for methylated DNA 
fragments after MBD-based capturing, we made 
use of the fragment CpG plot [24]. As this plot 
depicts the CpG content of the mapped 
fragments and the MethylCap kit theoretically 
only captures methylated cytosines in a CpG 
dinucleotide context, the fragment CpG plot can 
be used to evaluate the MBD-based enrichment. 
An overview of the CpG content of the mapped 
fragments per sample cohort is depicted in 
Figure 4. This fragment CpG plot clearly 
illustrates that the MBD-enriched samples of 
MBD cohort I and II have a high fraction of CpG- 
dense fragments, while the input (non-MBD-
enriched) samples of MBD cohort II are not 
enriched in CpG content. Additionally, using the 
number of mapped reads per kilobase CpG 
island per million (RPKM) values [25], the 
methylation level of each CpG island across the 
different subcohorts was determined. The 
density plot in Figure 5 indicates that the MBD-
enriched samples have a higher fraction of CpG 
islands with an RPKM > 1 compared to the input 
samples of MBD cohort II. Based on these 
analyses, it can be concluded that the MBD-
based capture successfully led to the enrichment 
of methylated DNA fragments. 
 
Figure 4. Fragment CpG plots demonstrate that the MBD-enriched samples have a high fraction of CpG-dense 
sequencing fragments. Shown are the fractions of mapped MBD sequencing fragments with different CpG 
counts. Per cohort, 100,000 randomly selected fragments of each sample were used to construct the plots. 
 
Validation of methylated genes in 
neuroblastoma 
 
Finally, TDF and BED files, containing sequence 
coverage and peak locations respectively, were 
loaded into IGV to visually inspect genes 
previously described to be methylated in NB. As 
an example, the MBD sequencing data of the 
PCDHB gene cluster is shown in Figure 6. This 
gene cluster is frequently methylated in NB 
[5,31], which is confirmed by the MBD 
sequencing data of both MBD cohort I and II. 
Additionally, 78 regions identified in the MBD 
sequencing data as being methylated, were
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Figure 5. CpG island RPKM-values confirm enrichment towards methylated DNA fragments upon MBD 
capture. Shown are the densities of the median RPKM-values per subcohort. RPKM: reads per kilobase CpG 
island per million. 
 
validated in two independent patient cohorts 
using methylation-specific PCR (MSP) [14]. These 
data confirm the validity of MBD sequencing in 
identifying methylated regions in NB. 
 
Usage notes 
 
The MBD sequencing data can be downloaded 
from the GEO database via accession numbers 
GSE69224 (for MBD cohort I; Data Citation 1), 
GSE69243 and GSE69268 (for MBD cohort II; 
Data Citation 2 and Data Citation 3; SuperSeries 
GSE69279 (Data Citation 4)). The unique GEO 
sample accession IDs and clinical annotation can 
be found in Table 1 (available online only). This 
table also contains the accession IDs of the 
matching expression and aCGH data, which 
allows easy data access and facilitates 
integration analyses. 
All output files from the different steps in the 
MBD sequencing data processing are provided 
through GEO. Analysis tools and scripts have 
been embedded in a Docker container, to deliver 
an environment that runs on any supported host 
platform (Windows, MAC, Linux). This Docker 
container, and all instructions on how it is made 
and how analyses can be run on the data, are 
made available through Docker Hub and GitHub 
(see Code availability). This allows researchers to 
try out the analysis pipeline that was used to 
generate the publically available data, without 
the need of additional infrastructure or software 
versions. The Docker container guarantees that 
the provided commands work and allows 
researchers to start exploring the data at the 
level they are experienced with. 
Alternative processing tools can be tested for 
read mapping (e.g., BWA [32]) or identification 
of enriched regions (e.g., PeakRanger [33] or 
BALM [34]), or absolute methylation scores can 
be calculated (MEDIPS [35]; see Code 
availability). Researchers inexperienced with 
MBD sequencing can easily visualize their genes 
of interest by downloading the BED and TDF files 
(see Code availability). Downstream differential 
methylation analyses can be done with DESeq 
[28] (as described in Decock et al. [14]) using 
count data sets provided in Supplementary
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Figure 6. Visualization of the MBD sequencing data in IGV confirms methylation of the PCDHB gene cluster. In 
A. the data of MBD cohort I is shown, in B. the data of MBD cohort II. The upper panels show the genes in the 
cluster, the location of CpG islands and the GC percentage. In the lower panels, sequence coverage of 6 high-
risk patient samples is shown (peak pattern), as well as the location of identified peaks (horizontal bars). 
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Tables 3-8, or other software can be used, such 
as DiffBind [36] and edgeR [37]. Differences in 
absolute methylation scores can be used for 
RankProd [38] analyses. 
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each MBD-enriched sample of MBD cohort I, the 
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the number of mapped reads in each Ensembl 
Transcript promoter region (-1500 bp to +500 bp 
around TSS) is given. 
 
Supplemental Table 5. Promoter count data for 
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Supplemental Table 7. Window count data for 
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Abstract 
 
Stage 4S neuroblastoma (NB) is a special type of NB found in infants with metastases at diagnosis and 
is associated with an excellent outcome due to its remarkable capacity to undergo spontaneous 
regression. As genomics have not been able to explain this intriguing clinical presentation, we here 
aimed at profiling the DNA methylome of stage 4S NB to better understand this phenomenon. To this 
purpose, differential methylation analyses between INSS stage 4S, stage 4 and stage 1/2 were 
performed, using methyl-CpG-binding domain (MBD) sequencing data of 14 stage 4S, 14 stage 4, and 
13 stage 1/2 primary NB tumors (all MYCN non-amplified in order not to confound results). Stage 4S-
specific hyper- and hypomethylated promoters were determined and further characterized for 
genomic localization and function by cytogenetic band enrichment, gene set enrichment, 
transcription factor target enrichment and differential RNA expression analyses. We show that 
specific chromosomal locations are enriched for stage 4S differentially methylated promoters and 
that stage 4S tumors show characteristic hypermethylation of specific subtelomeric promoters. 
Furthermore, genes involved in important oncogenic pathways, in neural crest development and 
differentiation, and in epigenetic processes are differentially methylated and expressed in stage 4S 
tumors. Based on these findings, we describe new biological mechanisms possibly contributing to the 
stage 4S-specific tumor biology and spontaneous regression. In conclusion, this study is the first to 
describe the highly characteristic stage 4S DNA methylome. These findings will open new avenues to 
further unravel the NB pathology in general and stage 4S disease specifically. 
 
Keywords: neuroblastoma, stage 4S (MS), DNA methylation, methyl-CpG-binding domain (MBD) 
sequencing, spontaneous regression 
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Introduction 
 
Neuroblastoma (NB) is a childhood tumor that 
originates from precursor cells of the 
sympathetic nervous system and is a 
heterogeneous disease with prognosis ranging 
from long-term survival to fatal outcome. NB 
tumor staging systems have been established, 
based on clinical and biological parameters (age 
of the patient, tumor stage, MYCN amplification, 
DNA index and histopathology), and are being 
used for therapeutic stratification. The special 
stage IV (IV-S) was first described in the staging 
system of Evans et al., introduced in 1971, and 
defined patients who would otherwise have 
been stage I or II (with localized primary tumors), 
but who had disseminated disease confined to 
liver, skin or bone marrow, or any combination 
of these, without involvement of the skeleton. 
Remarkably, these patients did not have the 
dismal prognosis of other metastatic NB, as most 
of these tumors are characterized by 
spontaneous regression without any therapeutic 
intervention [1,2]. Approximately twenty years 
later, the International Neuroblastoma Staging 
System (INSS) refined the criteria of this tumor 
stage, renamed as stage 4S, and limited it to 
children younger than 12 months of age at 
diagnosis [3]. In 2005, this age limit was 
extended to 18 months in the International 
Neuroblastoma Risk Group Staging System 
(INRGSS), as it was demonstrated that an age 
cutoff of 18 months resulted in a stratification 
that optimized the prognostic contribution of 
the age at diagnosis [4]. In the INRGSS, this 
special tumor stage is indicated as MS [5].  
Several genomic alterations have been identified 
in NB, but so far no specific changes, apart from 
hyperdiploidy and near-triploidy with numerical 
chromosome alterations common to localized 
tumors without MYCN amplification, have been 
associated with stage 4S NB. This indicates that 
other molecular mechanisms, such as epigenetic 
alterations, may play a role in stage 4S NB [6]. In 
this study, we therefore specifically focused on 
identifying patterns of DNA methylation that are 
characteristic of this particular NB tumor stage. 
 
Results 
 
Stage 4S tumors demonstrate a unique 
promoter methylation portrait 
 
In order to profile the stage 4S NB methylome, 
we re-analyzed methyl-CpG-binding domain 
(MBD) sequencing data of 41 MYCN non-
amplified primary NBs [7,8], including INSS stage 
1 (n = 7), stage 2 (n = 6), stage 4 (n = 14) and 
stage 4S (n = 14) tumors. As patients with stage 
4S NB, in sharp contrast to stage 4 patients, 
show excellent outcome despite widespread 
metastases at diagnosis, we first performed a 
differential methylation analysis between these 
tumor stages. In total, 5,914 and 10,974 
promoters were identified as being hyper- or 
hypomethylated in stage 4S tumors, respectively 
(Supplemental table 1). Next, stage 4S tumors 
were also compared to stage 1/2 tumors, which 
are also associated with a favorable patient 
outcome, but patients with stage 1/2 tumors do 
not present with metastatic disease. Here, 1,288 
and 3,854 promoters were hyper- and 
hypomethylated in stage 4S tumors, respectively 
(Supplemental table 1). Subsequently, we 
determined the number of stage 4S-specific 
hyper- and hypomethylated promoters by 
determining the overlap between these two 
differential methylation analyses and by 
excluding promoters differentially methylated in 
the stage 1/2 versus stage 4 comparison. As 
such, we identified 393 hypermethylated and 
1,150 hypomethylated promoters that typify the 
stage 4S methylome (Figure 1A; Supplemental 
table 1). Similarly, also for stage 4 and stage 1/2 
NB, specific promoter methylation patterns were 
determined (Figure 1A; Supplemental table 1). 
Principal component analysis using the 
normalized read counts of the promoters 
included in Figure 1A visualizes the NB stage-
specific promoter methylation patterns (Figure 
 results  
- 135 - 
 
1B). A dense clustering is observed for stage 4S 
tumors and this tumor stage seems most similar 
to stage 1/2. 
 
Specific chromosomal locations are enriched in 
stage 4S differentially methylated promoters 
 
Next, we determined the chromosomal 
distribution of the promoters contributing to the 
specific stage 4S methylation portrait. The 
percentages of hyper- and hypomethylated 
promoters located on the different 
chromosomes is indicated in Figure 2A and 
Figure 2B, respectively. Importantly, as 
chromosomes differ in length and gene density, 
these chromosome percentages were calculated 
based on the number of identified promoters 
corrected for the total number of promoters 
located on the corresponding chromosome. 
Stage 4S hypermethylated promoters are 
overrepresented (p < 0.05) on chr17 and chr19, 
and underrepresented (p < 0.05) on chr1, chr3, 
chr4, chr5, chr7, chr10, chr11, chr14, chr15, 
chr18, chr20 and chr21 (Figure 2A). Stage 4S 
hypomethylated promoters are overrepresented 
(p < 0.05) on chr3, chr7, chr8, chr13 and chr18, 
and underrepresented (p < 0.05) on chr2, chr6, 
chr12, chr16, chr17, chr19 and chr22 (Figure 2B). 
To further pinpoint specific chromosomal 
regions enriched in stage 4S differentially 
methylated promoters, cytogenetic band 
enrichment analyses in WebGestalt [9,10] were 
performed (Figure 2C and Supplemental table 2). 
These analyses indicate that stage 4S hyper- and 
hypomethylated promoters are not randomly 
distributed across the genome, but that specific 
chromosomal cytogenetic bands are significantly 
enriched in stage 4S differentially methylated 
promoters (Figure 2). 
 
 
Figure 1. MBD sequencing analysis of MYCN non-amplified stage 4S, stage 4 and stage 1/2 tumors identifies 
stage-specific promoter methylation portraits. A. Diagram of the promoters identified as hypermethylated in 
the respective sample groups. For example, 393 and 1,150 promoters are specifically hyper- and 
hypomethylated in stage 4S, respectively. B. Principal component (PC) analysis using the normalized read 
counts of the promoters included in the diagram. Shown are the data for the first two PCs. PC1 explains 29.9% 
of the variability of the data and PC2 10.1%. 
 
Specific subtelomeres are enriched in stage 4S 
hypermethylated promoters 
 
Telomerase activity upregulation and alternative 
lengthening of telomeres are key mechanisms in 
counteracting telomere shortening in NB and 
contribute to tumor cell immortalization [11–
14]. As DNA methylation of subtelomeres 
represents an additional way to suppress 
telomere elongation [15,16] and as tumor 
regression (and thus loss of immortality) is a 
hallmark of stage 4S NB, we specifically analyzed 
the subtelomeric methylation patterns of the 
different NB tumor stages. To this purpose, we 
first determined the proportions of promoters of 
the different stage-specific methylation portraits
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Figure 2. Stage 4S differentially methylated promoters are not randomly distributed across the genome.  A. 
Percentage of stage 4S hypermethylated promoters per chromosome, based on promoter density corrected 
numbers. Significantly under- and overrepresented chromosomes are indicated with a dark dot. The vertical 
line represents the percentage if the stage 4S hypermethylated promoters would be randomly distributed 
across the genome (null hypothesis). B. Percentage of stage 4S hypomethylated promoters per chromosome, 
based on promoter density corrected numbers. Significantly under- and overrepresented chromosomes are 
indicated with a dark dot. The vertical line represents the percentage if the stage 4S hypomethylated 
promoters would be randomly distributed across the genome (null hypothesis). C. Significantly enriched 
cytogenetic locations of stage 4S hyper- and hypomethylated promoters. A list of genes located in the enriched 
regions can be found in Supplemental table 2. 
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that are located in subtelomeres (1 Mb or 2 Mb 
regions proximal to the telomeres). Figure 3A 
and B illustrate that stage 4S hypermethylated 
and stage 4 hypomethylated promoters have a 
significantly larger proportion of 1 Mb and 2 Mb 
subtelomeric promoters (p < 0.001), compared 
to stage 1/2 and stage 4 hypermethylated and 
stage 4S hypomethylated promoters. Stage 1/2 
hypomethylated promoters also comprise a 
larger proportion of 2 Mb subtelomeric 
promoters (p < 0.001; Figure 3B), compared to 
stage 1/2 and stage 4 hypermethylated and 
stage 4S hypomethylated promoters. Next, using 
the gene lists of the differential methylation 
analyses, gene set enrichment analyses (GSEA) 
were performed to evaluate whether specific 
subtelomeres are enriched in differentially 
methylated promoters (Table 1). These analyses 
firmly demonstrate that multiple subtelomeres 
are enriched in stage 4S hypermethylated 
promoters compared to stage 4 and stage 1/2 
tumors. Remarkably, not a single subtelomere is 
enriched in stage 4 hypermethylated promoters. 
Table 1 further shows that the chr5p 1 Mb and 2 
Mb subtelomeres are enriched in promoters 
hypermethylated in stage 4S compared to both 
stage 1/2 and stage 4, and in stage 1/2 
compared to stage 4. TERT, the gene encoding 
the catalytic subunit of telomerase, is located on 
the chr5p 2 Mb subtelomere, and its promoter is 
hypermethylated in stage 4S compared to stage 
4 (Supplemental table 1). Using publically 
available mRNA expression data [17], we could 
further demonstrate that TERT is expressed at 
lower levels in stage 4S compared to stage 4 (p < 
0.001; log2 fold change = 0.82). 
 
 
Figure 3. Stage 4S hypermethylated, and stage 4 and 1/2 hypomethylated promoters are frequently located 
on subtelomeres. Depicted are the percentages of the stage-specific differentially methylated promoters 
located in the 1 Mb (A.) and 2 Mb (B.) subtelomeres. Stage 4S hypermethylated and stage 4 hypomethylated 
promoters have a significantly larger proportion of 1 Mb and 2 Mb subtelomeric promoters, compared to stage 
1/2 and stage 4 hypermethylated and stage 4S hypomethylated promoters. Stage 1/2 hypomethylated 
promoters also comprise a larger proportion of 2 Mb subtelomeric promoters, compared to stage 1/2 and 
stage 4 hypermethylated and stage 4S hypomethylated promoters. 
 
Genes involved in important oncogenic 
pathways, neural crest development and 
differentiation, and epigenetic processes are 
differentially methylated and expressed in 
stage 4S tumors 
To functionally characterize the stage 4S 
differentially methylated promoters, we first 
examined whether these promoters share 
common DNA motifs, by analyzing transcription 
factor target enrichment in WebGestalt [9,10]. In
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Table 1. One third of subtelomeres are enriched in stage 4S hypermethylated promoters. 
comparison 
enriched 1Mb subtelomeres enriched 2 Mb subtelomeres 
ST NES 
nom     
p-val 
FDR      
q-val 
ST NES 
nom    
p-val 
FDR     
q-val 
stage 4S 
versus 
stage 4 
hypermethylated 
stage 4S 
chr4p 1.58 0.037 0.040 chr1p 2.21 < 0.001 < 0.001 
chr5p 2.29 < 0.001 < 0.001 chr4p 1.92 < 0.001 0.002 
chr10q 1.87 < 0.001 0.002 chr4q 1.47 0.041 0.045 
chr13q 2.12 < 0.001 < 0.001 chr5p 2.60 < 0.001 < 0.001 
chr16p 2.32 < 0.001 < 0.001 chr5q 1.49 0.011 0.042 
chr17q 1.68 0.006 0.022 chr8q 1.35 0.022 0.083 
chr19p 2.28 < 0.001 < 0.001 chr9q 1.58 < 0.001 0.029 
 
chr10q 1.78 < 0.001 0.003 
chr13q 1.97 < 0.001 0.001 
chr16p 2.50 < 0.001 < 0.001 
chr16q 2.17 < 0.001 < 0.001 
chr17q 1.65 < 0.001 0.020 
chr19p 2.80 < 0.001 < 0.001 
chr20q 1.83 < 0.001 0.004 
hypermethylated 
stage 4 
none none 
stage 4S  
versus 
stage 1/2 
hypermethylated 
stage 4S 
chr4q 2.04 < 0.001 < 0.001 chr4q 2.12 < 0.001 < 0.001 
chr5p 1.59 0.022 0.030 chr5p 1.81 < 0.001 0.006 
chr9q 2.30 < 0.001 < 0.001 chr5q 1.96 < 0.001 < 0.001 
chr12q 1.60 0.027 0.031 chr8q 1.79 < 0.001 0.006 
chr13q 1.72 < 0.001 0.013 chr10q 1.73 < 0.001 0.008 
chr17p 1.81 0.008 0.008 chr13q 1.75 < 0.001 0.009 
chr17q 2.22 < 0.001 < 0.001 chr20q 3.56 < 0.001 < 0.001 
chr20q 2.19 < 0.001 < 0.001 chr21q 1.64 < 0.001 0.018 
chr22q 1.53 < 0.001 0.044 chr22q 1.28 0.047 0.109 
hypermethylated 
stage 1/2 
chr1p 1.38 0.035 0.141 none 
stage 1/2  
versus 
stage 4 
hypermethylated 
stage 1/2 
chr5p 2.29 < 0.001 < 0.001 chr4p 1.49 0.023 0.054 
 
chr5p 1.92 < 0.001 < 0.001 
chr10p 1.49 0.035 0.059 
hypermethylated 
stage 4 
none none 
Note. For each of the three sample group comparisons, the subtelomeres (ST) significantly enriched for 
promoters hypermethylated in each of the sample groups are indicated, as well as their corresponding 
normalized enrichment score (NES), nominal p-value (nom p-val < 0.05) and false discovery rate q-value (FDR q-
val < 0.25). 
 
total, 24 and 320 motifs were significantly 
enriched for stage 4S hyper- and 
hypomethylated promoters, respectively 
(Supplemental table 3), of which the top 10 
(ranked based on the ratio of enrichment) are 
shown in Table 2. Motifs enriched in stage 4S 
differentially methylated promoters represent 
binding sites for transcription factors implicated 
in controlling cell cycle, apoptosis, neural crest 
development and neural differentiation (Table 
2). Further, we performed GSEA on the gene lists 
of the differential methylation analyses, using 
the oncogenic signatures database containing 
gene sets that represent signatures of cellular 
pathways dysregulated in cancer [18]. Enriched 
gene sets were only identified for promoters
   
 
 
Table 2. Specific transcription factor targets are enriched in stage 4S differentially methylated promoters. 
hypermethylated in stage 4S 
transcription 
factor target 
TF 
enrichment analysis differential expression analysis 
C E O genes R q 
stage 4S 
versus 
stage 4 
stage 4S 
versus 
stage 1/2 
q q 
CCGNMNNTNACG  75 0.28 3 HMG20B, HSPD1, FOSB 10.58 0.035 0.198 0.777 
NTNGCGTGNNN AHR 209 0.79 6 TSSK6, SLC9A5, FHOD1, FOSB, CIRBP, LPHN1 7.60 0.012 0.051 0.292 
TTCNRGNNNNTTC  150 0.57 4 MKNK2, HSPD1, FOSB, CCT4 7.06 0.034 0.225 0.944 
TAAWWATAG MEF2A 163 0.62 4 EIF5A, SLC9A5, ALDOA, JSRP1 6.49 0.036 < 0.001 < 0.001 
SGCGSSAAA 
E2F1 
TFDP1 
RB1 
167 0.63 4 MCM2, MCM7, SLC9A5, FHOD1 6.34 0.038 < 0.001 0.001 
TGAMCTTTGMMC
YT 
HNF4A 260 0.98 6 PRKRA, NDUFA3, PRKCSH, RTN2, C4A, ALDOA 6.11 0.017 0.033 0.147 
TTTSGCGS E2F1 228 0.86 5 GPN3, MCM2, MCM7, SLC9A5, FHOD1 5.80 0.034 < 0.001 0.001 
NCSCGCSAAAN 
E2F1 
TFDP1 
234 0.88 5 EIF5A, TNPO2, GPN3, MCM2, MCM7 5.65 0.034 0.053 0.044 
GCCATNTTN YY1 238 0.90 5 NCOR1, PIGL, PRKCSH, PTBP1, LPHN1 5.56 0.034 0.121 0.003 
NKCGCGCSAAAN 
E2F1 
TFDP1 
239 0.90 5 EIF5A, TNPO2, MCM2, MCM7, PRKCSH 5.54 0.034 0.053 0.044 
 (continues) 
Note. Shown are the top 10 significantly (q < 0.05) enriched transcription factor targets (motifs) in stage 4S hyper- and hypomethylated promoters. For each enriched motif, 
matching transcription factor (TF) annotation is shown (if available), as well as the number of genes in the category (C), the expected number in the category (E), the 
number of genes hyper- or hypomethylated in stage 4S in the category (O), the annotation for the genes in O, the ratio of enrichment (R) and the q-value. Global test q-
values of the differential expression analyses are also indicated. 
 
  
   
 
 
Table 2. Specific transcription factor targets are enriched in stage 4S differentially methylated promoters. 
(continued) 
hypomethylated in stage 4S 
transcription 
factor target 
TF 
enrichment analysis differential expression analysis 
C E O genes R q 
stage 4S 
versus 
stage 4 
stage 4S 
versus 
stage 1/2 
q q 
NNTGTTACTAAAA
ATAGAAMNN 
 25 0.32 3 SLCO5A1, PPARGC1A, MGST3 9.27 0.011 0.045 0.213 
NTGCGTGGGCGK EGR3 86 1.11 7 CELF4, GPR176, ATP6V1C1, EPHB1, KCNQ5, UBE2W, CLTC 6.29 < 0.001 < 0.001 < 0.001 
CARAACTAGGNCA
AAGGTCA 
PPARA 37 0.48 3 SS18, MARCH10, PPARGC1A 6.27 0.026 0.046 0.379 
KMCATNNWGGA  87 1.13 7 CELF4, PDE4D, ADAMTSL1, RUNX1T1, OSBPL6, ZFAT, ARNTL 6.22 < 0.001 0.530 < 0.001 
TGATTTRY GFI1 291 3.77 23 
RUNX1T1, FOXN3, WDPCP, AGR2, ALPK2, MYOT, SND1, 
CREB5, CDK14, IGF2BP3, FOXP2, NRXN3, MIR137HG, PTEN, 
C12orf42, ALDH1A2, JAZF1, ZNF521, MYBPC1, ZBTB20, 
PPARGC1A, MAPK10, RIMS2 
6.11 < 0.001 < 0.001 < 0.001 
NNGAATATKCAN
NNN 
POU2F1 211 2.73 16 
ADAMTSL1, NPAS3, RUNX1T1, PHLPP1, NRXN3, FOXP2, 
MARCH10, PPFIA2, ZNF521, ZBTB20, LPL, PDE4D, CACNA1D, 
PPARGC1A, RGS8, ARPP21 
5.86 < 0.001 < 0.001 < 0.001 
CTBATTTCARAAW CEBPG 252 3.26 19 
BRAF, RUNX1T1, NR6A1, FOXN3, PTK2, CREB5, WDR64, 
KCNQ5, CXCL9, FOXP2, SPAG9, PPFIA2, ALDH1A2, ST18, 
ZBTB20, C8orf46, SLIRP, PPARGC1A, PABPC1 
5.83 < 0.001 < 0.001 0.007 
NNNNNNKCTAW
AAATAGMNNNN 
 226 2.92 17 
LARS, SLC8A3, CELF4, ALPK2, CKMT2, KCNQ5, CACNA2D3, 
ARHGEF38, ARNTL, FBXO40, TSC22D1, TNNT2, PPARGC1A, 
C8orf46, ADRA1A, MLLT3, ARPP21 
5.81 < 0.001 0.040 0.067 
CNGTAWNTG MSX1 173 2.24 13 
FOXP2, BCAR3, KCNAB1, ADAMTSL1, ELMO1, C12orf42, 
RUNX1T1, NR6A1, ARNTL, CBLN2, SND1, INHBA, IGF2BP3 
5.81 < 0.001 0.340 0.010 
AGATAAGATAA EVI1 55 0.71 4 CREB5, CACNA1D, PPARGC1A, RUNX1T1 5.62 0.014 < 0.001 0.324 
Note. Shown are the top 10 significantly (q < 0.05) enriched transcription factor targets (motifs) in stage 4S hyper- and hypomethylated promoters. For each enriched motif, 
matching transcription factor (TF) annotation is shown (if available), as well as the number of genes in the category (C), the expected number in the category (E), the 
number of genes hyper- or hypomethylated in stage 4S in the category (O), the annotation for the genes in O, the ratio of enrichment (R) and the q-value. Global test q-
values of the differential expression analyses are also indicated. 
   
 
 
Table 3. Oncogenic signatures are enriched in stage 4S hypomethylated promoters. 
gene set 
enrichment analysis 
differential 
expression analysis 
description of gene set stage 4S versus stage 4 stage 4S versus stage 1/2 
stage 4S 
versus 
stage 4 
stage 4S 
versus 
stage 1/2 
NES 
nom   
p-val 
FDR 
q-val 
NES 
nom   
p-val 
FDR 
q-val 
q q 
BCAT_BILD_ET_AL_DN 1.38 0.033 0.053 1.47 0.002 0.026 0.002 0.205 
genes downregulated in primary epithelial breast cancer 
cell culture overexpressing activated CTNNB1 (PMID: 
16273092) 
BMI1_DN.V1_DN 1.30 0.025 0.088 1.30 0.002 0.102 0.002 < 0.001 
genes downregulated in DAOY medulloblastoma cells 
upon knockdown of BMI1 by RNAi (PMID: 17452456) 
CAHOY_NEURONAL 1.49 0.001 0.042 1.27 0.021 0.131 < 0.001 < 0.001 genes upregulated in neurons (PMID: 18171944) 
CRX_NRL_DN.V1_DN 1.38 0.006 0.056 1.23 0.030 0.182 < 0.001 < 0.001 
genes downregulated in retina cells from CRX and NRL 
double knockout mice (PMID: 17653270) 
EGFR_UP.V1_DN 1.40 0.001 0.056 1.26 0.007 0.131 < 0.001 < 0.001 
genes downregulated in MCF7 breast cancer cells positive 
for ESR1 and engineered to express ligand-activatable 
EGFR (PMID: 11888208) 
EIF4E_DN 1.31 0.035 0.076 1.42 < 0.001 0.036 < 0.001 < 0.001 
genes downregulated in HMEC primary mammary 
epithelium cells upon overexpression of EIF4E (PMID: 
17638893) 
ERB2_UP.V1_DN 1.25 0.041 0.145 1.41 < 0.001 0.038 < 0.001 0.005 
genes downregulated in MCF7 breast cancer cells positive 
for ESR1 and engineered to express ligand-activatable 
ERBB2 (PMID: 11888208) 
KRAS.AMP.LUNG_UP.V1_UP 1.37 0.006 0.063 1.30 0.006 0.113 0.003 < 0.001 
genes upregulated in epithelial lung cancer cell lines 
overexpressing KRAS (PMID: 19847166) 
KRAS.KIDNEY_UP.V1_UP 1.66 < 0.001 0.004 1.50 < 0.001 0.021 < 0.001 < 0.001 
genes upregulated in epithelial kidney cancer cell lines 
overexpressing an oncogenic form of KRAS 
MEK_UP.V1_DN 1.47 < 0.001 0.044 1.37 < 0.001 0.054 < 0.001 < 0.001 
genes downregulated in MCF7 breast cancer cells positive 
for ESR1; MCF7 cells stably overexpressing constitutively 
active MAP2K1 (PMID: 16585219) 
(continues) 
Note. For each gene set significantly enriched in promoters hypomethylated in stage 4S compared to stage 4 and stage 1/2, the corresponding normalized enrichment score 
(NES), nominal p-value (nom p-val < 0.05) and false discovery rate q-value (FDR q-val < 0.25) are shown. Global test q-values of the differential expression analyses are also 
indicated, as well as a description of the gene set (with PubMed ID of the source publication; as described in the Molecular Signatures Database [18]).  
   
 
 
Table 3. Oncogenic signatures are enriched in stage 4S hypomethylated promoters. 
(continued) 
gene set 
enrichment analysis 
differential 
expression analysis 
description of gene set stage 4S versus stage 4 stage 4S versus stage 1/2 
stage 4S 
versus 
stage 4 
stage 4S 
versus 
stage 1/2 
NES 
nom   
p-val 
FDR 
q-val 
NES 
nom   
p-val 
FDR 
q-val 
q q 
MEL18_DN.V1_DN 1.36 0.004 0.062 1.20 0.040 0.244 < 0.001 0.006 
genes downregulated in DAOY medulloblastoma cells 
upon knockdown of PCGF2 gene by RNAi (PMID: 
17452456) 
PIGF_UP.V1_UP 1.31 0.009 0.076 1.38 < 0.001 0.053 < 0.001 0.005 
genes upregulated in HUVEC endothelium cells by 
treatment with PIGF (PMID: 15516835) 
PRC2_EDD_UP.V1_DN 1.30 0.014 0.088 1.32 < 0.001 0.106 < 0.001 < 0.001 
genes downregulated in TIG3 fibroblast cells upon 
knockdown of EED (PMID: 16618801) 
PRC2_EZH2_UP.V1_DN 1.33 0.003 0.071 1.21 0.034 0.209 0.021 < 0.001 
genes downregulated in TIG3 fibroblast cells upon 
knockdown of EZH2 (PMID: 16618801) 
RAF_UP.V1_DN 1.39 < 0.001 0.056 1.30 < 0.001 0.105 0.002 < 0.001 
genes downregulated in MCF7 breast cancer cells positive 
for ESR1; MCF7 cells stably overexpressing constitutively 
active RAF1 (PMID: 16585219) 
RAF_UP.V1_UP 1.33 0.007 0.068 1.25 0.009 0.139 0.002 < 0.001 
genes upregulated in MCF7 breast cancer cells positive for 
ESR1; MCF7 cells stably overexpressing constitutively 
active RAF1 (PMID: 16585219) 
STK33_NOMO_UP 1.21 0.040 0.204 1.27 < 0.001 0.127 0.007 < 0.001 
genes upregulated in NOMO1 acute myeloid leukemia 
cells after knockdown of STK33 by RNAi (PMID: 19490892) 
STK33_SKM_UP 1.27 0.007 0.115 1.28 < 0.001 0.120 0.002 < 0.001 
genes upregulated in SKM1 acute myeloid leukemia cells 
after knockdown of STK33 by RNAi (PMID: 19490892) 
STK33_UP 1.33 < 0.001 0.070 1.31 < 0.001 0.109 0.004 0.004 
genes upregulated in NOMO1 and SKM1 acute myeloid 
leukemia cells after knockdown of STK33 by RNAi (PMID: 
19490892) 
Note. For each gene set significantly enriched in promoters hypomethylated in stage 4S compared to stage 4 and stage 1/2, the corresponding normalized enrichment score 
(NES), nominal p-value (nom p-val < 0.05) and false discovery rate q-value (FDR q-val < 0.25) are shown. Global test q-values of the differential expression analyses are also 
indicated, as well as a description of the gene set (with PubMed ID of the source publication; as described in the Molecular Signatures Database [18]). 
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hypomethylated in stage 4S compared to stage 
4, in stage 4S compared to stage 1/2 and in stage 
1/2 compared to stage 4 (Supplemental table 4). 
Of note, 19 gene sets (Table 3) were specifically 
enriched in promoters hypomethylated in stage 
4S compared to both stage 1/2 and stage 4, 
including gene sets involved in downstream 
signaling of important oncogenes and epigenetic 
actors. Transcription factor target gene sets 
(Table 2) and the leading edge genes of the 
oncogenic signatures gene sets (Table 3) 
significantly enriched in stage 4S differentially 
methylated promoters were further tested for 
differential expression, using the global test [19] 
and publically available mRNA expression data 
[17]. In total, 25 of the 39 (64.10%) gene sets 
were identified as differentially expressed in 
stage 4S compared to both stage 4 and stage 1/2 
(Table 2 and Table 3). Finally, using covariates 
plots [19] and differential gene expression 
analyses on the individual gene level, we 
evaluated which genes contributed the most to 
the significant global test results (Supplemental 
table 5 and Table 4). 
 
Discussion 
 
Genome-wide characterization studies in NB 
often combine patients with stage 4S or other 
low-risk tumors into one group for comparison 
to high-risk patients, as low-risk patients 
generally have an excellent outcome, which is in 
sharp contrast to high-risk patients who often 
show fatal progression. Patients with stage 4S 
tumors demonstrate a typical pattern of 
metastatic spread at diagnosis and have the 
capacity to undergo spontaneous regression, 
and these characteristics are not exhibited by 
stage 1/2 tumors. As genomics alone have not 
been able to explain this intriguing clinical 
presentation [6], we aimed to characterize the 
DNA methylation pattern of stage 4S NB, in 
order to reveal new biological insights into this 
special type of NB.  
By performing differential methylation analyses 
between stage 4S and stage 1/2 and stage 4, we 
could clearly define a unique stage 4S promoter 
methylation portrait. We further showed that 
stage 4S-specific hyper- and hypomethylated 
promoters are located on specific chromosomal 
locations. Non-random chromosomal 
distribution of regions differentially methylated 
between tumor and normal samples [20,21], and 
between different tumor stages [21,22], has 
been previously reported for other cancer types. 
In this study, we show that specific chromosomal 
cytogenetic bands are enriched in stage 4S 
differentially methylated promoters, and most 
importantly, that stage 4S tumors show 
characteristic hypermethylation of specific 
subtelomeric promoters. Telomere length and its 
regulatory mechanisms are well-studied in NB 
[11–14,23–25]. Most stage 4S tumors have low 
telomerase activity or short telomeres 
[11,12,23], and it has been suggested that the 
association between stage 4S and spontaneous 
regression might be related to differences in 
telomere length regulation [6]. While 
subtelomeric DNA methylation has been shown 
to suppress telomere elongation in other cancer 
types [15,16], such telomere length regulatory 
mechanism is unexplored in NB. In this study, we 
have shown that specific subtelomeric 
promoters are hypermethylated in stage 4S 
tumors compared to stage 1/2 and stage 4 
tumors, which suggests that subtelomeric DNA 
methylation may represent an additional 
mechanism by which telomere length and 
spontaneous regression are controlled in NB. 
Therefore, the role of DNA methylation in 
telomere length regulation in stage 4S NB should 
definitely be further explored. 
Further, we have shown that multiple 
transcription factor target gene sets are enriched 
in stage 4S differentially methylated promoters. 
Methylation of cytosines within transcription 
factor recognition motifs has been shown to 
cause structural changes influencing DNA-
protein interactions (either in a positive or 
negative manner) and transcription 
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Table 4. Multiple stage 4S differentially methylated genes are also differentially expressed. 
hypermethylated in stage 4S 
enriched gene set gene 
stage 4S versus stage 4 stage 4S versus stage 1/2 
q logFC 
over-
expression 
in 
q logFC 
over-
expression 
in 
E2F1, E2F1_TFDP1_RB1 and 
MEF2A 
SLC9A5 < 0.001 0.833 stage 4 0.002 0.500 stage 1/2 
hypomethylated in stage 4S 
enriched gene set gene 
stage 4S versus stage 4 stage 4S versus stage 1/2 
q logFC 
over-
expression 
in 
q logFC 
over-
expression 
in 
CAHOY_NEURONAL 
DYNC1I1 0.010 1.035 stage 4 < 0.001 1.517 stage 1/2 
HS3ST2 0.021 0.680 stage 4 0.031 0.589 stage 1/2 
NSF 0.006 0.470 stage 4 < 0.001 0.538 stage 1/2 
GPR22 < 0.001 1.272 stage 4S 0.016 0.847 stage 4S 
CALB1 < 0.001 1.718 stage 4S 0.048 0.850 stage 4S 
CRX_NRL_DN.V1_DN 
GPR124 0.011 0.471 stage 4S 0.050 0.344 stage 4S 
PVRL3 < 0.001 1.153 stage 4S 0.009 0.719 stage 4S 
EGFR_UP.V1_DN 
C9orf3 < 0.001 0.833 stage 4S 0.011 0.574 stage 4S 
DERA < 0.001 0.897 stage 4S 0.023 0.451 stage 4S 
EGR3 
ATP6V1C1 0.002 0.380 stage 4 < 0.001 0.444 stage 1/2 
CLTC 0.008 0.391 stage 4 0.002 0.419 stage 1/2 
GPR176 0.031 0.184 stage 4 0.018 0.185 stage 1/2 
UBE2W 0.048 0.177 stage 4 0.031 0.177 stage 1/2 
EIF4E_DN 
CLTC 0.008 0.391 stage 4 0.002 0.419 stage 1/2 
NPEPPS 0.002 0.348 stage 4 0.004 0.305 stage 1/2 
TP53BP1 0.027 0.287 stage 4 0.010 0.304 stage 1/2 
LMO7 0.001 0.490 stage 4S 0.028 0.323 stage 4S 
SH3YL1 0.004 0.428 stage 4S 0.049 0.282 stage 4S 
ERB2_UP.V1_DN 
NPEPPS 0.002 0.348 stage 4 0.004 0.305 stage 1/2 
C9orf3 < 0.001 0.833 stage 4S 0.011 0.574 stage 4S 
LAMB1 < 0.001 0.690 stage 4S 0.022 0.354 stage 4S 
KRAS.AMP.LUNG_UP.V1_UP 
DYNC1I1 0.010 1.035 stage 4 < 0.001 1.517 stage 1/2 
C8B 0.038 0.340 stage 4S 0.006 0.408 stage 4S 
GCKR 0.027 0.240 stage 4S 0.032 0.215 stage 4S 
KRAS.KIDNEY_UP.V1_UP 
DYNC1I1 0.010 1.035 stage 4 < 0.001 1.517 stage 1/2 
ESRRG 0.021 0.475 stage 4 0.018 0.449 stage 1/2 
CALB1 < 0.001 1.718 stage 4S 0.048 0.850 stage 4S 
MEK_UP.V1_DN 
NPEPPS 0.002 0.348 stage 4 0.004 0.305 stage 1/2 
C9orf3 < 0.001 0.833 stage 4S 0.011 0.574 stage 4S 
TCF12 0.001 0.370 stage 4S 0.015 0.261 stage 4S 
MEL18_DN.V1_DN DIO2 0.048 0.460 stage 4 0.019 0.497 stage 1/2 
PIGF_UP.V1_UP LRRC17 < 0.001 0.568 stage 4S 0.031 0.283 stage 4S 
PRC2_EDD_UP.V1_DN CBX8 < 0.001 0.815 stage 4 0.002 0.588 stage 1/2 
(continues) 
Note. For each gene set differentially expressed in stage 4S compared to stage 4 and stage 1/2 (Table 2 and 
Table 3), differentially expressed individual genes are shown. Q-values are indicated, as well as the log2 fold 
change (logFC) and the group in which the gene is overexpressed.  
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Table 4. Multiple stage 4S differentially methylated genes are also differentially expressed. 
(continued) 
hypomethylated in stage 4S 
enriched gene set gene 
stage 4S versus stage 4 stage 4S versus stage 1/2 
p logFC 
over-
expression 
in 
p logFC 
over-
expression 
in 
RAF_UP.V1_DN 
C9orf3 < 0.001 0.833 stage 4S 0.011 0.574 stage 4S 
PALLD 0.042 0.330 stage 4S 0.019 0.347 stage 4S 
TCF12 0.001 0.370 stage 4S 0.015 0.261 stage 4S 
RAF_UP.V1_UP 
CABYR 0.003 0.462 stage 4 < 0.001 0.589 stage 1/2 
GATA2 0.032 0.711 stage 4S 0.012 0.760 stage 4S 
STK33_NOMO_UP 
KIAA1467 < 0.001 0.560 stage 4 0.002 0.447 stage 1/2 
NPEPPS 0.002 0.348 stage 4 0.004 0.305 stage 1/2 
UBE2W 0.048 0.177 stage 4 0.031 0.177 stage 1/2 
STK33_SKM_UP 
UBE2W 0.048 0.177 stage 4 0.031 0.177 stage 1/2 
PALLD 0.042 0.330 stage 4S 0.019 0.347 stage 4S 
STK33_UP UBE2W 0.048 0.177 stage 4 0.031 0.177 stage 1/2 
Note. For each gene set differentially expressed in stage 4S compared to stage 4 and stage 1/2 (Table 2 and 
Table 3), differentially expressed individual genes are shown. Q-values are indicated, as well as the log2 fold 
change (logFC) and the group in which the gene is overexpressed. 
factor activity [26]. As such, DNA methylation 
serves as a regulatory mechanism for 
transcription factor activity. Therefore, the 
transcription factor target gene sets enriched in 
stage 4S differentially methylated promoters 
may indicate differential activity of the 
respective transcription factors in stage 4S 
tumors compared to stage 1/2 and stage 4 
tumors. Of note, this assumption is reinforced by 
the fact that several of the identified 
transcription factors of which multiple target 
genes are differentially methylated in stage 4S 
show proven dependency on the DNA 
methylation status of the binding site for 
transcription factor- DNA interaction. For 
example, DNA methylation inhibits the binding 
of E2F1 and CEBPG [26–28]. Additionally, the 
differentially methylated target gene sets are 
differentially expressed in stage 4S NB, further 
strengthening the possibility that DNA 
methylation affects the activity of these 
transcription factors. Of note, E2F1 also binds to 
the TERT promoter [29], which is 
hypermethylated in stage 4S compared to stage 
4, and TERT is expressed at lower levels in stage 
4S compared to stage 4. This indicates that TERT 
DNA methylation might also regulate telomerase 
activity in stage 4S NB.  
Furthermore, our transcription factor target 
enrichment analyses particularly demonstrate 
that the DNA methylation portrait of stage 4S NB 
is dominated by differential methylation of 
target genes of transcription factors involved in 
neural crest development and (sympathetic) 
neural differentiation (MSX1 [30,31], EVI1 
[32,33], EGR3 [34], AHR [35,36], MEF2A [37,38], 
YY1 [39], PPARA [40], POU2F1 [41] and GFI1 
[42,43]). These findings suggest that differences 
in the pathogenic mechanisms between stage 4S 
and stage 1/2 and stage 4 tumors are at least in 
part related to differences in transcriptional 
activity during neural crest development and 
differentiation, which might indicate that stage 
4S, stage 1/2 and stage 4 tumors arise during 
different phases of neural crest cell 
development. This is in line with the previous 
postulation that stage 4S NB originates from 
defective premigratory neural crest cells, which 
explains its clinical symptomology, as stage 4S 
tumor sites mirror developmental neural crest 
cell migration [44].  
One of the genes contributing the most to the 
significant differential expression of the target 
genes of E2F1 and MEF2A is SLC9A5. The SLC9A5 
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promoter is hypermethylated in stage 4S and 
these tumors show low SLC9A5 expression levels 
compared to stage 4 and stage 1/2 tumors. 
SLC9A5 is a member of the Na(+)/H(+) exchanger 
family and is abundantly expressed in neurons. 
In rat pheochromocytoma, a neuroendocrine 
tumor of the adrenal medulla, Diering et al. have 
shown that SLC9A5 modulates trafficking of TrkA 
between recycling endosomes and the plasma 
membrane, neurotrophin signaling and neural 
differentiation [45]. The authors demonstrate 
that upon knockdown of SLC9A5 in these tumor 
cells, there is no difference in the total 
abundance of TrkA compared to control cells, 
suggesting that reduced expression of SLC9A5 
has little effect on TrkA degradation or synthesis. 
However, although the overall TrkA protein 
levels did not change, the cell surface abundance 
of TrkA was reduced upon knockdown of SLC9A5 
[45]. Stage 4S NB tumors generally show high 
levels of TrkA, and depending on the presence or 
absence of nerve growth factor (NGF) in the 
tumor microenvironment, the tumors undergo 
neural differentiation or spontaneous 
regression, respectively. Therefore, 
neurotrophin deprivation (TrkA without NGF) 
and activation of apoptosis have been proposed 
to explain the phenomenon of spontaneous 
regression in NB [6]. Given the crucial role of 
SLC9A5 in regulating the cellular distribution of 
TrkA and NGF signaling [45], our findings suggest 
that over time stage 4S tumor cell surfaces might 
get depleted of TrkA (with an accompanying 
intracellular accumulation of TrkA) due to the 
low expression levels of SLC9A5, ultimately 
leading to apoptosis and regression. 
Our gene set enrichment analyses also highlight 
differential methylation of genes involved in 
important oncogenic pathways, especially of 
genes implicated in EGFR and RAS signaling. 
Although the exact mechanisms by which DNA 
methylation contributes to differential 
regulation of these pathways in stage 4S 
specifically cannot be determined in our study, 
our findings indicate that it is crucial to separate 
stage 4S tumors from other low-stage (stage 
1/2) tumors in studies focusing on NB biology, as 
this might reveal new insights into the stage 4S 
NB pathogenesis. The importance hereof is 
highlighted by the fact that all but one 
differentially methylated oncogenic signatures 
are also differentially expressed in stage 4S NB, 
confirming differential regulation of these 
oncogenic pathways in stage 4S on the one hand 
and stage 4 and stage 1/2 on the other hand. 
Finally, the enrichment analyses also illustrate 
that stage 4S tumors present differential activity 
of important epigenetic players, such as BMI1, 
PCGF2, EED and EZH2. Potentially, differential 
regulation of epigenetic mechanisms might also 
contribute to the regression phenotype of stage 
4S NB, as epigenetic alterations can more easily 
be reversed. Clearly, these epigenetic 
mechanisms need to be further studied in NB.  
In conclusion, this study is the first to describe 
the stage 4S DNA methylome and demonstrates 
that stage 4S NB tumors show characteristic 
DNA methylation patterns compared to stage 
1/2 and stage 4 tumors. Genomic localization 
and functional characterization analyses of this 
stage 4S DNA methylation portrait suggested 
new mechanisms that may contribute to the 
stage 4S-specific tumor biology and spontaneous 
regression. Future studies must confirm these 
observations and hypotheses. 
 
Materials and methods 
 
Neuroblastoma primary tumors 
 
Sample collection for MBD sequencing (n = 41) 
and expression profiling (n = 180) is described in 
Decock et al. [7] and Oberthuer et al. [17], 
respectively. All tumor samples were assigned to 
one of the three following subgroups, based on 
the INSS tumor stage [3] and MYCN amplification 
status: (1) MYCN non-amplified stage 4S (MBD 
sequencing: n = 14; expression profiling: n = 28), 
(2) MYCN non-amplified stage 4 (MBD 
sequencing: n = 14; expression profiling: n = 46) , 
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or (3) MYCN non-amplified stage 1 or 2 (MBD 
sequencing: n = 13; expression profiling: n = 
106). Detailed criteria for patient inclusion in the 
study are described in Decock et al. [8,46]. MYCN 
amplified tumor samples were excluded. 
Detailed clinicobiological characteristics of the 
different sample cohorts are shown in 
Supplemental table 6. The study was approved 
by the ethical committee of the Ghent University 
Hospital (approval number: B67020109912). 
 
DNA methylome and transcriptome profiling 
 
A detailed description of the generation and raw 
data analysis of the MBD sequencing data is 
provided in Decock et al. [7] Data can be 
accessed through the Gene Expression Omnibus 
numbers GSE69243 and GSE69268. For the 
mRNA expression analyses, microarray data of 
180 NB tumors were used [17]. 
 
Bioinformatics and statistical analyses 
 
Differential methylation analyses on the MBD 
sequencing data were performed as described in 
Decock et al. [8], using DESeq [47] and promoter 
region count matrices with data on all Ensembl 
transcripts (release 68). Promoters located on X 
and Y chromosomes were excluded to avoid 
gender-related confounding. To estimate the 
background signal and to be able to exclude 
possible falsely identified differentially 
methylated regions (DMRs) in the DESeq 
analyses, a filtering procedure based on two 
correction steps was applied on the resulting 
DMR lists. A first correction step consisted of 
excluding DMRs which were also significantly 
identified in the same comparison on the input 
(non-MBD-enriched) sample data (input 
correction) [8]. Secondly, computational 
simulation analyses were performed, in which 
100 random patient annotation swaps were 
executed to create two artificial sample groups 
on which the same statistics were applied as on 
the biologically relevant groups. Only biologically 
relevant DMRs with a π-value (= -ln p-val * log2 
fold change) [48] that equals or outperforms the 
π-value of the corresponding simulation DMR 
were considered for further evaluation (swap 
correction). DESeq normalized read counts of 
the stage-specific DNA methylation portraits 
were used for principal component analysis in R 
(package factoextra). 
Cytogenetic band enrichment analysis and 
transcription factor target enrichment analysis 
were performed using WebGestalt [9,10] with 
gene symbols as input list. The entire human 
genome was used as reference list. Benjamini-
Hochberg multiple testing correction was 
applied [49] and only statistically enriched terms 
(q < 0.05) with at least two genes were 
considered. 
Non-corrected transcript lists, including all 
transcripts included in the differential 
methylation analyses (preranked on the π-value) 
were used for GSEA [18,50]. To this purpose, 
Ensembl transcript IDs were converted to gene 
symbols. For genes with multiple transcripts, the 
data of the Ensembl transcript with the highest 
absolute π-value was retained. Tested gene set 
databases are the oncogenic signatures (version 
5.1) of the Molecular Signatures Database [18] 
and two in-house created subtelomere gene set 
lists. These two subtelomere gene set lists 
contain all genes in the 1 Mb or 2 Mb 
subtelomeres, which are defined as the 1 Mb or 
2 Mb genomic regions [24] proximal to the 
telomeres (10 kb chromosomal ends; hg19). 
GSEA was also performed on the input data to 
exclude falsely identified enriched gene sets. 
The sets of differentially methylated 
transcription factor targets and the leading edge 
genes of the enriched oncogenic signature gene 
sets were further tested for differential 
expression using the globaltest R package [19] 
and publically available mRNA expression data 
[17]. For significantly differentially expressed 
gene sets, covariates plots [19] were generated 
to inspect the contributions of each gene to the 
test result. Differential expression analyses on 
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the individual gene level were performed using 
the R package limma [51]. Benjamini-Hochberg 
multiple testing correction was applied [49]. 
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Supplemental table 1. Neuroblastoma tumors 
are characterized by a stage-specific DNA 
methylation pattern. For each Ensembl 
transcript ID, gene and promoter annotation is 
given, as well as the corresponding p-value, log2 
fold change and π-value (= -ln p-value * log2 fold 
change) of the differential methylation analyses. 
For transcripts considered differentially 
methylated upon input and swap correction (see 
materials and methods), it is indicated which 
sample group is hypermethylated and whether 
the transcript is part of a stage-specific DNA 
methylation portrait.  
 
Supplemental table 2. Specific chromosomal 
cytogenetic bands are enriched in the stage-
specific differentially methylated promoters. 
Shown are the significantly (q < 0.05) enriched 
cytogenetic bands in stage 4S, stage 4 and stage 
1/2 hyper- and hypomethylated promoters. For 
each enriched gene set, the differentially 
methylated genes are indicated. C: the number 
of reference genes in the category (cytogenetic 
band); E: the expected number in the category; 
O: the number of genes hyper- or 
hypomethylated in the corresponding stage in 
the category; genes: annotation for the genes in 
O; R: ratio of enrichment.  
 
Supplemental table 3. Specific transcription 
factor targets are enriched in stage 4S 
differentially methylated promoters. Shown are 
the significantly (q < 0.05) enriched transcription 
factor targets (motifs) in stage 4S hyper- and 
hypomethylated promoters. C: the number of 
reference genes in the category (transcription 
factor target); E: the expected number in the 
category; O: the number of genes hyper- or 
hypomethylated in stage 4S in the category; 
genes: annotation for the genes in O; R: ratio of 
enrichment.  
 
Supplemental table 4. Gene set enrichment 
analyses identify oncogenic signatures in stage-
related differentially methylated promoters. 
Shown are the gene sets significantly (nom p-val 
< 0.05 and FDR q-val < 0.25) enriched in 
promoters hypomethylated in stage 4S 
compared to stage 4, in stage 4S compared to 
stage 1/2 or in stage 1/2 compared to stage 4. 
Gene sets also identified in the corresponding 
input data comparisons are excluded. NES: 
normalized enrichment score; nom p-val: 
nominal p-value; FDR q-val: false discovery rate 
q-value.  
 
Supplemental table 5. Transcription factor 
target and oncogenic signatures gene sets are 
differentially expressed between stage 4S and 
stage 4 and stage 1/2. For each gene set 
significantly differentially expressed (q < 0.05; 
global test) between stage 4S and stage 4 and/or 
stage 1/2, data extracted from the covariates 
plots (p-values and sample group associations of 
individual genes) is shown. For each of the genes 
in all gene sets, also the results (q-value, log2 
fold change and sample group with 
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overexpression) of the differential expression 
analysis on the individual gene level (limma) are 
shown.  
 
Supplemental table 6. In total, 221 annotated 
primary neuroblastoma samples were included 
in the study. A. Detailed characteristics. Each 
sample is characterized by a unique patientID 
and is assigned to a biological subgroup (stage 
4S, stage 1/2 or stage 4) and subcohort (MBD 
sequencing or expression). Clinical 
characteristics given are the age of the patient at 
diagnosis in months, International 
Neuroblastoma Staging System (INSS) stage, and 
overall survival (OS) and event-free survival (EFS) 
status and time after diagnosis in days. The OS 
status indicates whether the patient is alive (0) 
at the last known follow-up or died of disease 
(1). Similarly, the EFS status indicates events 
such as relapse, progression or death. All 
samples are MYCN non-amplified. NAs represent 
missing values. B. Summary. Per subcohort an 
overview of the clinical characteristics is given.  
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4.1 Defeating pitfalls and limitations in biomarker research: the successful establishment of a 
prognostic DNA methylation signature for neuroblastoma 
Aiming at personalized medicine, molecular biomarker research is extremely important, especially 
for diseases showing a high degree of clinical heterogeneity such as NB. Revolutions in molecular 
characterization of NB tumors have led to the identification of a large amount of putative prognostic 
biomarkers, but only very few have shown clinical validity and utility; only MYCN oncogene 
amplification (§1.2.1.4), chromosome 11q aberration (§1.2.1.5.2.2) and DNA ploidy (§1.2.1.5.1) 
status are standardly used in patient stratification (§1.2.4) [154]. One of the main reasons for this is 
that many discovery studies suffer from pitfalls and limitations, such as an inadequate study design, 
insufficient sample numbers and lack of biomarker validation. In our search for prognostic DNA 
methylation biomarkers for NB, we aimed to defeat these issues. An overview of the research results 
is given in Figure 14. 
At the time of project initiation, most DNA methylation biomarker studies in NB were candidate 
gene-based; only few made use of whole-genome DNA methylation detection methodologies (re-
expression profiling upon treatment with DAC, MeDIP chip and Illumina 27 K methylation array 
analysis (§review paper; [228]); Figure 14). Though, whole-genome sequencing technologies had not 
yet been applied to study DNA methylation patterns in NB. By the start of our project, the 
implementation of the Illumina HM450 array (§1.1.4.2) was not yet fully optimized and whole-
genome bisulfite sequencing (§1.1.4.4) was not yet cost-efficient. Therefore, given the expertise of 
the UGent sequencing reference center NXTGNT (www.nxtgnt.ugent.be) in MBD sequencing 
(§1.1.4.3), this NGS-based technology was selected as the method of choice for DNA methylation 
biomarker discovery in our project. As proof of principle, we set up a pilot study (§paper 1; [229]; 
Figure 14) in which eight NB cell lines were profiled using microarray re-expression analysis and MBD 
sequencing. Using these cell line data, a bioinformatics pipeline for the analysis of MBD sequencing 
data was developed and methylated promoters were identified. To further select candidate 
prognostic biomarkers, these data were integrated with publically available primary tumor 
expression data and locus-specific DNA methylation analysis in a limited number of primary tumors. 
Subsequently, fast and accurate validation of the candidate prognostic biomarkers was obtained 
through the implementation of a semi-automated, high-throughput MSP pipeline [229]. Through the 
successful establishment of this validation technology, we ensured the possibility to translate the 
identified biomarkers into a clinically useful assay, as at present, MSP is still considered the gold 
standard methodology for measuring DNA methylation in clinical assays [120]. Although NGS may 
hold the future for clinical assay testing, NGS-based methodologies are currently immature to be 
clinically implemented for DNA methylation biomarker testing [120, 232–234]. Encouraged by the 
results of these initial experiments [229] and having specified the technological aspects of our study 
design, we set out a more profound DNA methylation biomarker discovery, verification and 
validation trajectory, a valorization project supported by the Fournier-Majoie Foundation 
(www.fournier-majoie.org). 
In the extended discovery phase, MBD sequencing was applied to 87 primary tumor DNA samples, to 
allow differential methylation analysis between prognostic patient groups and candidate biomarker 
prioritization (§paper 2; [230]; Figure 14). Next, more than 350 primary tumor DNA samples were 
collected for biomarker verification and validation. It should be noted that such large numbers of 
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samples are unprecedented in NB DNA methylation biomarker research. For rare diseases such as 
NB, one of the bottlenecks biomarker research faces, is the small number of available biospecimens. 
Consequently, our biomarker project depended on the establishment of international collaborations, 
in order to collect sample sizes that were large enough to be of statistical significance. During the
 
           
Figure 14. The research project resulted in five publications. At the start of the project, the literature on 
prognostic DNA methylation biomarkers in neuroblastoma (NB) was reviewed [228]. The first original research 
paper represents a pilot study in which the technological aspects of the project were specified [229]. The 
second paper describes the results of the more profound discovery, verification and validation trajectory [230]. 
The methyl-CpG-binding domain (MBD) sequencing data that were used in this second paper were also 
described in detail in a data descriptor [110]. Finally, a fourth paper was written on the characterization of the 
stage 4S NB methylome [231]. MSP: methylation-specific PCR. 
tumor collection stage 4S 
review paper 
tumor collection pilot study 
paper 1 
tumor collection extended discovery 
43 candidate biomarkers 
89 primary tumors 
8 NB cell lines 
MSP 
MSP 
paper 2 
paper 3: data descriptor 
paper 4 
MBD cohort I 
42 tumors 
MBD cohort II 
60 tumors 
tumor collection verification/validation 
MSP 
MSP cohort I 
78 candidate biomarkers 
132 tumors 
MSP cohort II 
78 candidate biomarkers 
177 tumors 
• development MBD sequencing analysis 
pipeline 
 
• establishment MSP validation pipeline 
 
• identification of HIST1H3C and GNAS as 
candidate prognostic biomarkers 
• differential methylation analysis 
between prognostic patient groups 
 
• identification of candidate prognostic 
biomarkers  
 
• MSP assay design localisation 
 
 
• verification on MSP cohort I 
 
• validation on MSP cohort II 
 
• establishment of individual prognostic 
MSP assays 
 
• establishment of prognostic 58-marker 
methylation signature 
stage 4 stage 4S stage 1/2 
• characterization of stage 4S methylome  
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project, multiple research centers and biobanks across the world were contacted, sample request 
applications were filed, material transfer agreements were set up, biospecimens were moved across 
national borders and sample annotation was gathered. In total, nine national biobank resource 
centers and reference centers for the study and diagnosis of NB contributed to sample collection for 
this biomarker project and enabled access to biospecimens: the Ghent University Hospital (Belgium), 
the Centre Léon Bérard (Lyon, France), the Hospital Clínico Universitario (Valencia, Spain), the Sydney 
Children's Hospital (Australia), the Institut Curie (Paris, France), the Children's Cancer and Leukemia 
Group (Leicester, UK), the Our Lady’s Children’s Hospital Dublin (Ireland), the University Hospital 
Brno (Czech Republic) and the University Children’s Hospital Essen (Germany). Of note, the 
investments it took to build up this sample collection prolonged the project’s time frame to a 
considerable degree, especially due to administrative hurdles that needed to be tackled. To speed up 
NB biomarker studies in the future, it is important to intensify the effort and resources put in 
expanding the infrastructure of international biobanks and databases, such as the interactive 
International Neuroblastoma Risk Group database (iINRGdb) [154]. Such repositories of high quality 
samples with updated clinical and treatment annotation should remarkably facilitate sample 
application and collection procedures for research projects.  
 
Partly as a consequence of difficulties in sample collection, validation of the clinical significance of 
the identified biomarkers is often overlooked in NB studies, especially in relatively new and rapidly 
evolving research fields such as epigenetics. Unfortunately, this is a general trend in cancer 
biomarker research and has far-reaching consequences researchers often do not take into account 
when publishing unvalidated results [235, 236]. For example, publication of a new, high-profile 
biomarker is frequently accompanied by press releases generating high expectations about the new 
biomarker. However, follow-up reports demonstrating that the same biomarker failed to be 
validated for clinical use are generally ignored by the media, leaving the general public with skewed 
information. To improve biomarker research, it might be appropriate not to call a molecule a 
biomarker until it has passed at least one independent validation study, avoiding misinterpretations 
and highly misleading conclusions [235]. In our project, the DNA methylation biomarker candidates 
identified by primary tumor MBD sequencing were additionally tested on independent tumor cohorts 
using MSP, allowing to validate their clinical significance (§paper 2; [230]; Figure 14). Importantly, we 
also reported in detail on patient and biospecimen characteristics, the assay methods, study design 
and statistical analysis methods [110, 230]. This is extremely important, as in addition to lack of 
independent validation, inadequate reporting also hinders biomarker research progress [237].  
 
As such, we were able to identify and validate multiple individual prognostic MSP assays (located in 
CCDC177, NXPH1, lnc-MRPL3-2, lnc-TREX1-1, SPRED3, TNFAIP2, NPM2, CYYR1 and one on a region 
from chromosome 8 with no further annotation), as well as a robust prognostic 58-marker 
methylation signature of which a methylation score cutoff of 25% allows accurate OS and EFS 
prediction in the global NB patient cohort. Importantly, in the validation cohort, this signature was an 
independent predictor of OS after controlling for known NB risk factors, clearly indicating its clinical 
relevance. Further investigations must confirm these results and integration with other biomarkers 
should be explored [230] (Figure 14). 
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4.2 Finding prognostic biomarkers for high-risk neuroblastoma: a tough nut to crack 
 
Having collected a considerable number of both high-risk survivors and high-risk non-survivors for 
our study, we also tested the prognostic relevance of the selected MSP assays within the high-risk 
cohorts (§paper 2; [230]). This analysis is very valuable for the reason that the need for prognostic 
biomarkers is the highest within this group of patients. Ideally, high-risk prognostic biomarkers would 
allow pretreatment identification of ultra-high-risk patients, i.e. patients currently dying of the 
disease although intensively being treated. Recent comprehensive whole-genome sequencing 
studies have shown that high-risk NB tumors can be genetically subdivided into three major 
subgroups, based on the presence of MYCN amplification, TERT rearrangements and ATRX 
alterations, but currently these findings have not shown utility as prognostic biomarker [238, 239]. 
Previously, our center developed a 59-mRNA [222] and 25-miRNA signature [224] using RNA from 
fresh frozen tumors, each enabling identification of patients with increased risk in the current risk 
groups (§1.2.4), including the high-risk patient group, but these signatures await further validation on 
formalin-fixed paraffin-embedded tumor samples. Next to tumor mRNAs and miRNAs, also tumor 
DNA methylation patterns have been searched for prognostic biomarkers for high-risk NB [240, 241]. 
However, these DNA methylation studies could not validate the biomarkers [241] or incorrectly 
included low-risk samples in the so-called validation cohort [240]. Unfortunately, also in our project 
we could not validate prognostic high-risk biomarkers using MSP, although differential methylation 
analyses on the MBD sequencing data illustrated that high-risk survivors and high-risk non-survivors 
show different methylation patterns. Importantly, this does not mean that high-risk DNA methylation 
biomarkers cannot be found. It only indicates that the methylation differences in the differentially 
methylated regions (of 2 kb or 5 kb) in the MBD sequencing data between these high-risk groups are 
too subtle to be easily translated in an MSP assay which only interrogates a few CpGs. Therefore, the 
possibility of establishing high-risk methylation biomarkers based on genome-wide bisulfite 
sequencing, which allows analysis of the methylome at the single CpG level, should be addressed in 
the future. These future studies might also benefit from focusing on more homogeneous high-risk 
patient groups, for example by only studying MYCN amplified or non-amplified samples, as the 
heterogeneity within our high-risk cohorts might also have counteracted the possibility of 
establishing high-risk DNA methylation biomarkers [230]. 
 
4.3 Sharing is caring 
 
Along with the 87 tumors in our prognostic biomarker project, also 15 stage 4S NB tumors were 
profiled by MBD sequencing. The MBD sequencing data of these 102 primary NB tumors are unique 
in the NB research field, as it represents the first sample cohort in which the full tumor heterogeneity 
is being assessed by genome-wide methylation analysis using NGS. Given the rare occurrence of NB, 
we are therefore convinced that this data set is a valuable resource of methylation information and 
that other researchers must be able to use it. Although there is a growing international agreement 
on the need of sharing research data, especially for rare diseases, open science is not the standard 
[242, 243]. Next to ethical and legal frameworks hindering open science, also researchers themselves 
are sometimes not that keen on sharing, as they fear that the valuable work they have put into their 
sample collection and data generation will not be recognized. As a consequence, researchers often 
hold on to data until they have extracted every last possible publication from it. Fortunately, things 
are changing and particularly scientific publishing is at a turning point [242, 243]. This is evidenced by 
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the growing number of scientific journals specifically focusing on data sharing, for example Matters 
(www.sciencematters.io), Genomics Data (www.journals.elsevier.com/genomics-data) and Scientific 
Data (www.nature.com/sdata). To make our data more discoverable, interpretable and reusable for 
other researchers (inexperienced with MBD sequencing), the MBD sequencing data were published 
as a data descriptor in Scientific Data (§paper 3; [110]; Figure 14). In this data descriptor, we provide 
details on sample annotation (including accession IDs to matching expression and aCGH data), 
methodological approach and bioinformatics analyses, as well as easy access to the (analyzed) MBD 
sequencing data and analysis tools and scripts [110]. Additionally, this data descriptor is 
accompanied by an ISA-Tab metadata file, providing a machine readable overview of the study, 
which allows exploration via the ISA-explorer tool (http://scientificdata.isa-explorer.org). Shortly 
upon publication of our data descriptor we were contacted by another research group willing to 
make use of the MBD sequencing data to analyze the methylation status of a certain gene [244]. This 
request clearly illustrates the opportunities data sharing has to offer and why every researcher 
should embrace it.  
 
4.4 The stage 4S DNA methylome sheds light on mechanisms contributing to spontaneous 
regression 
 
To further exemplify the possibilities of reusing our MBD sequencing data, we characterized the DNA 
methylome of stage 4S NB (§1.2.1.3). This NB tumor stage is a very intriguing clinical presentation; 
despite patients present with metastatic disease, they usually have a favorable prognosis, often 
caused by spontaneous tumor regression. Previous studies have shown that most stage 4S NB 
tumors are MYCN non-amplified and hyperdiploid (near-triploid with whole chromosome gains), and 
demonstrate characteristic mRNA and protein expression patterns [245–248]. For example, Bénard 
et al. have developed a stage 4S NB classifier by comparing mRNA expression levels of stage 4S and 
stage 4 NB tumors [246], and Lavarino et al. have shown that distinct gene expression profiles 
correlate with distinct genomic abnormalities between these two NB tumor stages [247]. Based on 
these characterization studies, several mechanisms have been proposed to explain the regression 
phenotype of stage 4S NB (summarized in [245]), but the precise molecular determinants underlying 
this phenomenon remain to be elucidated. This is partly caused by the fact that recent genome-wide 
characterization studies in NB have combined patients with stage 4S or other low-risk tumors with 
favorable prognosis (stage 1/2) into one group for comparison to high-risk patients with unfavorable 
prognosis (stage 4), hindering the opportunity to gain new insights into the stage 4S NB biology. By 
comparing MBD sequencing data of MYCN non-amplified stage 4S tumors to data of MYCN non-
amplified stage 1/2 and stage 4 tumors, we described for the first time stage 4S-specific hyper- and 
hypomethylated promoters, which were characterized for genomic location and function (§paper 4; 
[231]; Figure 14). As such, we found that stage 4S tumors show characteristic hypermethylation of 
specific subtelomeric (§1.1.2.1) promoters and based on the literature we suggested that 
subtelomeric DNA methylation might represent an additional regulatory mechanism by which 
telomeres are shortened and spontaneous regression is induced in stage 4S NB. One of the first 
studies describing a link between subtelomeric DNA methylation and telomere length homeostasis is 
published by Gonzalo et al. [249]. Using mice embryonic stem cells, they showed that Dnmt1 or 
Dnmt3a and Dnmt3b knockdown leads to a global decrease in subtelomeric DNA methylation levels, 
and demonstrated that dramatic telomere elongation is present in these DNMT deficient cells. 
Furthermore, they prove that loss of DNA methylation leads to increased telomeric sister-chromatid 
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exchange events at telomeres, possibly resulting in telomere lengthening. As such, subtelomeric DNA 
methylation can be considered a negative regulator of telomere recombination and telomere length 
[249]. Later on, this has been confirmed by Vera et al. in human cancer cells [250]. Nevertheless, the 
effect of subtelomeric DNA methylation on telomere length might also directly result from altered 
expression of other telomere length regulators located in subtelomeres. For example, in humans, the 
TERT and TERRA promoters are located in subtelomeric regions, more specifically on chr5q and 
chr20q [251], respectively. TERT is hypermethylated in stage 4S NB compared to stage 4 NB, and this 
might lead to downregulation of telomerase levels, contributing to telomere shortening in stage 4S 
NB. Although no differential methylation of the TERRA promoter between the different NB tumor 
stages could be detected in our study (data not shown), this telomere length regulator should 
definitely be further analyzed in NB, as it has been shown that TERRA plays a crucial role in 
alternative lengthening of telomeres (ALT) [252], a process which is also described in NB [253]. 
Additionally, we also found differential methylation and expression of genes involved in important 
oncogenic pathways, neural crest development and differentiation, and epigenetic processes. One of 
these genes is SLC9A5, modulating the cellular distribution of TrkA (NTRK1) and nerve growth factor 
(NGF) signaling [254]. Importantly, TrkA expression and NGF signaling have been suggested to play an 
important role in NB spontaneous regression [245]. As such, hypermethylation and lower expression 
levels of SLC9A5 in stage 4S NB might also contribute to the stage 4S regression phenotype. 
Importantly, it should be stressed that this study is the first to describe the stage 4S DNA methylome 
and thus that independent validation of stage 4S-specific differential methylation (of individual 
genes) is needed. Nevertheless, exploring the DNA methylome of stage 4S tumors has opened new 
avenues to further unravel its intriguing biology.  
 
4.5 Latent mysteries in neuroblastoma epigenetics may decipher the clinical enigma 
 
In contrast to the impressive amount of knowledge that has been acquired on the NB genome and 
transcriptome during the last decades, profound DNA methylation studies in NB have lagged behind. 
Nevertheless, recent findings have triggered the NB research field to dig deeper into this relatively 
unexplored discipline.  
 
Our project mainly focused on the establishment of prognostic tumor DNA methylation biomarkers. 
However, applications of DNA methylation biomarkers in cancer management are versatile (§1.2.3) 
and these should definitely be further explored in the context of NB. For example, the possibilities of 
identifying DNA methylation biomarkers for minimal residual disease monitoring should be further 
examined and methylation detection methodologies should be further optimized to allow non-
invasive biomarker measurement in blood. It has previously been shown that methylation of 
RASSF1A in bone marrow samples can be used for minimal residual disease testing in NB [255] and 
methylation of this gene was detected in pretreatment serum of NB patients [256]. Therefore, using 
the recently described MethyLight digital droplet PCR technology [68], it is worthwhile to test 
whether serum RASSF1A methylation can be used for minimal residual disease monitoring, as well as 
to investigate whether our identified prognostic DNA methylation biomarkers can also be detected in 
the blood of NB patients.  
 
Additionally, the link between MYCN and DNA methylation needs to be further clarified. Literature 
suggests an important function of MYCN in regulating the NB epigenome (and vice versa), as it 
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directly interacts with important epigenetic factors, such as DNA methyltransferases DNMT1 and 
DNMT3A and the MBD protein MeCP2, and colocalizes with them at certain gene promoters, of 
which some are known to be hypermethylated in NB, for example RASSF1A [257, 258]. Additionally, 
it has been shown that BMI1, encoding a member of the Polycomb group family that effectuates 
chromatin modifications, is a direct target of MYCN [259, 260]. Furthermore, we and others have 
shown that MYCN non-amplified and amplified NB cell lines and primary tumors show differential 
methylation patterns [229, 240, 261]. For example, in our pilot study, we have demonstrated that the 
HIST1H3C and ACSS3 promoter is specifically hypermethylated in MYCN amplified NB [229]. 
Nevertheless, more in-depth analyses are needed to truly characterize the complex interplay 
between MYCN and the different epigenetic actors. 
 
Other epigenetic players frequently deregulated in cancer but unexplored in NB are the 5-
hydroxymethylcytosine base (and its oxidation products 5-formylcytosine and 5-carboxylcytosine) 
and the TET enzyme family (§1.1.1.1) [9]. 5-hydroxymethylcytosine is present in high levels in neural 
cells and therefore might have a crucial role in the pathogenesis of NB tumors, which originate from 
precursor cells of the sympathetic nervous system. So far, it has only been shown that hypoxia in NB 
cells results in transcriptional activation of TET1, leading to an accumulation of 5-
hydroxymethylcytosine density at hypoxia-responsive genes [262], and that TET proteins negatively 
regulate neural differentiation in NB cell lines [263], but more exhaustive studies are currently 
lacking. Clearly, possible mechanisms deregulating the levels of the oxidation products of 5-
methylcytosine in NB should be further examined. 
 
Finally, given that epigenetic processes are highly influenced by environmental factors, it needs to be 
determined whether DNA methylation differences between primary tumors, metastases and relapse 
tumors can be detected. An initial study of 16 matching primary and relapse NB tumors showed that 
primary tumor DNA methylation patterns are globally preserved in relapse tumors, but differential 
methylation analyses were not assessed [264]. Nevertheless, these analyses might unravel new 
aspects of NB metastasis and tumor evolution, and might offer new possibilities for treatment [121]. 
 
4.6 Conclusions 
 
By exploring the NB DNA methylome using MBD sequencing and by validating site-specific DNA 
methylation using MSP, we successfully established new prognostic DNA methylation biomarkers for 
NB. Nevertheless, the quest for prognostic NB markers did not yet come to an end, and especially in 
the high-risk patient group, the need for additional markers persists. To speed up NB (biomarker) 
research, sharing data should become the standard. To contribute to the policy of open science, the 
MBD sequencing data were made available via a data descriptor and its reusability was 
demonstrated by portraying the stage 4S NB DNA methylome. As such, we discovered new biological 
mechanisms possibly contributing to the NB pathology. Further exploration of the NB DNA 
methylome and other epigenetic factors will unravel new aspects of NB biology and will open new 
horizons in NB biomarker research. 
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